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Abstract 
 
Prostate cancer affects 1 in 8 men in the UK. Treatment options for advanced 
prostate cancer patients with hormone refractory and metastatic disease are limited 
and therefore investigations are required to identify novel therapeutic targets. 
Receptor activity modifying protein 1 (RAMP1) is a vital component for many 
different G protein-coupled receptors (GPCRs) from the calcitonin peptide family. It 
also has been linked with the clinical progression of prostate cancer and found to be 
an important driver of tumour growth in prostate cancer cell lines. 
 
To further investigate the role of RAMP1 in prostate cancer, CRISPR/Cas9 was 
used to generate RAMP1 knockouts in a PC3 cell line. RAMP1 knockouts were 
validated using endpoint and quantitative PCR with Sanger sequencing. These 
RAMP1 knockouts were then tested in vitro and showed to have significant 
reductions in cell viability, invasion, adhesion and colony formation abilities. 
Increased levels of apoptosis were also found in RAMP1 knockouts. In vivo, deletion 
of RAMP1 resulted in almost complete inhibition of subcutaneous tumour growth. 
Immunohistochemistry staining revealed no differences in markers for Ki67 and 
CD31, respectively suggesting alternative causes for tumour growth inhibition. 
Treatment with human CGRP antagonists had no effect on tumour growth. These 
results may suggest that RAMP1 is acting in a CGRP-independent manner. Analysis 
of downstream signaling pathways in RAMP1 KO cells also revealed an association 
with Akt and STAT3.  
 
These results show that RAMP1 may be vital for the survival of aggressive 
prostate cancer cells and that this protein plays an important role in the 
development of tumour growth. Although it remains unknown through which 
mechanism RAMP1 is promoting prostate cancer, the dysregulation of 
phosphorylated Akt and STAT3 implicates RAMP1 as an important instigator of 
oncogenic pathways associated with promoting hormone refractory and metastatic 
prostate cancer. Future investigations may focus on which GPCR RAMP1 is acting 
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with to promote prostate cancer and whether this receptor protein can be targeted 
therapeutically to aid advanced prostate cancer patients.  
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 CHAPTER 1: General Introduction 
 
1.1. Hallmarks of Cancer 
 
 It is now estimated that there are more than 200 types of cancer and that 1 
in 2 people in the UK will get cancer at some point in their lifetime. Cancers of the 
lung, bowel, breast and prostate accounted for almost half of all cancer deaths in 
the UK in 2012. Statistics show that cancer has become increasingly prevalent over 
the last 50 years, rising in males and females 23% and 47% respectively, since the 
1970s [1]. This increase in incidence does not necessarily represent a higher 
prevalence of cancer but rather the advances made in diagnosing disease and also 
the fact that people are living longer and therefore survive previous causes of death 
e.g. stroke, heart failure. Cancer is strongly associated with old age and therefore an 
ageing population creates a higher incidence of cancer [2]. 
 
Over the last few decades great strides have been made in translation 
research that provides clinical treatments and improved survival rates. However, it 
has become increasingly clear that the complex biology of tumours cannot be fully 
understood by focusing on the cancer cells alone but requires understanding of the 
‘tumour microenvironment’ [3]. This includes non-cancerous or stromal cells such as 
fibroblasts, immune cells and the proteins they secrete which may influence cancer 
progression both positively and negatively. Cross-talk between stromal cells can 
occur through the extracellular matrix which provides a structural scaffold for cells. 
Tissues can communicate through a complex network of interactions using 
autocrine, paracrine or juxtacrine signaling. This provides information needed to 
maintain a healthy cellular environment. If these intercellular signals get disrupted 
it can lead to functional disorder. Abnormal interactions can result in the genomic 
instability of the stromal cells providing them with a tumourigenic potential. 
Proliferating cancer cells can interact with their microenvironment and further 
enhance abnormal signaling to promote tumour growth [4].  
 
 13 
A pivotal review by Hanahan and Weinberg first described what is now 
famously known as the ‘hallmarks of cancer’ [5]. A second review accompanied this 
ten years later detailing the mechanisms used by cancer cells to alter the function of 
stromal cells and promote tumorigenesis (see Fig 1.1) [6]. These hallmarks include 
the ability of cancer to evade immune detection, even when promoting 
inflammation and invading surrounding tissues. Cancer cells can also avoid growth 
suppressors and resist apoptosis whilst initiating processes such as angiogenesis and 
proliferation to further promote their survival. Their effect on the surrounding 
stroma creates genomic instabilities and mutations which ultimately lead to the 
deregulation of cell metabolism [6] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Diagram showing the different hallmarks of cancer and drugs that are in development or in 
some cases approved for clinical use for inhibiting these processes. (Reprinted from Hardy & 
Weinberg with permission from Elsevier [6].) 
 
Cancer is not one disease but many different ones sharing the same inherited 
loss of inhibition of proliferation, so that many different tumour types interact with 
the wide range of tissues within the body whether as primary tumours within those 
Figure 1.1.1 The hallmarks of cancer.  
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tissues or as secondary tumours that have spread to a new site. While some tumours 
occur in primary sites that are in themselves innocuous e.g. skin melanomas, which 
are problematic because they metastasize to vital organs, others arise in sites where 
the presence of a primary tumour poses a health risk in the site itself. This creates a 
plethora of potential therapeutic targets and often these targets will have important 
physiological functions and their inhibition will often have disastrous consequences. 
Care must therefore be taken when selecting possible targets for therapeutic 
intervention. Often this is achieved by investigating the molecular mechanisms 
associated with cancer and determining the signaling pathways that may be affect 
by pharmacological intervention.  
 
1.2. Prostate Cancer  
 
1.2.1. Incidence and Diagnosis 
 
 The prostate is a male sexual gland, situated anterior to the rectum and 
between the bladder and penis [7]. Its dual function is to produce a number of 
secretory products that condition the urethral surface for spermatozoa and to 
contribute to the production of semen [8]. Prostate cancer is the most common 
cancer in men with 1 in 8 men in the UK begin diagnosed within their lifetime [1]. 
The most significant risk factor associated with prostate cancer is age, with the 
average age of diagnosis being 72 [9]. In the UK, 54% of prostate cancer cases are 
diagnosed in males aged 70 or over [1]. A genetic risk also exists and it is estimated 
that a man may be 2-3 times more likely to develop prostate cancer if a close family 
member has also suffered from the disease [1]. Common genetic mutations that 
predispose to prostate cancer include BRCA1, BRCA2, HOXB13 and many others (see 
Fig 1.2) [10]. Prostate cancer can often be asymptomatic but the most common 
complaint in both malignancy and benign tumours is urinary problems such as 
disrupted micturition, increased frequency and nocturia [11]. Often, these 
symptoms can be caused by benign prostate hyperplasia or an enlarged prostate 
instead of cancer. Diagnostic tests must differentiate between benign or malignancy 
and include tools such as for digital rectal examination (DRE) and transrectal 
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ultrasound (TRUS)-guided biopsy [12]. It has been estimated that in 18% of patients, 
prostate cancer is detected by DRE alone, irrespective of blood test results [13]. 
These results must then be confirmed with ultrasound or biopsies to differentiate 
between benign or malignant disease. TRUS has now become the standard method 
of obtaining material for biopsy in prostate cancer patients. Blood tests are available 
and look for biomarkers such as prostate specific antigen (PSA) a glycoprotein 
produced by prostate gland cells (benign or malignant) [14]. This protein is encoded 
by the prostate-specific gene kallikrein 3 (KLK3) and in its mature form is secreted 
into the semen [15]. Under normal conditions, low levels of PSA are detected in the 
blood but increased serum levels may represent disruption to the prostate gland 
caused by prostate cancer although exact mechanisms still remain unclear [16]. In 
fact, PSA screening has become widely used since its discovery in 1979 and thereby 
promoted earlier detection of prostate cancer cases before significant clinical 
symptoms have manifested [17].   
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Reprinted from Attard et al with permission from Elsevier [10]. 
 
 
PSA was regarded as a relatively useful biomarker for prostate cancer for 
some years before its limitations became evident. A lack of specificity was found, as 
PSA can become elevated by noncancerous events such as inflammation or infection 
leading to incorrect diagnoses [15, 16]. This has sparked a search for new biomarkers 
of prostate cancer, using “-omics” technologies such as deep sequencing of DNA and 
RNA transcriptome profiling. These investigations aim to profile prostate tumours by 
investigating alterations in DNA, RNA and epigenetic methylation [18]. Many new 
biomarkers have been found using this method including PCA3, a long non-coding 
RNA shown to be elevated in more than 90% of PC cases and has emerged as a new 
non-PSA based diagnostic test [19, 20]. Other candidates such as TMPRSS2-ERG [21] 
and AMACR [22] have also been identified but found only useful when used in 
 
Figure 1.2 Genetic mutations that increase familial risk of prostate cancer. 
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combination with other biomarker tests due to their low specificity to prostate 
cancer [18].  
 
 
1.2.2. Staging and Treatment 
 
After diagnosis, local staging of the disease is often determined with further 
biopsies and using magnetic resonance imaging (MRI). This is because TRUS-guided 
biopsies are often not specific enough for accurate staging and have a tendency to 
underestimate progression of the disease. The 2009 Tumour Node Metastasis (TNM) 
classification is used for staging both primary prostate tumours and regional lymph 
nodes (See Table 1.1) [12]. Another method for grading prostate cancer is the 
Gleason score. This system was developed after a study from 1979 to 1964 enrolled 
270 prostate cancer patients and Dr Donald Gleason created a grading system based 
on the different histological patterns seen in patient biopsies [23]. He observed that 
most tumours displayed two distinct patterns and so a score was created that added 
the two most common grade patterns in a tumour (scores range from 2-10) to 
achieve a “Gleason score” (see Fig 1.3.) Revisions have since been made to the 
Gleason’s scoring system however it is still commonly used for grading histological 
prostate tumour sections. Although these modifications add to the specificity of the 
system, diagnosis has now become very complex and can be confusing to both 
patients and clinicians. Nevertheless the Gleason scoring system remains a robust 
predictor of prostate cancer prognosis and therefore plays a significantly important 
role in the management and treatment of the disease [24] .  
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Histological staining of prostatic tumours with their Gleason score. (A) Gleason grade 
group 1 (3 + 3 = 6). (B) Gleason grade group 2 with cribiform glands. (C) Gleason 
grade group 4 (4 + 4 = 8) with irregular cribiform glands. (D) Gleason grade group 4 
(4 = 4 = 8) with fused cytoplasmic vacuoles. (E) Gleason grade group 4 (4 + 4 = 8) with 
glomeruloid glands (F) Gleason grade group 4 (4 + 4 = 8) with poorly formed glands. 
Gordetsky and Epstein CopyrightÓ with permissions [24].  
 
 
 
 
 
Figure 1.3 Histological staining of prostatic tumours with their Gleason score. 
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Table 1.1 Tumour Node Metastasis (TNM) classification is used for staging of prostate 
cancer.  
 
Staging of prostate cancer can then inform on appropriate treatment options 
either of the local primary tumour or metastatic disease. Many low risk PC patients 
are put under active surveillance (AS) and are initially not treated unless a threat of 
progression occurs in follow-up testing. AS was put into action to avoid unnecessary 
treatment of patients with clinically confined low risk prostate cancer. This decision 
is based on findings that show men with well differentiated PC have a 20-year 
survival rate of 80-90% and as prostate cancer often occurs in men aged 70+ years 
old this may be pragmatic [25, 26]. Radical prostatectomy (RP) a surgical treatment 
for localised prostate cancer and has been shown to have an increased survival in a 
subset of patients when compared with AS in two different randomised trials [27, 
28]. However, this benefit in survival has a negative correlation with age, as patients 
less than 65 years of age were found to benefit in overall and metastasis-free survival 
[27]. The Prostate Cancer Intervention Versus Observation Trial recruited 731 
patients from 1992 to 2002 and found that this effect was only deemed statistically 
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significant in patients with high-risk PC or PSA levels of <10ng/mL. These patients 
experienced a 31% increase in overall survival (p = 0.02) and an absolute risk 
reduction of 10.5% (P = < 0.01). Significant reductions in the development of bone 
metastases was also seen in patients who were treated with RP compared with AS 
(4.7% versus 10.6%, P = < 0.01).  Nerve-sparing radical prostatectomy is a preferred 
treatment to RP as it avoids many of the side effects such as urinary incontinence 
and erectile dysfunction. This technique is becoming more common and can be 
performed by a method known as robot-assisted laparoscopic RP (RALP). This new 
technique is yet to be critically evaluated due to the lack of long-term follow up 
studies [29]. 
 
Three-dimensional conformal radiation therapy (3D-CRT) is considered the 
gold standard radiotherapy method for many cancers [12]. Its value in treating 
prostate cancer patients was first shown almost 20 years ago when a randomised 
controlled trial was conducted to compare toxicity of 2D and 3D-CRT. It was 
concluded that 3D-CRT not only was as sufficient as 2D techniques but also had lower 
risks of late radiation-induced proctitis for patients [30]. However, since then further 
advancements have led to the development of intensity-modulated radiation 
therapy, a more optimised form of 3D-CRT. This technique is widely used because of 
its advantage of allowing doses to be altered without any corresponding toxicity [31].  
Active surveillance, radical prostatectomy and radiotherapy treatments are 
considered useful for low-intermediate risk patients however no consensus is found 
when determining treatment for high-risk, clinically localised prostate cancer. 
Radical prostatectomy is suggested as a reasonable first step for patients with 
tumours of a small volume however further management of high-risk patients may 
be determined on a case-by-case basis [12].  
 
Metastatic prostate cancer patients have been recommended for androgen 
deprivation therapy (ADT) for many decades [32]. Originally, surgical castration 
(specifically bilateral orchidectomy) was regarded as a successful treatment for 
advanced prostate cancer patients [33]. However, the majority of patients would 
prefer not to undergo surgical castration due to the psychologically traumatic impact 
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on erectile function and libido [34]. Since the days of surgical castration, 
Gonadotropin-releasing hormone (GnRH) antagonists have proved to achieve and 
maintain levels of serum testosterone equivalent to surgical castration [35]. GnRH 
antagonists have many advantages over surgical castration and represent a common 
method of treatment for advanced prostate cancer patients who have a high risk of 
metastatic disease that may include neurological manifestation, urinary obstruction 
and bone pain all relating to metastasis. GnRH treatment has been described as the 
mainstay of treatments for advanced prostate cancer patients by the European 
Association of Urology (EAU) [36]. However, a few years later, guidelines published 
by the EAU also recognised the use of luteinising hormone-releasing hormone 
(LHRH) agonists as a standard of care [37]. Recent studies found that LHRH 
antagonists can be used to induce a more rapid decrease in testosterone levels 
compared with previous hormone treatments without any flare. Testosterone flare 
is a phenomenon seen where levels are transiently increased in patients treated with 
GnRH agonists creating symptoms such as bone pain and urinary problems during 
the first few weeks of treatment courses [38]. Long term treatment of ADT can lead 
to reductions in bone mineral density and increase fracture risk, requiring patients 
to be monitored regularly [39].  
 
Unfortunately, despite the effectiveness of ADT, all patients’ prostate 
cancers will eventually become castration resistant if they do not die of other causes. 
This is defined as either development of metastatic disease or three consecutive 
increases in PSA levels in the presence of castrate levels of testosterone [40, 41]. 
Studies have tried to show the molecular mechanisms responsible for castration 
resistance. It appears that the androgen receptor itself is involved directly and may 
be mutated when cancer becomes resistant to ADT. These mutations may amplify 
androgen receptor gene expression allowing it to become sensitive to lower doses 
of androgens or other steroids [42]. However, indirectly coactivators may increase 
this sensitivity of the receptor through a variety of signalling mechanisms [43]. 
Prostate cancer cells have also been found to bypass the androgen receptor pathway 
entirely and promote proliferation through alternative signalling pathways [44]. One 
potentially relevant pathway is the neuroendocrine (NE) differentiation of tumours 
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which may allow secretion of neurotransmitters that promote proliferation in 
prostate cancer [45, 46].  
 
Despite reports that relapsing patients can survive 5 years with ADT, the 
majority will die from castration resistant metastases [47]. Patients who advanced 
to progressive metastatic castration resistant prostate cancer have a median survival 
time of 9-12 months [48]. 80% of these advanced patients will have bone metastases 
which are a major cause of disability and death and represent increasing costs in 
treatment [37]. Zoledronic acid is the sole bisphosphonate that has been shown to 
reduce bone pain and skeletal metastases in prostate cancer patients [49].  
Alternatively, Radium-223 can act as a calcium mimic and target bone growth around 
bone metastasis sites with heavy alpha particles that have an ultra-short range [50]. 
A study of 921 castration-resistant prostate cancer patients found overall survival to 
be increased 25% (P = < 0.0001) [51]. Docetaxel is a current standard of care for 
castration resistant patients and is a heavily studied chemotherapeutic that is used 
in the treatment of a variety of cancers [52]. However, castration resistant patients 
eventually become also resistant to docetaxel due to drug efflux [53].  EAU guidelines 
suggest that due to the lack of evidence on timing or sequence of therapies, clinicians 
should try to include advanced metastatic patients in clinical trials for the best 
chance of survival. In fact, it is estimated that any patient with castration-resistant 
prostate cancer is currently involved in a clinical trial [37].  
 
Prostate cancer prognosis may be good for patients diagnosed with low risk 
localised tumours however it still remains poor for advanced patients. All therapies 
including ADT, radio- and chemo-therapy only act to slow the progression of prostate 
cancer metastasis. Therefore, it is imperative to study the mechanisms of this 
process and identify key proteins that may be targeted therapeutically.  
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1.3. G Protein-Coupled Receptors (GPCRs): The Calcitonin Peptide Family   
 
 Adrenomedullin (AM) and calcitonin gene-related peptide (CGRP) are 
members of the calcitonin peptide family. This family is so named as all members 
share structural similarities with calcitonin (CT) a hypocalcemic hormone secreted 
from the thyroid gland. The Calcitonin Gene-Related Peptide (CGRP) is appropriately 
named as it is an alternative splicing of the CT gene [54]. CGRP is mostly expressed 
in the central and peripheral nervous systems often in nerves innervating 
vasculature [55]. Adrenomedullin was first described in 1993 when identified in a 
human pheochromocytoma patient. It is a potent vasodilator, acting directly on 
renal, cerebral and lung circulation systems as well as the vascular supply of bone 
[56]. The physiological and pathological functions of both AM and CGRP are 
summarised in Figures 1.5 & 1.6. The receptors for these peptides are unusual in that 
they are formed by two separate proteins, a seven-transmembrane domain G 
protein-coupled receptor and a receptor activity modifying protein (RAMP). In the 
case of AM and CGRP, the receptor is the calcitonin-like receptor (CLR). This receptor 
binds with RAMP1 to form a CGRP receptor and with RAMP2 and RAMP3 to form 
two distinct AM receptors (AM1 and AM2) (See Fig 1.4) [57]. RAMPs share 30% 
amino acid sequence homology and can also interact with other receptors to form 
GPCRs for multiple ligands. All RAMPs can traffic the calcitonin receptor (CTR) to the 
cell surface forming three distinct amylin receptors (AMY1, AMY2, AM3) [54].  
 
RAMP1 and RAMP3 have been shown to interact with the calcium sensing 
receptor (CaSR) [58]. Unpublished work in our group has also provided evidence that 
RAMP1 may traffic a receptor known as GPRC6A to the cell membrane.  GPRC6A is 
named from the GPCR, class C, group 6 subtype A receptor (and previously described 
as a second calcium sensing receptor) [59, 60]. It is a receptor that can be activated 
by multiple ligands including cations, L-amino acids and osteocalcin [59, 61]. GPRC6A 
also plays an important role in the regulation of testosterone in both physiology and 
pathology [62]. RAMPs 2 and 3 have also been shown to interact with two distinct 
parathyroid hormone receptors (PTH1 and PTH2) at the cell surface [63] (See Table 
1.2). The calcitonin family and their receptors have a wide range of physiological and 
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pathological functions which have been widely discussed in the literature [64-68]. 
Due to their well-established roles in vital cellular mechanisms it is therefore 
unsurprising that they also feature as promoters of tumorigenesis across many 
different cancer types.  
 
 
The CGRP and Adrenomedullin (AM) receptors are composed of the calcitonin-like 
receptor (CLR) bound with a receptor activity modifying protein (RAMP).  
 
 
Table 1.2 The calcitonin peptide family and the G protein-coupled receptors. 
 
 
 
Figure 1.4 CGRP and AM1/2 Receptors. 
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Figure 1.5 The role of CGRP in physiology and pathology. 
CGRP is known to activate vasodilation by acting on both vascular smooth muscle 
and endothelial cells. It is also expressed and released from the trigeminal ganglion 
and associated with pain pathways. CGRP is upregulated during pregnancy but its 
effect remains unknown [55].  
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Figure 1.6 The role of adrenomedullin in physiology and pathology. 
Adrenomedullin is a vasodilator that regulates blood pressure and hormone levels. It 
is also involved in glomerular filtration and blood pressure in the kidney and is 
upregulated during pregnancy to aid placentation [69]. 
 
  
1.3.1. Structure of Adrenomedullin and CGRP 
 
 Adrenomedullin (AM) consists of 52 amino acids and has one intramolecular 
disulfide bond [56]. Structural features important for biological activity such as the 
ring and carboxyl terminal amide structures remain preserved across species [70]. 
The human AM precursor (preproAM) is 185 amino acids in length and gives rise to 
either proAM (PAMP) or mature adrenomedullin, the former can be found to be 
expressed in vivo regulating hypotension in rats [71]. The human AM gene consists 
of 4 exons and 3 introns, the mature AM peptide being transcribed from exon 4, 
whereas PAMP is coded in intron 2 (see Fig 1.5) [70]. 
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AM has four exons and three introns which are translated to the precursor molecules 
preproAM and proAM which are then processed into mature AM and PAMP. 
 
 
Although two CGRP peptides have been described (aCGRP and bCGRP) they 
differ from each by three amino acids and have proved so far to be indistinguishable 
in physiological function [72]. Unless otherwise stated aCGRP is predominantly 
described as CGRP. The amino acid sequences for CGRP also are well preserved 
across many different species [73]. This 37-amino acid peptide has a disulfide bond 
between residues 2 and 7 and a carboxyl terminal amide. Studies using proton 
nuclear magnetic resonance (1H NMR) show that residues 8-18 form an alpha helix 
and that conformation of both alpha and beta peptides are identical [74].  
 
 Adrenomedullin and Prostate Cancer 
 
 Adrenomedullin has been implicated in many different solid cancers 
including lung, breast, ovarian, adrenal and brain tumours [56, 75-78]. It has also 
been found to be upregulated at an mRNA level in human prostate cancer cell lines 
Figure 1.7 Structure of the adrenomedullin gene. 
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after androgen deprivation and can act as a growth factor in DU145 cells suggesting 
an autocrine loop which could potentially drive tumour growth [79, 80]. Expression 
of AM is significantly higher in malignant tissues and correlates with high Gleason 
scores in prostate cancer when compared with adjacent healthy tissue controls [80]. 
AM has also been associated with neuroendocrine differentiation, a reported early 
marker of androgen independence [81]. AM was also shown to induce a 
neuroendocrine phenotype in LNCaP cells via both AM1 and AM2 receptors 
characterized by observed increases in neuritic processes and expression of neuro-
specific enolase (NSE). In vivo studies also show that in castrated animals, treatment 
with AM results in up to 250% increase in tumour volume [82].  
 
 An important trait of prostate cancer cells is the ability to proliferate 
uncontrollably. The current literature features discrepancies when investigating 
whether AM has influence on the proliferation of prostate cancer cells. It would 
appear that the effect of AM in vitro can be heavily dependent on cell culture 
conditions.  One study has found that treatment with AM in DU145 cells results in a 
20% increase in proliferation after 4 days (P = 0.05), however no effect was found in 
PC3 and LNCaP cell lines. The authors suggest that because these cell lines were also 
found to secrete AM peptide, they may not be susceptible to treatment as maximal 
proliferative effects have already been achieved [80]. Conversely, a separate study 
found that treatment with AM results in decreases in proliferation in PC3 (20%) and 
LNCaP (50%) cell lines. The reported effect was dose-dependent with significant 
decreases in proliferation only occurring at a range of 10nM-1µM [83]. These results 
are contrary to previously reported data by Rocchi et al. and the authors argue this 
is due to differences in experimental conditions. They claim that previous reports 
used serum-free medium in proliferation experiments whereas they used a 1% fetal 
calf serum (FCS) concentration. Therefore, it may be that prostate cancer cell lines 
only display this effect when grown in “stress-free” conditions.  
 
Interestingly, it has been shown that in the mammary cell line T47D, 
overexpression of AM results in cells growing at lower rates in low serum 
concentrations compared with mock transfected controls.  The same overexpressing 
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cells, when grown in serum-free conditions showed increases in proliferation [84]. 
The authors also comment on unpublished work which shows results that are 
concomitant with Rocchi et al. It is reported that prostate cancer cells cultured in 
serum-free media did not show the same inhibition on cell growth. This is also 
represented in work by Rocchi et al. which shows that expression of AM mRNA is 
much higher in prostate cancer cell lines that have been injected into athymic mice 
xenografts compared with cell lines cultured in vitro [80]. Other studies have found 
that blocking of the AM receptors using a cocktail of antibodies leads to reduced 
growth of DU145 in vitro and in mouse xenografts. This reduction was also seen in 
LNCaP xenografts but only in castrated animals, suggesting that not only may AM be 
regulating tumour growth in vivo but also play an important role in androgen 
independence [85].  
 
The effect of AM gene knockdown or knockout on proliferation in prostate 
cancer cells has yet to be explored. However, in vivo studies have found the 
knockdown of AM results in reduced growth of SW480 colon tumour xenografts. 
Immunohistochemistry analysis of these tumours showed no significant differences 
in Ki67 between control and knockdown sections. This is reflective of studies in vitro 
which found that the proliferation of SW480 cells was only minimally effected by 
silencing of AM. Findings indicate that the reduced growth was attributed to the 
effect of AM depletion on tumour angiogenesis and apoptosis. These conclusions 
were drawn from knockdown tumours showing higher levels of staining for CD31 an 
endothelial marker and cleaved caspase 3 [86]. It can therefore by hypothesized that 
AM may affect tumour growth in vivo through non-proliferative mechanisms or by 
influencing the tumour microenvironment rather than tumour growth directly.  
 
 Although the effect of AM on proliferation in prostate cancer remains 
ambiguous, in other cell lines it has been shown that variation of ERK1/2 levels are 
seen after treatment with AM and that after stimulation of proliferation with AM, 
levels of phosphorylated ERK are increased [87-89].  Although AM receptors, like 
many GPCRs, have been associated with elevation of cAMP following activation, 
reports have found that in prostate cancer cells, AM receptors can function 
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independently from cAMP and stimulate ERK1/2 signaling instead. In order to 
hypothesise AM’s role in proliferation of prostate cancer cells it is apt to also look at 
its effect on cell signaling pathways associated with this process. Activation of the 
MAPK signaling has also been shown in DU145 cells when stimulated with different 
doses of recombinant AM. Phosphorylation of CRAF, MEK1/2 and ERK1/2 was 
achieved after treatment with 10-7 mol/L AM for 5 minutes. Interestingly, inhibition 
of MEK (an upstream ERK1/2 activator) disrupts AM activated phosphorylation of 
ERK1/2. These effects were reversed by pretreatment with an anti-AM antibody 
cocktail (for both AM1 and AM2 receptors). The MAPK cell signaling pathways has 
been implicated with many hallmarks of cancer including cell proliferation, migration 
and apoptosis [90]. AM may therefore be influencing proliferation and metastasis of 
prostate cancer cells by influencing this survival pathway.  
 
 Prostate cancer cells must evade apoptotic mechanisms in order to promote 
tumour growth. Studies have been able to show that AM promotes survival of 
prostate cancer cell lines when apoptosis is induced with either serum deprivation 
or treatment with chemotherapeutic agent etoposide (a topoisomerase II inhibitor). 
Overexpression of AM in PC3 cell lines protects against etoposide effects and 
maintains a Bcl2/Bax expression level consistent with untreated cells [91]. Blocking 
of AM has also shown to increase the number of apoptotic cells in DU145 prostate 
orthotopic tumours 6-fold compared with controls (P = < 0.001). Apoptosis was 
observed to occur mostly in tumour-associated lymphatic vessels thereby 
preventing the prostate tumours from inducing lymphoangiogenesis [85]. This 
process is key to tumour growth as lymph and blood vessels are recruited to increase 
nutrient supply for growing cancer cells. AM has been predicted as a key protein 
involved in angiogenesis for many cancers, this is precedent when considering AM 
was first identified as a potent vasodilator and is expressed in endothelial cells [92, 
93]. In prostate cancer, AM has also been found both in vitro and in vivo to 
upregulate IL-13, an interleukin also implicated in angiogenesis [94, 95].  
 
 Cellular migration and invasion also plays a pivotal role in metastasis of 
prostate cancer and many of the components responsible for cellular migration rely 
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on intracellular calcium levels [96]. Transient receptor potential (TRP) channels are 
a family of calcium channels and have been shown be involved with carcinogenesis, 
including prostate cancer specifically [97, 98]. Specifically, TPRV2 channel is involved 
with cellular migration and promoting androgen dependence in prostate cancer [99]. 
It has been reported that TRPV2 modulates AM stimulation of cell motility in PC3 
cells and that when this gene is knocked down, the effect of AM on adhesion, 
migration and invasion is also removed. The authors also show that AM can increase 
the invasive phenotype of PC3 cells through b1-integrin and FAK activation [100]. It 
is clear that AM regulates many of the hallmarks of cancer including proliferation, 
apoptosis, lymphoangiogenesis, migration, adhesion and invasion. However, there 
is little evidence of which AM receptors are responsible if not both, as most studies 
use AM peptide to treat prostate cancer cells in vitro or alter AM gene expression to 
use cells in in vivo studies. Previous in vivo studies have found that RAMP3 knockout 
in mice has no adverse effects on physiology whereas RAMP2 knockout mice die in 
utero. This shows that RAMP2 and RAMP3 have distinct physiological functions 
which may be reflected also in pathology. By studying the individual receptor 
components (CLR, RAMP2 and RAMP3) in prostate cancer, the mechanism of AM-
associated tumourigenesis may be explored further.  
 
 
 CGRP and Prostate Cancer  
 
 Clinical evidence exists linking CGRP with prostate cancer. It was first 
reported that CGRP serum levels correlate with prostate cancer stage and 
histological grade (P = 0.01). However, years later the same group reported 
interesting findings when analysing samples from patients who had received 
hormonal therapy (HT). Highest levels of serum CGRP were again found to be in 
patients with late stage disease but in patients treated with HT this was not the case. 
The authors therefore suggest that care should be taken when considering CGRP as 
a potential biomarker of prostate cancer (as was originally mentioned in the previous 
paper) [101, 102]. In vitro studies have investigated the relationship between many 
neuropeptides, including CGRP, and prostate cancer cell lines. Invasion across 
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Matrigel membranes (an extracellular matrix reconstituted substance) of LNCaP and 
PC3 cells after stimulation with 10-7 mol/L was increased by 30% (P = < 0.01). This 
effect was reflected when exploring haptotactic migration (experiments tested the 
ability of cells to adhere to ECM proteins and then degrade them to migrate towards 
a fibronectin substrate) [103]. CGRP was also seen to promote invasion in DU145 cell 
lines by 30% after treatment with 10-8 mol/L, however doses of 10-6 mol/L were 
required to elicit significant effects on haptotactic migration of DU145 cells (P = < 
0.01). CGRP doses of 10-7 resulted in 48% increase in LNCaP cells when testing 
haptotactic migration ability [104].   
 
 There is a significant lack of evidence implicating CGRP in prostate cancer, 
although it has been shown that this is a clinically relevant peptide to study. In order 
to more fully understand mechanisms by which CGRP may be promoting prostate 
cancer growth, it is important to investigate its receptors components as well. 
RAMP1 knockdown in PC3 and LNCaP cells results in decreases in proliferation and 
the number of colonies grown on soft agar plates is halved compared with control 
wild type cell lines (P < 0.05). RAMP1 knockdown xenografts also result in reduced 
tumour growth by 30% after 30 days and histological analysis of tumour sections 
reveals fewer numbers of Ki67 (a proliferative marker) positive cells in RAMP1 
knockdown tumours [105]. RAMP1 is a key component of the CGRP receptor, 
ensuring the calcitonin-like receptor (CLR) is trafficked to the cell surface [57]. It is 
therefore possible that the effect seen after RAMP1 gene deletion is due to 
insufficient CGRP receptor expression. However, RAMP1 has been shown to be 
involved in other receptors, such as the CaSR and GPRC6A both of which have been 
shown to correlate with prostate tumour progression [58, 60, 106, 107].  RAMP1 
knockdowns resulted also in reduced phosphorylation of ERK1/2 and MAPK mRNA 
transcripts. However, all aforementioned receptors have been reported to signal 
through ERK pathways, so this does not provide evidence of which upstream effector 
is responsible for the effect of RAMP1 depletion [107-109].  
 
 CGRP correlates with prostate cancer progression and has a pro-tumorigenic 
effect on prostate cancer cell lines in vitro. However, further evidence is still required 
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to link CGRP to mechanisms of metastasis such as proliferation and apoptosis and 
also to further elucidate its role in vivo. It may be that this neuropeptide is indirectly 
affecting prostate tumours by influencing the tumour microenvironment. In the case 
of prostate cancer, 90% of metastases are skeletal, therefore when considering 
targets, the bone environment should also be explored [110].  
 
 
Table 1.3 The roles of adrenomedullin and CGRP in prostate cancer. 
 
 
 GPRC6A and Prostate Cancer  
 
 GPRC6A has been shown to traffic with RAMP1 in thyroid human carcinoma 
cells in unpublished work [60]. This receptor has been shown to be activated by 
many ligands including osteocalcin, which in high serum levels is a biomarker for 
prostate cancer [111]. GPRC6A also interacts with testosterone and has also been 
linked with promoting androgen independence in aggressive prostate cancer cell 
lines, such as PC3 cells [62]. It is highly expressed in human prostate cancer tumours 
and stimulates proliferation of prostate cancer cells in vitro. In addition, knockdown 
of GPRC6A results in inhibition of prostate cancer cell migration and invasion [107]. 
Knockout of GPRC6A in transgenic mouse models of prostate cancer, results in 
reduced hyperplasia and a 23% increase in survival rates [107]. Intriguingly, human 
genome wide association studies (GWAS) have found single nucleotide 
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polymorphisms (SNPs) in GPRC6A that are linked with the development of prostate 
cancer in Asian populations and an individual SNP (rs1606365) which is associated 
with aggressive prostate cancer [112-114]. This GPCR is therefore clinically relevant 
to advanced prostate cancer patients and its involvement with RAMPs should be 
further investigated.  
 
 Adrenomedullin and CGRP: The Bone Microenvironment 
 
 The calcitonin peptide family and their receptors have long been associated 
with the regulation of bone metabolism. CGRP can inhibit osteoclast motility and 
cause quiescence through cAMP-dependent mechanisms [115]. Alternatively, both 
CGRP and AM have been shown to influence osteoblast activity by stimulating 
proliferation and triggering bone formation in vivo [116]. Specifically, AM treatment 
results in increases in mouse tibial cortical width and trabecular bone volume, 
suggesting it has a strong anabolic effect in the regulation of bone mass. It is 
therefore unsurprising that AM may be able to influence the bone environment to 
promote tumour growth. Breast cancer also commonly metastasizes to bone in 
advanced stages and therefore lessons may be learned from studies of this disease. 
Findings show that AM may be capable of aiding tumour growth after metastasis to 
the bone has occurred. Ex vivo models using co-cultures of breast cancer cell lines 
with mice calvarial bone showed that receptor activator nuclear factor-kB ligand 
(RANKL) is decreased in bone but upregulated in tumour cells. This is not surprising 
as RANKL has long been known to be involved in regulation of bone remodeling and 
in pathology can influence the bone microenvironment to promote carcinogenesis 
[117, 118]. Interestingly, this effect was then reversed after treatment of co-cultures 
with 10-8 mol/L AM. Addition of an AM antagonist (16311) blocked expression of 
RANKL in both bone and tumour cells. Previous research has shown that crosstalk 
between breast and prostate tumour cells and osteoblasts aids to increase 
metastatic growth via a vicious cycle in which IL-6 and RANKL can upregulate each 
other in metastatic environment [119, 120]. It has not been investigated what role 
AM may play on IL-6 but by upregulating RANKL in tumour cells it is promoting the 
vicious cycle of bone metastasis growth in breast cancer. These findings may be 
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applicable in prostate cancer, as bone metastasis mechanisms are often similar [121, 
122]. 
  
 Due to its neuropathic properties, CGRP is often associated with bone pain 
induced by cancer metastasis [123]. When labelling sensory nerves with an anti-
CGRP antibody, it was observed that following injection of prostate cancer cells into 
mouse femurs, nerves began to grow around the injection site. In tumour-bearing 
mice, these fibres grew in a disorganized manner compared with control animals 
which showed a linear structure with clear single fibre morphology. The fibres also 
seemed to sprout directly from prostate cancer cell colonies [124]. The presence of 
CGRP positive nerves in in vivo prostate cancer models such as this, suggest that 
secretion may influence the bone environment. Growth factors such as nerve growth 
factor (NGF) were found to be expressed in prostate cancer cells in vivo when 
normally NGF is not expressed in these cells. It may be possible that tumour-
associating factors such as CGRP can trigger pathological sprouting of sensory 
neurons in prostate tumours to promote a neuroendocrine phenotype, a 
characteristic of advanced prostate cancer and androgen independence [81].  
 
 Taken together these findings suggest that both AM and CGRP may be 
influencing prostate tumour growth and metastasis either directly or indirectly. A 
lack of evidence exists investigating the individual receptor components of the 
GPCRs these peptides signal through. In order to understand the mechanisms 
involved in both the bone microenvironment and prostate tumour growth, these 
components can be explored in both in vitro and in vivo models. Prostate cancer cell 
lines may shed light on expression and influence of this peptide family but ultimately 
in vivo models may be better designed to test hypotheses in a realistic setting of 
prostate cancer metastasis.  
 
 Hypothesis and Objectives 
 
 Given the current evidence of AM and CGRP in promoting prostate cancer 
progression, it is hypothesized that these peptides, with their corresponding 
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receptors (CLR, RAMP1, 2 and 3) are involved in prostate tumour growth and 
metastasis. To test this hypothesis the following objectives have been set:  
 
Objective 1: To determine the expression of AM, CGRP, RAMPs 1-3 and CLR in PC3 
prostate cancer cells.  
 
Objective 2: To use CRISPR/Cas9 gene editing to delete RAMPs 1-3 in PC3 cells and 
to validate this gene knockout using RT-PCR, qPCR and Sanger sequencing.  
 
Objective 3: To determine the effect of RAMP deletion in PC3 cells in vitro by 
measuring proliferation, migration, invasion, adhesion, colony formation and 
responses to apoptosis.  
 
Objective 4: To determine the effect of RAMP deletion in PC3 cells in vivo by using a 
subcutaneous xenograft mouse model and investigating tumours with 
immunohistological analysis targeting Ki67 and CD31 markers.  
 
Objective 5: To determine if effects of RAMP deletion are due to CGRP stimulation 
by using CGRP antagonist Telcagepant in in vivo experiments. 
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 CHAPTER 2: Characterisation of the    
PC3 Cell line 
 
 Introduction 
 
 
 In order to investigate the molecular mechanisms involved in prostate cancer 
(PC), robust, relevant models are often required. Although animal models are often 
the more beneficial, prostate cancer is a disease that only occurs naturally in mature 
male canines which, in addition to many limiting factors, can rarely be obtained for 
research investigations [125]. Researchers have therefore made great efforts in the 
past to develop prostate cancer cell lines that can mimic various stages of the disease 
and also with tissue specific metastasis sites. These cell lines are often selected for 
their aggressiveness and ability to form tumours in vivo (most commonly in mouse 
models). The first initial tissue culture cell lines used by PC researchers were LNCaP, 
PC-3 and DU-145 and still today these cell lines are the most widely used in published 
research. A PubMed search in 2017 for these terms generated 1,912, 6,239 and 
7,760 published articles respectively.  
 
 The first of these tissue culture cell lines to be established was DU145. These 
are epithelial cells isolated from a brain tumour mass from a 69 year old white man 
with PC and lymphocytic leukemia [126]. This cell line lacks the androgen receptor 
for 5a-dihydrotestosterone produced by testosterone. Androgen sensitivity is 
characteristic of early PC development and patients can be treated with androgen 
therapy but often experience remission by which point the PC cells have become 
androgen insensitive [127]. DU-145 therefore represent a late stage PC and mimic 
this with the ability to metastasise. Subcutaneous injection of DU145 cells into NOD 
SCID mice produced metastatic sites in the liver, lung, lymph nodes and spleen [128]. 
The ability of DU-145 cells to home to bone has also been investigated using 
 38 
humanized SCID mice. DU-145 (and PC-3) cells colonise to implanted fragments of 
human bone and form osteolytic lesions [129].  
 
 LNCaP cells were first isolated from a needle aspiration biopsy of a lymph 
node metastatic lesion from a 50 year old white man [130]. Interestingly, this cell 
line was first solely used to demonstrate androgen sensitivity and displayed poor 
tumorigenesis in mouse models without the use of Matrigel or co-injection of 
mesenchymal or stromal cell [131, 132]. This emphasises the importance of the 
extracellular matrix and paracrine growth factors in PC growth and metastasis. Sub 
cell lines were obtained by culturing LNCaP cells after being grown in castrated mice, 
as a result the C4-2 and C4-2B lines show metastasis to lymph nodes and bone 
following subcutaneous injection in mice [133].  
 
 The PC3 cell line was derived from a lumbar vertebral metastasis found in a 
62 year old white man in 1979 [134]. This is a highly metastatic cell line which has 
bene reported to establish lymph node metastases after intravenous injection and 
orthotopic implantation in mice [135, 136]. Intracardiac injection of PC3 cells yields 
bone metastases with osteolytic responses, specifically in the spine and long bones 
[137]. PC3 cells are also androgen insensitive and do not express the androgen 
receptor [138]. This cell line therefore represents a high invasive clinical state seen 
in PC patients who often show increased incidence of bone metastases [139]. This is 
a common metastasis site in PC and consequently researchers are focused on 
investigating models of PC in order to understand the molecular mechanisms behind 
this characteristic of the disease.  
 
 Calcitonin gene related peptide (CGRP) and adrenomedullin (AM) are two 
hormones reported to be linked with prostate cancer. They both signal through 
different G protein-coupled receptors (GPCRs) (See Table 1.) and the individual 
receptor components such as calcitonin-like receptor (CLR) and receptor activity 
modifying proteins (RAMPs) also have been associated with the development of 
prostate cancer both in the clinic and bench side. Evaluation of 129 PC patient blood 
samples reported CGRP serum levels significantly higher in patients with higher 
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clinical stages and histological grades. Authors of this publication predicted CGRP 
may be a useful biomarker for untreated PC patients in the future [101].  Another 
publication searching for prostate cancer biomarkers found RAMP1 to be 
differentially expressed when comparing benign and malignant prostate tissue 
mRNA [140].  
 
 Prostate cancer cell lines have been used to investigate the role of these 
targets. For example, PC3 cells have an increased invasive and migratory capacity 
when stimulated with CGRP in vitro  [103, 104, 125]. Using the genomics tool 
Oncomine, a cancer-specific database, researchers were able to report that RAMP1 
mRNA is upregulated in prostate cancer most significantly when comparing data 
from other human cancers. This led the group to develop a RAMP1 knockdown in 
PC3 cells and were able to show reduced proliferation and decreased tumour growth 
and volume in vivo [105].  
 
 The role of adrenomedullin and its receptor components CLR, RAMP2 and 
RAMP3 have not been fully investigated in prostate cancer. Blocking of AM with an 
antibody cocktail for these components shows reduction of prostate cancer cell 
growth and migration [85]. AM can regulate these effects by acting on calcium 
channels, for example the transient receptor potential channel, TRPV2. Knockdown 
of this channel with siRNA abolished all effects seen on PC cells after AM treatment 
such as increased migration and invasion. AM is known to be associated with other 
metastatic cancers such as breast and lung. It is therefore worth investigating its 
potential in promoting prostate cancer progression.  
   
In order to measure functional CGRP and AM expression in the PC3 cell line 
it is important to investigate all receptor components of CGRP and AM at both a 
mRNA and protein level, using RT-PCR and Western blotting. There is a lack of 
publications on the expression of receptor components such as RAMP1, 2, 3 and CLR 
at the surface of PC3 cells. It is therefore not known whether these receptors and 
corresponding ligands are functional in this cell line. To investigate this flow 
cytometry can be used to measure protein levels both inside and at the surface of 
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the cells. Many GPCRs including CGRP and AM can often activate via cAMP 
mechanisms. This means that when the receptor is stimulated with the ligand cAMP 
is released and this can be detected using LANCE cAMP TR-FRET assays. PC3 cells will 
therefore be stimulated with CGRP or AM and responses in cAMP activity measured.  
 
 Hypotheses:  
 
1. PC3 cells express RAMP1, RAMP2, RAMP3, CLR and AM at both a mRNA and 
protein level in vitro.  
2. PC3 cells express functional CGRP and AM receptors in vitro 
 
 Research Questions:  
 
1. Do PC3 cells express RAMPs 1-3, CLR and AM at an mRNA and protein level? 
2. Do PC3 cells express RAMPs 1-3 at the cell surface? 
3. Are CGRP and AM receptors functional in PC3 cells? 
 
 
 Methods and Materials  
 
2.4.1 Maintenance of Cell Lines 
 
PC-3 cells were maintained in T-175 cm2 culture flasks (Nunclon, Thermo 
Scientific) in RPMI 1640 medium supplemented with Glutamax™ (Gibco), 1% 
Penicillin and Streptomycin (5,000 units/mL, Sigma-Aldrich) and 10% fetal calf serum 
(Sigma-Aldrich) at 37°C in a 5% CO2 incubator. These cell culture conditions have 
been previously reported in the literature to be sufficient in support growth of PC3 
cells [80, 100, 105]. Media was changed twice a week until cells were observed to be 
70% confluent under an INVERSO inverted microscope (Medline Scientific Ltd) and 
deemed ready for passaging. 
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2.4.2 Passage of Cells 
 
Cells were washed once with sterile Phosphate Buffered Saline (PBS, GIBCO) 
and then incubated with 1X TrypLE Express Enzyme (Gibco) for 5 minutes at 37°C in 
a 5% CO2 incubator to allow cells to detach from the bottom of the culture flask. Cells 
were then centrifuged at 300 x RPM for 5 minutes to form a pellet and then 
resuspended in 10mL fresh media. Cell suspension was added to a new flask with the 
appropriate media at a ratio of 1:10. Cells were then maintained as described above. 
 
2.4.3 Cell Counting 
 
Cells were detached and suspended as described above and 10µL cell 
suspension was mixed with 10µL 0.4% Trypan blue solution. 10µL of this mix was 
pipetted into a Countess chamber slide (Invitrogen) and inserted into a Countess™ 
Automated Cell Counter (Invitrogen). 
 
 
2.4.4 RNA Extraction  
 
Cells were grown to 70% confluency in T-75 culture flasks and then counted 
as described previously (Section 2.4.1-3). 5 x 105 cells were harvested for RNA 
extraction and were first washed with 1mL ice cold PBS and centrifuged at 300 x G 
for 5 minutes. RNA extraction was performed with the Reliaprep RNA Cell Miniprep 
System using protocols provided.  The supernatant was discarded and cells were 
resuspended in 250µL BL + TG Buffer containing guanidine thiocyanate, guanidine 
hydrochloride and 1-Thioglycerol to lyse cells and release RNA by denaturing 
nucleoprotein complexes. Samples were then stored at -20°C.  RNA was extracted 
using the ReliaPrepä RNA Cell Miniprep System (Promega) following protocols 
provided. This included inactivation of endogenous ribonuclease (RNase) activity and 
the removal of contaminating DNA and proteins. Lysates were added to columns and 
centrifuged at 14,000 x G for 1 minute, liquid was then discarded from the collection 
tube. 500uL RNA wash buffer was then added to the column and then centrifuged 
again for 30 seconds. Liquid from the collection tube was discarded once more and 
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DNase I treatment was prepared by adding 24µL Yellow Core Buffer, 3µL 0.09M 
MnCl2 and 3µL DNase I enzyme per sample. Samples were then incubated at room 
temperature with DNase treatment for 15 minutes before being washed with 200µL 
column wash. Columns were centrifuged again and liquid from the collection tube 
discarded, this was repeated twice more with 500µL RNA wash buffer. Extracts were 
then eluted in 30µL nuclease-free water and quantified using a Nanodrop 2000 
spectrophotometer at 260nm and 260nm (Thermo Fisher). 
 
2.4.5 cDNA Synthesis  
 
cDNA was synthesised from RNA samples using the High Capacity RNA-to-
cDNA kit (Applied Biosystems). 2µg of RNA was quantified with Nanodrop and then 
used for each reaction, a negative control or RT- reaction contained no reverse 
transcriptase to determine any genomic DNA contamination in RNA samples. 
Reagents were thawed on ice and then mixed as per protocol provided (see Table 
2.1). Tubes were briefly centrifuged to remove air bubbles and placed in a ProFlex 
PCR System thermocycler (Life Technologies). Conditions were programmed as was 
described in the manufacturers protocol (see Table 2.2) and then samples were 
stored at -20◦C.  
 
 
 
 
Table 2.1 Reverse transcription reaction recipe. 
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2.4.6 Endpoint Polymerase Chain Reaction (PCR) 
 
Primers were designed using the Primer3 web tool (ELIXIR) for each target, 
including a housekeeping gene, GAPDH (See Table 2.3) GAPDH was used as a 
negative control to determine environmental contamination of samples rather than 
as a loading control. Although this is commonly used in RT-PCR the expression of 
targets was not quantified and was only investigated for either presence or absence 
in PC3 cell mRNA. Primer3 shortlisted possible primer pairs for each target and then 
these were selected based on a few different criteria. Primer pairs with similar 
melting temperatures were preferably selected and with a high GC content. Guanine 
and cytosine form three hydrogen bonds together creating a stronger match 
compared with adenosine and thymine (only two bonds). This creates a stronger 
annealing process during PCR and ensures a higher level of success when targeting 
DNA with primers. Primers were also preferably no more than 20 nucleotides long 
as this has been found to be an optimal length.  
 
cDNA samples were amplified using GoTaq G2 polymerase using protocols 
provided and temperatures optimised for each pair of primers (see Table 2.4). 
Reagents were all thawed on ice and mixed in autoclaved PCR reaction tubes using 
sterile pipette tips. Reactions were vortex to mix contents and then briefly 
centrifuged to avoid air bubbles. Reactions were run on a ProFlex PCR System 
thermal cycler (Life Technologies) using conditions listed in Table 2.5.  
 
Table 2.2 Reverse transcription reaction cycle. 
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These primers target RAMP1, 2, 3, CLR, AM and GAPDH were synthesised by Eurofins 
and diluted with nuclease-free water on arrival to 100pmol/µL and stored at -20° C. 
 
 
 
 
Table 2.3 Endpoint PCR primers. 
Table 2.4 Endpoint PCR recipe 
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2.4.7 Gel Electrophoresis 
 
 PCR products were visualised on 1.5% agarose gels prepared with 
1.5g agarose (Fisher Scientific) and 100mL 1X TBE (Tris-borate-EDTA, Scientific 
Laboratory Supplies) buffer heated in a 750W microwave oven for 120 seconds. The 
solution was then stirred to dissolve agarose and heated again for 40 seconds. 
0.5µg/mL (final concentration) ethidium bromide (Sigma-Aldrich) was added to the 
agarose mixture in order to bind to DNA and be detected using a UV light source. 
Then the solution was poured into an electrophoresis gel casting tray with a 16-well 
comb to set for 15 minutes. The gel was then transferred to an electrophoresis gel 
chamber containing 1X TBE buffer. 10µL of PCR product was loaded to each well. A 
10µL FullRanger 1kb DNA Ladder (Geneflow) was loaded to the first lane of each 
agarose gel. GoTaq G2 Mastermix buffer was sufficient density for PCR products to 
be loaded straight into agarose gels. The gel was run at 200 volts for 45 minutes and 
then visualised using a Gel Doc XR+ Gel Documentation System (Bio-Rad).  
 
2.4.8 Sanger Sequencing 
 
PCR products were validated with Sanger sequencing to confirm correct 
targets were amplified.  Products were provided at 50ng/µL with forward and 
reverse primers diluted to 1µM and sequencing was performed by the University of 
Table 2.5 Endpoint PCR cycle 
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Sheffield Core Genomic Facility using BigDyeä Terminator v3.1 Cycle Sequencing Kit 
(Thermo Fisher) and run on an Applied Biosystems 3730 DNA Analyser. Sequencing 
data was generated in “abi” file format and analysed using 4Peaks v1.8 software 
(Nucleobytes). Sequences were then compared to NCBI target sequences using 
BLAST (Basic Local Alignment Search Tool, NCBI).  
 
2.4.9 Protein Extraction 
 
Cells were grown to 70% confluency in T-75 flasks and then incubated on ice 
for 10 minutes. HaltÔ Protease and Phosphatase Inhibitor Cocktail (Thermo 
Scientific) was diluted 1:100 with NP-40 buffer (150mM NaCl, 50mM Tris Base pH 
8.0, 1% NP-40) to form the cell lysis buffer. Protease inhibitors included in lysis buffer 
were aprotinin, bestatin and leupeptin which inhibit serine and cysteine proteases. 
Phosphatase inhibitors included sodium fluoride and sodium orthovanadate which 
inhibit serine, threonine and tyrosine phosphatases. Culture medium was removed 
from cells and then washed with 10mL ice cold PBS. 1mL lysis buffer was added and 
cells were incubated on ice for 5 minutes. Cells were scraped from the flask and 
lysate transferred to a cold 1.5mL Eppendorf tube. The cell lysate was kept on ice 
and sonicated at input 60 for 30 seconds before being centrifuged at 13,000 x G for 
20 minutes at 4°C. Lysate supernatant was then transferred to a fresh tube and 
aliquoted before being stored at -20°C.  
 
2.4.10 Bicinchoninic Acid (BCA) Assay 
 
Protein extracts were quantified using a DC Protein Assay kit (Bio-Rad). This 
is a colorimetric assay that can quantify proteins after they are solubilised in 
detergent. The experiment relies on the reaction of protein samples with alkaline 
copper tartrate solution and Folin reagent. Samples first react with copper tartrate 
and then reduce Folin reagent by the loss of 1-3 oxygen atoms, this creates several 
reduced species which have a characteristic blue colour with a maximum absorbance 
of 750nm and minimum 405nm. A working solution was made by adding 20µL 
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albumin was prepared at 5 different dilutions in lysis buffer to produce a standard 
curve for each assay (See Table 2.6). 
 
 
Serial dilutions were performed starting from stock concentration of 1.43mg/mL and 
including a blank of only lysis buffer to account for background signal.  
 
 
 Protein samples were added in triplicates at 5µL to a 96-well 
microplate either neat or diluted 1:10 with lysis buffer. Protein standards were also 
added in duplicates at 5µL. 25µL working solution (reagent A + reagent S) was then 
added. 200µL reagent B (a dilute Folin reagent) was added to each well and gently 
mixed. Any bubbles that were formed were popped with a dry pipette tip. After 15 
minutes incubation at room temperature absorbance was read using a Ensight 
Perkin Elmer plate reader at 750nm. A standard curve was plotted using GraphPad 
Prism 7 and unknown values of protein samples were interpolated from the standard 
curve linear equation: y = mx + c (see Fig 2.1.) 
 
Table 2.6 Protein standard concentrations for BCA assay. 
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2.4.11 Western Blotting: Gel Electrophoresis and Transfer 
 
 Western blotting is an efficient method for measuring protein 
expression in cell lysates. After protein concentrations have been quantified the 
samples can be diluted in laemmli buffer and mixed with DTT (dithiothreitol) to aid 
denaturation of protein by reducing disufide bonds. Proteins are then separated by 
size when loaded onto an electrophoresis gel and a charge is placed on the gel. 
Proteins are then transferred from the gel to a “transfer membrane” in order to 
probe with antibodies. Blocking of the membrane prevents non-specific protein 
interactions before a primary antibody is added which binds to the protein of 
interest. A secondary antibody is then added to bind to the primary and is often 
conjugated to an enzyme e.g. horse radish peroxidase (HRP). The bands can then be 
detected using chemiluminescence substrates and a film or photo imager.  
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Figure 2.1 BCA standard curve. 
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 Once quantified, protein samples were diluted with distilled water 
and Laemmli buffer (Bio-Rad) (containing 62.5mM Tris-HCl, pH 6.8, 25% glycerol, 2% 
SDS and 0.01% Bromophenol Blue) with a reducing agent, 350mM DTT 
(dithiothreitol) (Fisher Scientific) to a final volume of 50µL. Protein samples were 
then denatured using a heat block at 95°C for 10 minutes. 10µL of Precision Plus 
Proteinä Dual Colour Standards (Bio-Rad) and 50µL of protein samples were loaded 
onto 4-20% Mini-PROTEANâ TGXä Precast Protein Gels (Bio-Rad) and placed in a 
Vertical Electrophoresis Cell (Bio-Rad) filled with 1x Tris/Glycine/SDS running buffer 
(Bio-Rad). The gels were then run at 150 volts for 45 minutes – 1 hour.  Gels were 
then transferred onto Trans-Blot PVDF membranes (Bio-Rad) using a Trans-Blotâ 
Turboä Rapid Transfer System (Bio-Rad). A mixed molecular weight pre-
programmed transfer protocol was used at 25 volts for 7 minutes.  
 
2.4.12 Western Blotting: Blocking and Probing 
 
 Transfer membranes were then placed in shallow containers filled 
with the appropriate blocking buffer (see Table) and incubated for 1 hour at room 
temperature on a plate shaker at 600rpm. Primary antibody was diluted in blocking 
buffer at the appropriate concentration (see Table 2.7.) and then incubated with the 
transfer membrane overnight at 4°C on a plate shaker at 600rpm. The blot was then 
washed with 1X TBS-T (NaCl 150mM, Tris base 20mM, 0.1% Tween-20, pH 7.6) for 
10 minutes on the plate shaker at 600rpm. This washing was repeated three times. 
The blot was then incubated for 1 hour at room temperature on a plate shaker at 
600 rpm in a blocking buffer containing the appropriate secondary antibody at the 
appropriate concentration (see Table 2.8.) The blot was then washed three times for 
5 minutes with 1X TBS-T buffer and then three times for 5 minutes with distilled 
water.  
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Details of primary antibodies and the optimised concentrations and blocking 
conditions. 
 
Details of secondary antibodies and the optimised concentrations. 
 
 
2.4.13 Western Blotting: Detection  
 
 Blots were detected using a SuperSignal West Femto Maximum 
Sensitivity Substrate (Thermo Scientific) by mixing 250µL Stable Peroxide Solution 
with 250µL Luminol/Enhancer Solution (per blot). The oxidation of luminol in the 
presence of horse radish peroxidase (HRP) and peroxide produces prolonged 
chemiluminescence when can then be visualised with a photo imaging system. The 
combined substrates are used to cover both sides of the blot and the blot is then 
placed in transparent plastic film for detection using a Gel Doc XR+ Gel 
Documentation System (Bio-Rad).  
 
Table 2.7 Western blotting primary antibodies. 
Table 2.8 Western blotting secondary antibodies. 
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2.4.14 Western Blotting: Optimisation 
 
Antibodies were optimised by first using any recommended 
concentrations or conditions from the manufacturers. Conditions were then 
optimised to reduce non-specific signal by changing the blocking buffer from 
3% BSA to 1-5% skimmed milk. Primary antibodies were then also titrated to 
find an optimal concentration. In some cases, denaturing temperatures were 
also changed but this rarely improved antibody performance. The secondary 
antibodies were kept at a constant concentration throughout all optimisation 
experiments.  
 
 
2.4.15 CGRP (Human) Fluorescent Immunoassay 
 
 
 Levels of CGRP peptide were measured in conditioned media of PC3 cells 
using a fluorescence enzyme immunoassay (EIA) kit (Phoenix Pharmaceuticals). First, 
2 x 105 PC3 cells were plated in 6 well plates and left to adhere for 24 hours in an 
incubator at 37°C. The cells were then washed once with 500µL PBS and 1% RPMI 
was added for another 24 hours. This conditioned media was then collected and 
treated with Halts protease inhibitor cocktail (Thermo Fisher) and stored at -80°C. 
The principle of the immunoassay uses an immunoplate pre-coated with a secondary 
antibody with blocked non-specific binding sites. First, 50µL of either sample, 
standard peptides or a positive control (CGRP peptide) were mixed with 25µL of the 
anti-CGRP primary antibody and incubated at 4°C overnight. The fc fragment of the 
primary antibody binds to the secondary antibody on the pre-coated immunoplate 
and any unbound material was then removed with four washes of 300µL assay 
buffer. 25µL of biotinylated peptide was then added to the plate and incubated for 
1.5 hours on a shaker (400 rpm) at room temperature. The primary antibody has a 
biotinylated Fab fragment that is competitively bound by both the biotinylated 
peptide and peptide standard or targeted peptide in the samples. 
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 After four washes with 300µL assay buffer, 100µL of streptavidin-
horseradish peroxidase (SA-HRP) was added to each well. The biotinylated peptide 
then interacts with SA-HRP which then catalyses the substrate. The plate was then 
read using an Ensight plate reader (Perkin Elmer) at 340nm excitation and 470nm 
emission wavelengths. The intensity of the fluorescent signal generated is inversely 
proportional to the amount of peptide in standard solutions or samples. This is 
because competitive binding of the biotinylated peptides with the standard or 
sample peptide to the primary antibody. A standard curve of known concentrations 
(see Fig 2.2) of CGRP peptide was generated and unknown concentrations of the 
conditioned media samples were extrapolated.  
 
 
 
 
 
 
 
 
 
 
 
 
Standard solutions were generated using serial dilution of stock concentration 100 
ng/mL and diluted with 1X assay buffer.  
 
Figure 2.2 CGRP immunoassay peptide standard concentrations. 
 53 
 
Figure 2.3 CGRP immunoassay standard curve. 
Unknown concentrations of CGRP in PC3 conditioned media was extrapolated from 
the standard curve. Fluorescence intensity is inversely proportional to the level of 
CGRP peptide.  
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2.4.16 cAMP LANCE Ultra TR-FRET 
 
 To measure cAMP activity in PC3 cells the LANCE Ultra cAMP assay (Perkin 
Elmer) was used. This is a time-resolved fluorescence resonance energy transfer (TR-
FRET) 
 
 
immunoassay which measures cAMP produced after modulation of adenylyl cyclase 
activity by GPCRs. The principle utilises the competition between a europium (Eu) 
chelate-labelled cAMP tracer and sample cAMP for binding sites on cAMP-specific 
monoclonal antibodies labelled with a ULight dye. When the Eu-labelled cAMP tracer 
binds to these antibodies a light pulse at 320-340nm excites the Eu molecule. The 
energy emitted by the excited Eu molecule is transferred by FRET to ULight 
Figure 2.4 LANCE Ultra cAMP assay principle. 
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molecules on the antibodies themselves, which in turn emit light at 665nm (see Fig 
2.4.)  
 
 To determine the optimal cell number and stimulation conditions, forskolin 
dose response curves were generated (see Fig 2.5.) Forskolin is a cell permeable 
diterpernoid isolated from the Indian Coleus plant and can activate adenylyl cyclase 
producing intracellular cAMP. cAMP standards were also used to generate dose 
response curves to optimise stimulation conditions (see Fig 2.6.) It was found that 
250 PC3 cells per well produced a curve that covers the most dynamic range 
compared with the cAMP standard curve. This suggests that the cell density is giving 
the highest signal to background ratio, calculated using maximal signal (untreated 
cells) and the minimal signal obtained with a saturating concentration of forskolin 
(fully activated cells). cAMP standard dose response curves showed the optimal 
stimulation buffer which are shown in Table 2.7. 
 
Dose response of Forskolin on PC3 cells to optimise cell number. 
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Figure 2.5 Forskolin dose response. All values are mean ± SEM, n=3.  
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Serial dilutions of ligands or forskolin for each assay were made first (See 
Tables 2.9 & 2.10) in stimulation buffer. Siliconized pipette tips were used at all times 
in the preparation of ligands or forskolin. Blanks of buffer alone were added to 
untreated cells to allow measurement of background signal. These were then 
transferred to a white opaque 384 microtiter plate (5µL per well) and centrifuged at 
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Figure 2.6 Dose response of cAMP standards. All values are mean ± SEM, n=3. 
Figure 2.7 cAMP stimulation buffer recipe. 
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300 x G for 1 minute. Cells were either used live or from -80°C frozen aliquots and 
counted using methods described previously. Overexpressing (OE) cell lines were 
used as positive controls, either expressing CGRP or AM and their receptor 
subcomponents (RAMP1-3 and CLR). 2,500 OE cells were added per well 250 PC3 
cells were added per well as was optimized previously. Cell suspensions were made 
in stimulation buffer and volumes of 5µL per well were added on top of ligand or 
forskolin dilutions. Plates were then centrifuged at 300 x G for 1 minute and 
incubated at room temperature for 30 minutes.  
 
 
Forskolin serial dilutions in stimulation buffer ranging from 1x10-4 to 1x10-9 final 
concentration. Dilutions were made up 2X and then added to cell suspension 1:1.  
 
 
 
Table 2.9 cAMP forskolin concentrations. 
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A working solution containing the 4X Eu-cAMP tracer was prepared by 
making a 1:50 dilution of Eu-cAMP tracer stock solution in cAMP detection buffer. 
4X ULight anti-cAMP working solution was prepared by making a 1:150 dilution of 
the ULight anti-cAMP stock solution in cAMP detection buffer. Both these working 
solutions were prepared in the dark and stored in foil covered tubes until use. After 
the cells were incubated with ligand or forskolin, 5µL of Eu-cAMP tracer working 
solution was added to each well and the plate was centrifuged at 300 x G for 1 
minute. Then 5µL ULight anti-cAMP working solution was added to each well and 
the plate was centrifuged at 300 x G for 1 minute and then incubated at room 
temperature in the dark for 1 hour. After incubation, the plate was read using an 
Ensight multimode plate reader (Perkin Elmer) under the conditions described in 
Table 2.11. 
 
 
Ligand serial dilutions in stimulation buffer ranging from 1x10-6 to 1x10-11 final 
concentration.  
 
 
Table 2.10 cAMP ligand concentrations. 
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  Table 2.11 Ensight plate reader settings for cAMP assays. 
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 Results 
 
2.5.1 Endpoint PCR  
 
cDNA samples taken from PC3 cells, including reverse transcription (RT) 
negative controls were amplified using endpoint PCR with GAPDH (housekeeping) 
primers to check RT negative controls for genomic DNA contamination. These 
samples were then used to check for the expression of RAMP1, 2, 3, CLR and AM. 
Reverse transcription negative controls showed no clear bands indicating no DNA 
contamination (see Fig 2.8.)  
 
cDNA samples taken from PC3 cells amplified using endpoint PCR and GAPDH primers 
(354 bp). Reverse transcription negative controls show no bands, indicating no 
genomic DNA contamination.  
 
PC3 cDNA samples were then amplified using primers designed for RAMP1, 
2, 3, CLR and AM (see Table 2.3.) After experimental repeats, PC3 samples showed 
bands for all targets and RAMP1-3, CLR and AM (see Fig 2.9). Negative controls were 
used to assess environmental contamination, these reactions contained nuclease 
free water instead of a DNA template and did not show any bands. Endpoint PCR 
products were then analysed using Sanger sequencing to validate correct target 
amplification. All targets were successfully sequenced and matched correctly to NCBI 
database sequences using Basic Local Alignment Search Tool (BLAST) (for RAMP1 as 
an example see Fig 2.10 or Appendix for RAMP2, 3, CLR and AM). 
 
Figure 2.8 Endpoint PCR GAPDH. 
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PC3 cDNA samples amplified using endpoint PCR and primers targeting RAMP1 
(193bp), RAMP2 (256bp), RAMP3 (227bp), CLR (302bp) and AM (276bp). All targets 
showed visible bands at different levels of intensity when repeated three times.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.9 Endpoint PCR RAMPs 1-3, CLR and AM. 
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(A) Sanger sequence for RAMP1 analysed using 4Peaks software shows 78% accurate 
base calling. Background noise found 1-20bp and 330-380bp, target size = 193bp. (B) 
Screenshot of Sanger sequence for RAMP1 aligned with NCBI NM_005855.3 RAMP1 
mRNA sequence. 96% identity match was found.  
 
Figure 2.10 RAMP1 sanger sequencing. 
 63 
 
2.5.2 Western Blot 
 
Expression of RAMP1, RAMP2, RAMP3 and CLR total protein was measured 
by Western Blotting. PC3 protein was extracted and quantified using a BCA assay 
(see Section 2.4.10) before probed with different target antibodies including a 
vinculin loading control (see Section 2.4.11-13.) After visualisation using a 
chemiluminescence substrate, bands were detected in all targets at the predicted 
monomer size. RAMP1 was detected at ~17kDa, RAMP2 at ~20kDa, RAMP3 at 
~28kDa and CLR was detected at ~55kDa (see Fig 2.11.)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Western blot on PC3 total protein extracts to measure RAMP1 (17kDa), RAMP2 
(20kDa), RAMP3 (28kDa) and CLR (55kDa) expression (n = 3). Vinculin was used as a 
positive control.  
 
 
2.5.3 CGRP Fluorescent Immunoassay 
 
 Conditioned media from PC3 cells was tested for levels of CGRP peptide using 
a fluorescent immunoassay. Concentrations were interpolated from a standard 
curve of known concentrations of CGRP peptide. Positive controls (CGRP peptide 
alone) ensured quality control of all assays. Three separate samples of PC3 
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Figure 2.11 Western blotting RAMP1-3 and CLR. 
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conditioned media were tested with 1% RPMI used as a negative control and to 
account for any background signal. Results show that PC3 conditioned media 
contained on average 35pg/mL of CGRP, 1% RPMI media alone had consistent results 
of only 1pg/mL (see Fig 2.12). The positive control was estimated to contain 40-120 
pg/mL CGRP and results show an average of 131 pg/mL confirming the quality of the 
immunoassay.  
 
 
Figure 2.12 CGRP fluorescent immunoassay. 
Levels of CGRP were measured using a fluorescent immunoassay. Levels of CGRP 
were calculated to be 35 pg/mL in PC3 conditioned media compared with 1 pg/mL in 
1% RPMI alone. Positive controls were found to contain 131 pg/mL CGRP. All values 
are mean ± SEM, n=3. P<0.05, (Students unpaired t-test).  
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2.5.4 Cyclic AMP Assays 
 
To assess whether CGRP or AM receptors are functional in PC3 cells, LANCE 
Ultra cAMP assays were used to detect changes in intracellular cAMP levels following 
stimulation with either CGRP or AM ligand and forskolin was used a positive control. 
It was found that PC3 cells when stimulated with forskolin always produce an 
increase in cAMP levels that was detected in a dose dependent manner (see Fig 
2.13). However, when stimulated with either CGRP or AM, PC3 cells did not show 
any increases in intracellular cAMP (see Fig 2.15 and 2.16). PC3 cells were stimulated 
also with Amylin as this also uses RAMP1 along with calcitonin-like receptor (CTR) as 
its functional receptor, however no changes in cAMP levels were detected (see Fig 
2.16). 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
         All values are mean ± SEM, n=3. 
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Figure 2.13 Forskolin dose response on PC3 cells.  
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  All values are mean ± SEM, n=3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
    All values are mean ± SEM, n=3.  
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Figure 2.14 Dose response of CGRP stimulation on PC3 cells.  
Figure 2.15 Dose response of AM stimulation on PC3 cells.  
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       All values are mean ± SEM, n=3.  
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Figure 2.16 Dose response of Amylin stimulation on PC3 cells.  
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 Discussion 
 
 The PC3 cell line was chosen for this investigation as it a highly invasive cell 
line that mimics aggressive stages of prostate cancer both cellular and mouse 
models. When injected subcutaneously cells develop tumours in nude mice and can 
metastasise after intracardiac inoculation to tissue specific sites such as bone. This 
is a characteristic of prostate cancer that can significantly affect a patient’s prognosis 
and therefore to understand the mechanisms behind in metastasis to bone, this cell 
line may be of consequential use. In order to study the effects of CGRP and AM in 
prostate cancer it was therefore important to first characterise this cell line and 
check for expression of both ligand and receptor components at an mRNA and 
protein level.  
 
 RNA was first extracted from PC3 cells and converted to cDNA to check 
expression of RAMPs 1-3, CLR and AM using RT-PCR. GAPDH housekeeping gene was 
first used as a control to check successful cDNA synthesis and lack of genomic DNA 
contamination. All targets were successfully amplified showing clear expression in 
varying intensities. RAMP1 was consistently expressed at a higher level in PC3 cells 
when compared with RAMP2 and RAMP3 but both CLR and AM were expressed at 
high levels across all experimental repeats (see Fig 2.9) All amplicons were 
sequenced using Sanger sequencing technique to show the correct target sequence 
was amplified (see Fig 2.10.) Sanger sequences were aligned with NCBI BLAST and all 
sequences showed at least 90% match with correct targets. This shows that 
components of both the CGRP and AM receptor are expressed at a mRNA level in 
PC3 cells.  
 
 To measure protein levels of RAMPs, CLR and AM, antibodies targeting these 
proteins were used for western blotting. The range of antibodies available for these 
targets is limited and those that are accessible often bind non-specifically or at 
unexpected molecular weights. It is therefore hard to draw solid conclusions from 
the results generated using these antibodies, without a high number of experimental 
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repeats. Results shown are examples of the most consistently observed. RAMPs 1-3 
and CLR were measured at a protein level by Western blotting using PC3 cell lysate 
protein extracts. Antibodies targeting AM were not available to test expression with 
Western blotting. An antibody targeting vinculin housekeeping gene was used as a 
positive control for the technique and was found at the correct size (125kDa) All 
targets were found to be present when stained with the appropriate antibodies at 
the expected size (RAMP1 = 17kDa, RAMP2 = 20kDa, RAMP3 = 28kDa, CLR = 55kDa). 
RAMP3 has an actual weight of 17kDa however manufacturers suggest its monomer 
molecular weight is 28kDa, it therefore uncertain whether this antibody is targeting 
RAMP3. Nevertheless, western blot data suggests that all RAMPs and CLR are 
expressed at a protein level in PC3 cells (see Fig 2.11). Presence of CGRP in PC3 
conditioned media was measured as not antibodies for western blotting could be 
optimised. Levels were found to be 35 pg/mL suggesting that PC3 cells do secrete 
CGRP (see Fig 2.12).   
 
 The effect of stimulation with CGRP or AM on PC3 cells was measured using 
LANCE Ultra cAMP assay to detect changes in intracellular cAMP. Forskolin produces 
direct stimulation of adenylyl cyclase and is used as a positive control for assay 
conditions. Stimulation with forskolin on PC3 cells consistently produced increases 
in intracellular cAMP in a dose dependent manner. This therefore shows that assay 
conditions were optimised correctly. However, when stimulated with CGRP or AM, 
doses ranging from 1x10-6 to 1x10-11 no changes in cAMP levels were seen in PC3 
cells. Amylin is another member of the calcitonin peptide family that can signal 
through RAMP1 and CTR, it was therefore also used to stimulate PC3 cells however 
no effect was seen either. This may suggest that although PC3 cells express the 
different components of CGRP and AM receptors at both mRNA and protein level, 
they do not have functional receptors in vitro. Alternatively, these receptors may be 
functioning through a cAMP-independent mechanism as has been seen previously 
in the literature [83]. Prostate cancer cell lines have been found to respond to AM 
stimulation through alternative pathways such as the MAPK signalling pathway, 
most specifically activating ERK1/2. It may be therefore that alternative methods are 
required for validating the effect of CGRP and AM stimulation on PC3 cells. 
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 It has therefore been shown that PC3 cells express all components of CGRP 
and AM receptors (RAMP1, RAMP2, RAMP3, CLR) at both an mRNA and protein level. 
To investigate the effect of these different receptor components in PC3 cells, a 
knockout cell line will be generated using CRISPR Cas9. The consequences of their 
deletion will then be measured in vitro and in vivo.  
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 CHAPTER 3: GENERATION OF 
CRISPR/CAS9 KNOCKOUT IN PC3 CELLS 
  
 Introduction 
 
In order to study the mechanistic role of CGRP and adrenomedullin in 
prostate cancer it is important to look at their individual receptor components: the 
calcitonin receptor (CLR) and three receptor activity modifying proteins (RAMPs 1-
3). To determine the role of these proteins, we can observe any functional 
consequences of RAMP gene deletion in prostate cancer cell lines. Current 
techniques in gene editing can be categorized into either gene knockdown (reduced 
expression of a gene) or knockout (deletion of a gene). The former is often achieved 
using short hairpin or silencing RNA, known as RNA interference (RNAi) [141]. These 
short sequences target transcripts and cause destabilization, often resulting in a 
transient reduction of gene expression. Although a gene may only be expressed at 
low levels when targeted with RNAi it can often still have functional consequences 
within the cell. This leads to many disadvantages when using this technique 
especially when drawing conclusions on the role of the gene of interest. 
Nevertheless, deletion of essential genes can lead to lethality in both cellular and 
animal models. Therefore, RNAi reduction of gene expression has its advantages 
when aiding the investigation of particular targets.   
 
An example of this has been recently documented when investigators found 
a possible role for a gene called MELK (Maternal Embryonic Leucine Zipper Kinase). 
RNAi studies suggested that the gene played an important role in cancer and this 
publication led to ongoing clinical trials testing a MELK inhibitor. However, after 
using a gene knockout technology (known as CRISPR/Cas9), to completely delete the 
MELK gene, it was found that cancer cells were not at all affected by the deletion. 
Further testing of the MELK inhibitor using MELK KO cell lines indicated that the 
inhibitor was acting on other cellular targets. RNAi techniques have a high chance of 
nonspecific targeting as short sequences are likely to occur elsewhere in the 
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genome.  These findings led authors to suggest that in future knockout techniques 
should be used to better identify cancer-dependent genes or drug targets before 
clinical trials can begin [142]. 
 
To create a gene knockout, many technologies exploit cellular repair 
mechanisms. The first is non-homologous end joining (NHEJ) which occurs if no DNA 
template is provided and can lead to inactivating mutations. The second repair 
pathway is homology-directed repair (HDR) which uses template DNA to repair the 
cell. It has been reported that following endonuclease-generated double-stranded 
breaks (DSBs) in mammalian cell DNA, homology-directed repair will account for 30-
50% of repair events [143]. This method of using cellular repair mechanisms and 
specific endonucleases enables precise editing by introducing point mutations at any 
given locus of the gene. An early example of gene knockout technology is the 
discovery of zinc finger nucleases (ZFNs) which were initially described in 1982 [144]. 
Zinc fingers (small protein motifs that require zinc ions for stable folding) are fused 
with FokI nucleases that recognise two adjacent sites and cleave single stranded 
DNA. Synthesis of ZFNs can be time consuming and identifying suitable pairs for 
specific loci is challenging.  
 
Despite the disadvantages of ZFNs, this technology was a popular form of 
genetic editing for almost 30 years before another technique was discovered using 
endonuclease-induced DSBs. Transcription activator-like (TAL) effectors are proteins 
secreted by Xanthomonas bacteria which then enter the nucleus of plant cells to 
activate expression of specific genes [145, 146]. The modular design of TAL effectors, 
including DNA binding proteins has been exploited to create customizable gene 
targeting proteins, now known as TALENS (see Fig 3.1). These proteins, like ZFNs, are 
fused with a FokI endonuclease but unlike ZFNs, synthesis of TALENs can be achieved 
in much shorter times [147]. TALENs have therefore exceeded ZFN technology and 
have become a ubiquitous tool for genetic editing in both cellular and animal models.  
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Figure 3.1 Diagrams of gene editing techniques 
 (A) Zinc finger nucleases consist of a zinc finger fused with a FokI endonuclease that 
cleave single strands of DNA at two different sites. (B) TALENs consist of a TAL 
effector and customizable DNA binding proteins also fused with a FokI endonuclease. 
(C) CRISPR-Cas9 consists of a guide RNA 20bp sequence with a tracer RNA to complex 
with a Cas9 endonuclease to induce double stranded DNA breaks.  
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The CRISPR (Clustered Regularly Interspaced Short Palindromic 
Repeats)/Cas9 system differs from these previous techniques as it uses a different 
endonuclease, known as Cas9. Cas9 complexes with a “guide” RNA (gRNA) sequence, 
homologous to the target locus. In the presence of the gRNA protospacer adjacent 
motif (PAM) site Cas9 is activated and induces a double stranded break in the DNA 
(see Fig 3.1). PAM sites always consist of an “NGG” sequence, which will occur often 
across the genome This makes the CRISPR/Cas9 system easy to customise as many 
different loci can be simultaneously targeted.  CRISPR/Cas9, like ZFNs and TALENs, 
exploits cellular repair mechanisms but the use of gRNA sequences ensures more 
specific editing and reduces cost and time. It is therefore a valuable technique for 
genomic engineering, including high-throughput techniques as multiple loci may 
targeted at once. 
 
CRISPR sequences were first identified in 1982, when they were first 
identified in the E. coli genome [148]. The function of these sequences was not fully 
understood until 2007, when researchers hypothesised that CRISPR sequences and 
Cas (CRISPR associated) genes were used in prokaryotes as an adaptive immune 
system. It was found that Cas proteins cut foreign DNA sequences into smaller 
fragments and then incorporate them into the CRISPR sequence. Cas proteins can 
then express the CRISPR loci to recruit CRISPR RNAs (crRNAs) which guide Cas 
endonucleases to bind to the foreign DNA and cleave it, destroying the invasive 
material (see Fig 3.2) [149]. This discovery of an adaptive immune system was then 
used by Jinek et al. to exploit CRISPR/Cas9 targeted DNA cleavage in vitro [150]. The 
first articles published using CRISPR/Cas9 genome editing were in cell culture. This 
included using Cas9 to induced double stranded breaks which were then repaired by 
NHEJ, creating indel (insertion or deletion) mutations in the sequence. Alternatively, 
it was also shown that CRISPR/Cas9 could be used in combination with a “donor 
DNA” sequence, complimentary to the site of interest. This donor DNA sequence 
could then be inserted into the breaks caused by Cas9 during homology-direct 
recombination (HDR). These insertions can be customised to include stop codons, 
expression cassettes, antibiotic resistance and even LoxP sites [151, 152].  
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CRISPR sequences and Cas proteins are targeted with CRISPR RNAs (crRNAs). Foreign 
material is first recognised and incorporated into CRISPR sequences. crRNAs are 
synthesised and are complimentary to the foreign DNA. crRNAs then complex with 
Cas proteins to target invading DNA sequences for cleaving.  
 
CRISPR/Cas9 with homology directed repair (HDR) has many advantages over 
previous CRISPR/Cas9 systems. The use of short gRNA sequences alone, relies on 
Non-Homologous End Joining (NHEJ) which can give unexpected results. For 
example, any indel mutations that cause a frameshift in the genomic sequence have 
a 1 in 3 chance of still being in the correct frame and coding for the same amino 
acids. This technique therefore has a high failure rate of generating successful 
knockouts. Previous reports using Surveyor or T7 endonuclease assays have 
reported indel mutation rates of 20-30%. These endonucleases can detect edited 
DNA strands and cleave the fragments producing two smaller products whereas 
unedited DNA strands remain intact. After amplifying these products with PCR, it is 
possible to visualise with gel electrophoresis and determine rates of successful indel 
mutations.  An additional drawback of this CRISPR method is that the gRNA sequence 
is likely to occur elsewhere in the genome apart from the target site. Consequently, 
off-target cutting of Cas9 can lead to unknown edits and so any functional changes 
Figure 3.2 Prokaryote adaptive immunity. 
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may not be due to the gene of interest but in fact a result of an off-target gene 
knockout. Off target effects can be minimised by designing “homology arm” 
sequences that are complimentary to the gene of interest and can include up to 
1,000 nucleotides. These complimentary sequences are less likely to occur 
elsewhere from the target site, minimising the likelihood of off target effects. When 
Cas9 has induced a double stranded cut at the target site, cells will readily repair the 
DNA using homology arm sequences provided via the HDR process. This technique 
also has the advantage of customisable DNA donor templates that are inserted 
during HDR. For example, fluorescence markers and antibiotic resistance genes can 
be incorporated into the gene aiding validation of gene knockouts by antibiotic 
selection and fluorescence cell sorting (FACS). These insertions can also include stop 
codons to ensure transcription is halted at the target site. 
 
There are currently no reports of knockouts generated in a cell line for either 
RAMP1, 2 or 3. Authors have reported a RAMP1 knockdown in PC3 cells, however 
only to link it as a target gene of a transcription factor named NKX3.1 [105]. A RAMP 
knockout cell line would therefore be an extremely useful tool for investigating the 
role of these proteins in prostate cancer. The CRISPR/Cas9 HDR system was selected 
as an appropriate technique to create knockouts for RAMPs 1-3 in PC3 cells, in order 
to investigate the role of these receptor subcomponents in prostate cancer. HDR 
plasmids were designed to target each gene with two “homology arms” located 
either upstream or downstream from the gRNA targeted sequence. These homology 
arms were around 800bp and were delivered into the cell in a plasmid. The HDR 
plasmid also contained a “donor” sequence for insertion into the double stranded 
break, containing an RFP marker, puromycin resistance and a stop codon. Large 
plasmids can be difficult to transfect, frequently having quite a low transfection 
efficiency. To accommodate this, three separate HDR plasmid with different gRNA 
locations were used simultaneously to increase the chances of a successful RAMP 
knockout. To validate the knockouts, cells were then selected with puromycin 
antibiotic to select positively transfected cells and then sorted using FACS into single 
cell colonies. Growing clonal colonies ensures that the entire cell population has a 
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RAMP gene knockout, as any wild type cells may outgrow the knockout cells and 
therefore increase RAMP expression of the cell population. 
 
After sorting cells into clonal populations, they were then tested for 
successful deletion of the RAMP gene. This was first characterised using endpoint 
PCR as this is a robust method that will clearly show changes to mRNA sequences 
when comparing with wild type PC3 cells. Any successful RAMP knockouts found 
were then selected for further validation using qPCR to quantify RAMP expression 
levels. Analysis of protein extracts from knockout cells by Western blot should 
determine successful RAMP deletion. However, antibodies for these proteins are not 
often reliable, giving unexpected band sizes as described in the previous chapter. 
 
 Hypothesis:  
 
1. CRISPR/Cas9 can be utilized to generated RAMP1-3 knockouts in a PC3 cell 
line.  
 
 Research Aims: 
 
1. To determine the effectiveness of the CRISPR/Cas9 technique in creating 
RAMP1-3 knockouts in a PC3 cell line.  
 
2. To validate successful CRISPR/Cas9 knockouts using PCR, Sanger sequencing 
and western blotting  
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 Methods & Materials 
 
 
3.4.1 Transfection of CRISPR Vectors into PC-3 Cells 
 
PC3 cells were grown and seeded into 6 well plates as described previously 
(Chapter 2, Section 2.4.1-3) at a density of 1.5x105 in order to be 60% confluent on 
the day of transfection. After 24 hours cells were washed with PBS and 2mL 
PenStrep-free media was added with RS-1 (4-Bromo-N-(4-bromophenyl)-3-
[[(phenylmethyl)amino]sulfonyl]benzamide) (Tocris Bioscience) at a concentration 
of 7.5μM. A mix containing 125μL OptiMEM media (Gibco) and 7.5μL Lipofectamine 
3000 (Thermo Fisher) was added to a mix containing 125μL OptiMEM and 5μL P3000 
and 2.5μg DNA. Mixtures were then incubated at room temperature for 10 mins 
before being added to the cells. Cells were co-transfected with a RAMP1/2/3 HDR 
plasmid and a RAMP1/2/3 CRISPR/Cas9 KO plasmid (Santa Cruz Biotechnology) (see 
Fig 3.3). Negative control cells were transfected with PBS alone. 24 hours after 
transfection, Scr7 pyrazine (Tocris Bioscience) was added at a concentration of 1μM 
in 10% RPMI media. 48 hours after transfection cells were selected with 2ug/mL 
puromycin for 5-7 days before being sorted into single cell colonies using FACS. This 
dose of puromycin has been previously reported when selecting clones in PC3 cells 
[153]. 
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Each HDR plasmid contained a 5’ and 3’ homology arm, complimentary DNA to the 
gene of interest. An expression cassette was also contained within this plasmid for 
insertion into the gene following double strand breaks caused by Cas9 endonuclease. 
This cassette contained an RFP marker, a puromycin resistance gene, a stop codon 
and LoxP sites. The CRISPR/Cas9 plasmid contained the gRNA situated in between 
each homology arm, the Cas9 endonuclease and a GFP marker.   
 
 
3.4.2 Fluorescence-Activated Cell Sorting of CRISPR Cells 
 
After transfection and selection of PC3 cells with CRISPR constructs targeting 
RAMPs 1-3, they were sorted into single cells using RFP fluorescence as a marker. All 
cell populations were grown in 6 well plates until 70% confluence and then detached 
and suspended in 10% RPMI media (see Chapter 2, Section 2.4.1-2). Cell samples 
were then processed by the Flow Cytometry Core Facility technician and sorted into 
96 well plates using a FACSAria IIu (BD Biosciences).  Cells were collected in PC3 
conditioned medium and grown into colonies for knockout screening. Single cells 
Figure 3.3 CRISPR/Cas9 HDR system. 
 80 
were monitored by taking bright field images using Ensight plate reader (Perkin 
Elmer).  
 
3.4.3 Endpoint Polymerase Chain Reaction  
 
Endpoint PCR was completed using previously described Methods and Materials (see 
Chapter 2, Section 2.4.6). After validating successful CRISPR clones, primers were 
redesigned to span the full-length mRNA of RAMP1 for further confirmation (See 
Table 3.1.) 
 
 
Table 3.1 Endpoint PCR primers for RAMP1 CRISPR validation. 
 
 
3.4.4 Reverse Transcription for Quantitative Polymerase Chain Reaction (qPCR) 
 
 RNA was extracted from clonal colonies (see previously described Methods) 
and converted to cDNA using a Precision nanoScriptä 2 Reverse Transcription kit 
(PrimerDesign). Oligo-dT primers were used to bind to polyA tail of mRNA (see Table 
3.2.) Annealing was completed at 65°C for 5 minutes and then samples were 
immediately cooled on ice. 
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 10µL RT reactions were made up (see Table 3.3.) and added to 10µL samples 
on ice. Reverse transcription negative controls were run for each sample by 
excluding nanoScript2 enzyme from the reaction mix. Each sample was then briefly 
vortexed followed by a pulse spin and incubated at 42°C for 20 minutes followed by 
heat inactivation at 75°C for 10 minutes. Incubations were done using a ProFlex PCR 
thermocycler (Life Technologies). cDNA samples were stored at -20°C until use.  
 
 
 
 
 
 
 
 
 
Table 3.2 cDNA synthesis primer annealing reaction. 
Table 3.3 cDNA synthesis total reaction 
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3.4.5 Quantitative Polymerase Chain Reaction (qPCR) 
 
 Primers were designed to target RAMP1 mRNA by PrimerDesign (see Table 
3.4) and mixed with DoubleDye hydrolysis probes labelled with a 6-
carboxyfluorescein (FAM) reporter (PrimerDesign). Primer/probe mixes were then 
added to a PrecisionPLUS Mastermix (PrimerDesign) with a ROX reference dye (see 
Table 3.5.) A GENORM reference kit was used containing primer/probes targeting six 
different reference genes including: ACTB, B2M, UBC, YHWAZ, ATP5B and RPL13A.  
 
 
 
 
 
 
 
 
 
 
 
 
 
cDNA samples were diluted with RNase/DNase free water to a concentration 
of 5ng/µL and 2.5µL of each sample was added to wells on a clear plastic 384 PCR 
plate in triplicates. Reverse transcription negative controls were tested using 
reference gene primers for genomic DNA contamination. 7.5µL of each master mix 
was then added to each well on top of cDNA samples. The PCR plate was then 
centrifuged at 1,000 x rpm for 1 minute and inserted into an Applied Biosystems 
Table 3.4 qPCR primers designed to target RAMP1. 
Table 3.5 qPCR Mastermix recipe. 
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HT7900 thermocycler. Reactions were run using amplification protocols detailed in 
manufacturers guide (see Table 3.6). qPCR data was analysed using SDS 2.0 software 
and curves were plotted on a linear scale. Thresholds were set at the linear phase of 
the curve and ct values recorded for each sample. RAMP1 KO and PC3 samples were 
then compared using the 2-^ [DD] ct method.  
 
 
 
 
 
3.4.6 Genomic DNA Polymerase Chain Reaction 
 
 
 Primers were designed spanning from the EF1-alpha promoter of the HDR 
CRISPR construct to sequences complimentary to RAMP1 exon 2, upstream from the 
design homology arm (See Fig 3.4) to validate correct targeting of the construct. 
Diagram illustrating positions of primers targeting RAMP1 DNA editing by 
CRISPR/Cas9 and insertion of expression vector into Exon 2. 
 
 
 
 
 
Table 3.6 qPCR amplification protocol. 
Figure 3.4 Genomic PCR primers. 
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3.4.7 Genomic DNA Extraction  
 
 Genomic DNA was extracted from wild type PC3 and RAMP1 knockout (KO) 
cells using methods previously described to count 5 x 104 cells suspended in 16µL 
PBS (See Chapter 2, Section 2.4.3). This cell suspension was then mixed with 4µL 5X 
microLYSIS-Plus buffer (Microzone) and samples were then extracted using a ProFlex 
PCR thermo cycler (Life Technologies) following the protocol detailed in the 
manufacturer’s instructions (See Fig 3.5.) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.4.8 Genomic PCR Reaction 
 
 DNA extracts were then amplified using primers targeting RAMP1 exon 2 and 
the EF1-alpha promoter of the vector insert (see Fig 3.4) and positive control primers 
targeting RAMP2 (see Table 3.7) Positive controls primers validated successful 
genomic DNA extraction from cell samples. All PCR reactions were completed using 
a Phusion High-Fidelity polymerase, a polymerase more suited to amplifying GC-rich 
and large PCR products. The manufacturers PCR reaction recipe (see Table 3.8) was 
optimised for annealing temperatures and DMSO was added to reduce amplification 
Figure 3.5 Thermal cycler protocol for genomic DNA extraction. 
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of non-specific targets. PCR products were then validated using Sanger sequencing 
as described previously (see Chapter 2, Section 2.4.8). 
 
 
Primers were designed to target RAMP1 exon 2 upstream from designed homology 
arms and the EF1-alpha promoter of the vector expression cassette inserted into the 
CRISPR site.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.7 Genomic PCR primers 
Table 3.8 Genomic PCR recipe 
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 Results  
 
3.5.1 Transfection of PC3 Cell Line with HDR CRISPR/Cas9 Constructs 
 
 PC3 cells were first transfected with a CRISPR/Cas9 construct which is 
transiently expressed and then a homology-direct repair (HDR) RAMP1/2/3 
construct which contains donor DNA sequences complimentary to the target gene 
and an expression cassette with an RFP marker, puromycin resistance gene and stop 
codon. Transfected cells showed RFP positive colonies after 1 weeks of selection with 
2µg/mL puromycin (see Fig 3.6) in RAMP1, 2 and 3 cells.   
 
 
Figure 3.6 Transfection images. 
Bright field and RFP images of cells transfected with CRISPR constructs targeting 
RAMP1, 2 and 3.  
 
 Transfected cells were then sorted into single cell clones using FACS targeting 
RFP positive cell populations. Unstained, non-transfected PC3 cells were used as a 
negative control to draw gates on RFP positive populations (see Fig 3.7). Cells were 
sorted into 96 well plates containing conditioned media and then monitored during 
growth to validate single cell colonies (see Fig 3.8-10.) 
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3.5.2 Fluorescent activated cell sorting of CRISPR transfected cells. 
 
(A) Unstained PC3 wild type cells were used to draw RFP positive gates. (B) RAMP1 
samples had 15.4% RFP positive cells. (C) RAMP2 samples had 4.5% RFP positive cells. 
(D) RAMP3 samples had 25.3% RFP positive cells.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7 FlowJo analysis of cell sorting. 
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RAMP1 single cell clonal colonies growing after sorted using FACS in PC3 conditioned media.  
 
 
 
Figure 3.8 Bright field images of RAMP1 single cell colonies 
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Figure 3.9 Bright field images of RAMP2 single cell colonies 
RAMP2 single cell clonal colonies growing after sorted using FACS in PC3 conditioned media.  
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RAMP3 single cell clonal colonies growing after sorted using FACS in PC3 conditioned media.  
 
 
 
Figure 3.10 Bright field images of RAMP3 single cell colonies 
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3.5.3 Validation of CRISPR Clones with Endpoint PCR 
 
After clonal colonies were confluent, cells were split into another 96 well for 
RNA extraction and cDNA synthesis (see Chapter 2, Section 2.4.4). These samples 
were then validated using endpoint PCR for RAMP1,2 or 3 knockout using primers 
designed for previous characterisation of PC3 cells (see Chapter 2, Section 2.4.6). 
RAMP1 PCR showed bands at the correct height for RAMP1 for PC3 wild type 
samples and negative control cells (PBS only). Different clonal populations were 
tested for RAMP1 only two clones showed RAMP1 expression whereas up to 8 
different clones showed no PCR band (see Fig 3.12). RAMP2 clones had reduced 
viability and only 2-3 clones were grown successfully to be validated with endpoint 
PCR. All clones showed a band at the correct height for RAMP2 compared with 
positive controls (see Fig 3.13). RAMP3 clones all showed to have PCR bands at the 
correct height for RAMP3 (see Fig 3.15). 
 
PCR targeting GAPDH to validate reverse transcription negative controls for RAMP1 
and RAMP2 clones are not contaminated with genomic DNA.  
 
Figure 3.11 Endpoint PCR GAPDH for RAMP1 and RAMP2 CRISPR clones 
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PCR targeting RAMP1 shows clear bands at the correct size (476bp) in wild type PC3, 
transfection negative controls and two clonal populations, B10 and A2. No band was 
detected in clonal populations C10, D5, C1, B5, B7, B12 and A7.  
 
 
 
PCR targeting RAMP2 shows clear bands at the correct size (256bp) in wild type PC3, 
transfection negative controls and two clonal populations, D10 and C9.  
 
Figure 3.12 Endpoint PCR RAMP1 
Figure 3.13 Endpoint PCR RAMP2 
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Figure 3.14 Endpoint PCR GAPDH for RAMP3 CRISPR clones 
PCR targeting GAPDH to validate reverse transcription negative controls for RAMP3 
clones are not contaminated with genomic DNA.  
 
 
 
Figure 3.15 Endpoint PCR RAMP3 
PCR targeting RAMP3 shows clear bands at the correct size (227bp) in wild type PC3, 
transfection negative controls and all clonal populations (A2, A8, D2, B8, C6, A5, D6, 
D5 and B5.) 
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3.5.4 Validation of CRISPR Clones with Genomic DNA and Endpoint PCR 
 
Primers were designed targeting the HDR insert with a reverse primer and 
the RAMP1 gene (upstream from the homology arm) with a forward primer. PCR 
reactions with these primers were performed on PC3 wild type and RAMP1 CRISPR 
genomic DNA samples. After visualisation using gel electrophoresis, bands were only 
observed in CRISPR clones A7, C1 and B7. No bands were observed in the PC3 wild 
type reaction or the negative control (reaction without DNA template). To ensure 
that genomic DNA samples were viable, positive control primers targeting another 
gene (in this case, RAMP2) were used. These primers showed clear bands in all 
samples (see Fig 3.16).  
 
PCR using RAMP1 primers targeting the genomic region upstream from the left 
homology arm and the HDR insert. (A) Bands were observed only in CRISPR clones 
B7, C1 and A7. No bands were visible in the PC3 wildtype (WT) or negative control 
(H20). (B) Clear bands for all samples were observed when using positive control 
primers.  
 
 PCR products that were successfully amplified using RAMP1 genomic DNA 
primers were then analysed using Sanger sequencing as described previously (see 
Chapter 2, Section 2.4.8). The sequences were then aligned with the EF1-alpha 
Figure 3.16 Endpoint PCR with RAMP1 genomic DNA 
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promoter sequence from the HDR insert, the RAMP1 homology arms that were 
designed for the CRISPR construct and also the RAMP1 gene upstream from this site 
(see Fig 3.17). Successful alignments determined that the CRISPR construct had 
targeted the RAMP1 gene correctly resulting in a large insertion that would 
effectively knockout the gene. For alignment and raw sanger sequencing data see 
Appendix. 
 
Schematic diagram indicates site of CRISPR editing within exon 2 of RAMP1. 
Sequencing data alignment analysis shows RAMP1 Exon 2 with the targeting 
homology arm sequence and then an EF1-alpha promoter validating correct insertion 
of the HDR expression cassette. 
 
 
 
 
Figure 3.17 CRISPR edited RAMP1 gene. 
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Representation of the crystal structure of the RAMP1 extracellular domain shows 
unedited RAMP1 protein (highlighted green) and the site of CRISPR editing (red). 
RAMP1 protein sequence downstream of the CRISPR site (grey) may not be 
transcribed due to insertion of the HDR stop codon or mutational frameshifts.  
 
 
3.5.5 Validation of CRISPR Clones with Quantitative PCR. 
 
 
RAMP1 clones known as A7, C1, D5, B12, B5 and D4 were selected for further 
validation using quantitative PCR targeting RAMP1 mRNA. First many reference 
genes including beta-actin (ACTB), ubiquitin C (UBC) and beta-2 microglobulin (B2M), 
were measured for both wild type and CRISPR samples. ACTB was then chosen as 
the reference gene with least variation between all samples to be used for further 
investigations (see Figs 3.19 & 3.20.) Samples were then measured for both ACTB 
and RAMP1 expression and samples were compared using DD CT analysis. Ct values 
for PC3 wildtype had an average of 30, whereas all clones were found to have ct 
values of 35+ (see Table 3.9.) Analysis of these samples was performed using DD CT, 
Figure 3.18 CRISPR edited RAMP1 crystal structure 
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comparing CRISPR samples to PC3 wildtype samples and then the fold change was 
represented as a percentage of PC3 wild type expression (see Fig 3.21.) Clones A7, 
C1 and D5 were found to have expression levels of 5-10%, whereas clones B12, B5 
and D4 had expression levels of 10-30% compared with PC3 wild type samples. 
 
 
Figure 3.19 qPCR amplification plot for ACTB 
Amplification plot of all samples, PC3 wild type and RAMP1 CRISPR knockouts, 
measuring ACTB expression. Ct values had an average of 26 and threshold was set at 
0.5 DRn.  
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qPCR ACTB expression in PC3 wild type and CRISPR samples shows no significant 
differences in ct values (ANOVA P = 0.2) All values are mean ±SEM, n=3. P = 0.2, (One-
way ANOVA). 
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Figure 3.20 qPCR ACTB expression levels. 
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Figure 3.21 qPCR RAMP1 expression. 
CRISPR samples were analysed using DD CT and expressed as a percentage PC3 wild 
type RAMP1 expression. A7, C1 and D5 CRISPR samples had 5-10% RAMP1 expression 
whereas B12, B5 and D4 had levels of 10-30%. All values are mean ±SEM, n=3. P-
value = <0.0001, (Students unpaired t-test). 
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3.5.6 Levels of RAMP2 and RAMP3 mRNA in RAMP1 CRISPR Clones Measured with 
Endpoint PCR.  
 
The expression of RAMP2 and RAMP3 mRNA in RAMP1 knockout clones was 
analysed using semi-quantitative endpoint PCR (see Fig 3.22). Primers were designed 
as previously described (see Chapter 2, Section 2.4.6.)  No differences were seen in 
levels of RAMP2 or RAMP3 compared with wild type PC3 positive controls. GAPDH 
reactions were used as loading controls for gel electrophoresis to ensure band 
density was not due to incorrect loading of products.  
 
 
Figure 3.22 Endpoint PCR GAPDH, RAMP2 and RAMP3 on RAMP1 KO clones 
Endpoint PCR targeting GAPDH (326bp), RAMP2 (256bp), RAMP3 (227bp). Samples 
include wild type PC3 as a positive control for RAMP2 and RAMP3 expression 
compared with RAMP1 KO clones A7, C1 and D5.  
Table 3.9 CT values for PC3 wild type and CRISPR samples. 
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3.5.7 Validation of RAMP1 CRISPR Clones with Western Blotting 
 
RAMP1 clones were then further validated for RAMP1 protein deletion by 
western blotting of extracts from each cell type. These were compared with wild 
type protein levels and normalised to a vinculin loading control. After three 
experimental repeats, results did not show any significant difference in RAMP1 KO 
and PC3 wild type protein expression.  
 
Western blot for RAMP1 displayed bands for PC3 wild type and RAMP1 knockouts. 
Bands are also seen when overlaid with the protein standards at the same size as 
RAMP1 (17kDa). Analysis using densitometry normalised samples to vinculin and 
showed no significant differences between PC3 wild type and RAMP1 CRISPR 
samples.  
 
 
 
 
Figure 3.23 RAMP1 western blot for CRISPR knockouts. 
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 Discussion 
 
 Homology arms were designed to target each of the three RAMPs and these 
were introduced via a plasmid. This plasmid also contained an expression cassette 
which was incorporated into the cut site during HDR. PC3 cells were co-transfected 
with a CRISPR/Cas9 plasmid (containing the gRNA sequence with Cas9) and HDR 
plasmid. To encourage homology directed repair (HDR) RS-1 was used as it is an 
activator of RAD51, which in turn activates homologous recombination. This has 
been found to enhance HDR up to 5 fold and increase CRISPR-mediated “knock in” 
efficiency both in vitro and in vivo [154]. After transfection, cells were treated with 
Scr7 pyrazine, an inhibitor of NHEJ which has been found to also enhance CRISPR-
mediated HDR up to 19-fold in vitro [155]. 
 
 After transfection, RFP labelled colonies were observed and it was noted that 
cells transfected with RAMP2 CRISPR constructs appeared unhealthy with a stressed 
morphology (see Fig 3.6 & 3.9). Transfection efficiencies were shown to be below 
25% for all RAMP constructs. This was indicated by the presence of RFP positive cells 
detected during fluorescence-activated cell sorting (FACS). Large plasmids such as 
these CRISPR and HDR constructs (estimated 3-4kb) are notorious for yielding low 
transfection efficiencies [156, 157] and to alleviate this effect, three pairs of CRISPR 
and HDR constructs were used targeting three different target sites to increase the 
incidence of successful gene knockouts. All samples contained RFP negative cells 
which were assumed wild type or “unedited”. This creates a gene knockdown when 
taken together as entire population and it is likely that wild type cells will outgrow 
or dominate any CRISPR edited cells creating an overall “wild type” phenotype in the 
cell population.  
 
 To isolate knockout populations, RFP positive cells were sorted into single 
cell populations using FACS and then grown into clonal colonies. This ensures that 
any cells with a RAMP knockout grow into an entire population of gene knockouts. 
Cells were sorted into 48 single wells on a 96 well plate to increase chances of 
successful gene knockouts and to keep the number of colonies at a manageable 
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amount. As cells progressed from single cells to colonies they were imaged every 4 
days to confirm single clonal populations (see Fig 3.8-10). It was observed that after 
cell transfection and sorting, few cells that had been transfected with RAMP2 
targeting CRISPR constructs survived. Those that were sorted into single cells were 
also appeared unhealthy in their morphology and only 2-3 clones were able to be 
grown into larger populations for validation. This is an interesting observation as it 
has been reported in the literature that RAMP2 knockout mice die in utero [158]. 
This lethality in vivo was found to be due to abnormal vascular development, 
however this may not relate to cell cultures. Nevertheless, it was also found that 
when overexpressed in an endothelial cell line, RAMP2 can reduce permeability and 
cell barrier function [158]. It was found that RAMP2 is an important regulator of tight 
junction formation and therefore it could be hypothesised that its deletion would 
have harmful consequences on cell structure. It was also found that when subjected 
to H2O2 – induced damage, RAMP2 overexpressing cells displayed increased viability 
compared to controls [158]. It could then be speculated that by effecting the 
structural integrity of the cell, RAMP2 deletion could also influence cell viability. This 
may explain why low numbers of RFP positive cells were found in the RAMP2 CRISPR 
population, if knockouts were present they may not have been viable cells.   
 
 Validation of successful CRISPR RAMP knockouts was primarily performed 
using endpoint PCR. RNA samples can be taken from as little as 1,000 cells using the 
Promega Reliaprep Mini Cell RNA Extraction kit (see Chapter 2, Section 2.4.4) and 
this was therefore an efficient way of screening clonal colonies as they grew into 
larger populations. The purpose of PCR experiments was to determine presence or 
absence of the RAMP gene, not levels of expression. Therefore, GAPDH was not used 
as a loading control but as a housekeeping gene to screen cDNA samples for 
contamination, including negative controls from reverse transcription reactions. 
Samples were taken from the CRISPR populations on three separate occasions and 
then tested for RAMP mRNA using endpoint PCR. The maximum concentration of 
cDNA was synthesised from RNA extracts (100ng/µL) in order to rigorously test for 
the presence of mRNA in CRISPR samples. Samples taken from RAMP1 CRISPR cells 
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included at least 7 clones that did not show a clear band after running PCR products 
on an agarose gel (see Fig 3.12). These were then selected for further validation as 
potential successful RAMP1 knockouts. Only two clones survived to be validated for 
RAMP2 knockouts and displayed clear bands at the correct size for RAMP2 (see Fig 
3.13.) All clones tested for RAMP3 knockouts also displayed bands at the correct size, 
eliminating them as successful knockouts (see Fig 3.15).  
 
 It is unclear why no RAMP2 or RAMP3 knockouts were generated. RAMP2 
knockouts may have had such reduced viability that no cells survived after 
transfection and therefore those sorted had a non-specific integration of the 
expression cassette. As was previously described, all CRISPR/Cas9 techniques carry 
a risk of non-specific targeting, leading to off target deletions [159-161]. The CRISPR-
HDR method reduces this risk but does not eliminate it completely. However, it can 
be argued that if RAMP1 CRISPR constructs contain efficient gRNAs, then the 
presence of a double stranded cut will be most likely repaired with the HDR insert. 
Therefore, there is no obvious reason why, with an efficient gRNA, off target 
integration of the HDR insert should occur. It has been shown that off-target effects 
are often governed by the efficiency of gRNA and Cas9 activity [162]. Therefore, in 
the absence of an efficient gRNA, the expression cassette may be integrated non-
specifically or into DNA breaks present in cells that are undergoing repair at the time 
of transfection. This integration would also be encouraged due to the presence of 
HDR enhancer RS-1 and NHEJ inhibitor Scr7 pyrazine. This is a possible explanation 
for the lack of successful RAMP2 and RAMP3 knockouts but despite these 
populations containing RFP positive cells post-transfection. Nevertheless, RAMP1 
knockouts were successfully generated and these cells can be used as a research tool 
to learn more about the mechanism of RAMP1 (and its associated ligands e.g. CGRP) 
in prostate cancer. 
 
 As the presence of RFP labelled cells does not necessarily correlate with 
successful knockout, it was important to establish whether the CRISPR construct had 
targeted the RAMP1 gene specifically. To determine this, primers were placed 
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outside the RAMP1 homology arms in the RAMP1 gene and in the HDR insert or 
expression cassette that would be inserted into the gene (specifically the EF1-alpha 
promoter). It is possible that non-specific integration of the CRISPR construct made 
lead to the homology arms being inserted into the genome. Therefore, primers 
placed upstream of the homology arm in the RAMP1 gene, would only produce PCR 
products from a RAMP1 CRISPR edited gene. Wild type PC3 cells would not have the 
CRISPR HDR insert and therefore produce no PCR products. Primers targeting 
another genomic DNA site were used to determine that the genomic DNA samples 
were not degraded as this would also fail to produce PCR products (see Fig 3.16). The 
primers targeting RAMP1 revealed that three CRISPR clones had been successfully 
edited (B7, C1 and A7) and this was further validated using sanger sequencing (see 
Fig). Not all clones showed visible bands and it is possible that they were edited in 
different sites as the cells were transfected with three different CRISPR constructs. 
The primers designed span two of these gRNAs but if clones had only been edited at 
the third site, this would not be detected.  
 
 Quantitative PCR was used to measure RAMP1 expression in CRISPR samples 
when compared with wild type PC3 data using the DD CT analysis method. For all 
clones tested, cycle threshold (Ct) values were above 35. This is often considered 
background/artefact as high ct values represent a very small amount of starting 
material.  Nevertheless, when comparing these high ct values with DD CT, expression 
levels of RAMP1 are less than 10% relative to wild type PC3 in 4 out of 6 CRISPR 
clones. qPCR primers were also designed targeting RAMP2 and RAMP3, however 
these did not yield any amplification of cDNA from wild type PC3 samples. 
Nevertheless, endpoint PCR does reveal positive results for RAMP2 and RAMP3 
mRNA. To test whether deletion of RAMP1 by CRISPR/Cas9 had affected the 
expression of RAMP2 or RAMP3 in the knockout clones, endpoint PCR was 
performed. Using a housekeeping gene, GAPDH, as a loading control it was clear that 
there are no obvious differences in band density for RAMP2 or RAMP3 for any 
knockout clones when compared with PC3 wild type signal. It is therefore assumed 
that RAMP1 KO clones were not affected in RAMP2 or RAMP3 expression although 
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in the future, qPCR primers may be redesigned to confirm this result in a quantitative 
manner.  
 
Further validation of the RAMP1 knockouts requires measurements of 
RAMP1 protein expression. Western blotting found no significant differences in 
protein levels between PC3 wild type and RAMP1 KO cells. A possible explanation 
for this may be that a truncated RAMP1 protein is being expressed, as the CRISPR 
editing occurs in early in the gene sequence (see Fig 3.18). Differences in the size of 
this truncated protein may not be detectable using western blot as already the 
RAMP1 protein has a small weight of 17kDa. However, the HDR insert does include 
a stop codon which should halt protein transcription. Therefore, alternative 
explanations for this result may point to reliability of the antibody used. RAMP1 
antibodies are not easily found and can be difficult to optimise, often giving bands 
of the incorrect size. Only one anti-RAMP1 monoclonal antibody could be optimised 
producing bands at the correct size of 17kDa. However, it was also observed to bind 
to the protein standards of the ladder at the same size (see Fig 3.23). This questions 
the reliability and specificity of this antibody, especially when cells that express no 
RAMP1 mRNA display bands for the RAMP1 protein when probed with this antibody.  
 
 Taken together the findings of these experiments suggest that a RAMP1 
knockout has been successfully generated in the PC3 cell line. Endpoint PCR results 
show no visible bands in multiple RAMP1 CRISPR clones, suggesting a lack of RAMP1 
mRNA. This result was supported by qPCR data showing extremely high ct values in 
CRISPR clones, when compared to wild type PC3 samples with DD CT analysis. Sanger 
sequencing data of PCR products using genomic DNA primers also validates the 
insertion of the CRISPR HDR construct into the site targeted by RAMP1 gRNA 
sequences. Sequencing data also reveals that the construct has targeted the RAMP1 
gene specifically. Conflictingly, western blot results show RAMP1 antibody binding 
to both PC3 wild type and RAMP1 CRISPR protein samples. However, it has been 
found in these investigations that the antibody used also binds non-specifically and 
often at unpredicted sizes. Further investigation is therefore needed to determine 
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the protein expression of these RAMP1 CRISPR clones.  The deletion of RAMP1 in 
PC3 cells will shed light on the role of this gene in prostate cancer and mechanisms 
affected downstream within the cell. RAMP1 knockout cells will be tested 
functionally in vitro at first, to determine the effect of RAMP1 on the tumorigenic 
potential of the cells.  
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 CHAPTER 4: FUNCTIONAL EFFECTS OF 
RAMP1 DELETION IN PC3 CELLS IN 
VITRO. 
 
 
 Introduction  
 
 
Increasing evidence has shown that patients diagnosed with fewer prostate 
cancer metastases have a better prognosis when compared with patients with 
advanced metastatic disease [163]. The process of primary tumours metastasising 
to secondary sites involves a series of interlinked and sequential steps [164]. These 
steps can also be defined as “hallmarks” of cancer and have been comprehensively 
reviewed by Weinberg, Hanahan & Roberts [5, 6]. In order to successfully determine 
the importance and role of RAMP1 in prostate cancer metastasis, the effect of its 
deletion can be measured in each of these important stages using cellular or in vitro 
experiments. A fundamental characteristic of cancer cells is their unique ability to 
sustain a hyper proliferative state without succumbing to cell death. To achieve this, 
cells undergo a variety of mutations that can alter both growth-promoting and pro-
apoptotic pathways. These pathways exist to promote a homeostasis in cell number 
and aid the maintenance of tissue architecture and function [6]. Cancer cells can 
achieve this by either producing growth factors themselves or can influence their 
surrounding environment by stimulating stromal cells to produce growth-promoting 
factors [165, 166]. To date, no studies have shown a link between RAMP1 mutations 
and prostate cancer, however in vitro and in vivo studies have shown a correlation 
between RAMP1 and cell proliferation. After depletion of RAMP1 using shRNA in PC3 
and LNCaP cells, proliferation was reduced by approximately 40% in vitro and 
xenograft studies using RAMP1 knockdown cells showed reduced tumour growth of 
40% [105]. Subsequent immunohistological staining of RAMP1 knockdown tumours 
found reduction in Ki67 and pHH3. These are both markers of proliferation and have 
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been shown to be statistically relevant as prognostic markers of prostate cancer 
progression [167]. 
 
The method of counting cell proliferation in vitro has been established for 
more than 50 years, when the dye Trypan blue was first used to determine cell 
viability [168]. Cell viability can be defined as the health of cells and can be estimated 
by measuring cellular markers of activity. Cell viability assays are able to determine 
the ability of cells to respond to stress. By measuring the population of healthy/living 
cells overtime, the growth rate or proliferation of a population can also be deduced. 
By excluding non-viable or dead cells, the quantification of Trypan blue positive cells 
is achieved using a microscope and a haemocytometer. Although this method can 
often be accurate, it is time-consuming and more open to human error than other 
methods of counting cells [169]. Since then, new techniques have been developed 
to measure cellular metabolic activity (such as levels of tetrazolium salts or the 
corresponding reduction potential of the cells) producing high-throughput assays 
based on colorimetric, fluorimetric or luminescence readings [170]. These commonly 
used assays can be applied when testing the effect of RAMP1 deletion in PC3 cells 
on cell proliferation and viability. Studies have not yet elucidated the mechanism of 
RAMP1 in cell proliferation. This could be either by influencing pathways in the 
cancer cell directly or by targeting the surrounding stroma. This can be investigated 
by measuring the differences in downstream signalling pathways in RAMP1 KO PC3 
cells compared with PC3 wild types.  
 
Increased proliferation of cancer cells triggers pathways that activate 
programmed cell death or apoptosis. This is often due to increased proliferation 
causing DNA damage in the cells or mutations that lead to the upregulation of 
oncogenes [6]. Apoptosis is regulated by a number of different protein families, one 
of which is the caspase family. Caspases can be classed into upstream regulators (e.g. 
caspase 8) and downstream effector components (e.g. caspase 3/7). Apoptosis is 
mostly controlled by a balance of pro- and anti- apoptotic signals.  Members of the 
Bcl-2 family are inhibitors of apoptosis which bind to proapoptotic signals such as 
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Bax and Bak, deactivating them [171, 172]. Cancer cells can often “hijack” these 
regulatory pathways in order to evade cell death. Previous reports have not linked 
RAMP1 with apoptosis regulation and no significant differences were seen in caspase 
3 activity after RAMP1 depletion in PC3 cells [105]. However, independent from the 
context of cancer, the RAMP1/CLR complex has been reported to exert anti-
apoptotic effects on cardiomyocytes under oxidative stress by increasing Bcl-2 
expression [173]. Parallels may be drawn from these findings as cancer cells often 
need to adapt to hypoxic settings [6] and similar mechanisms would be useful under 
these conditions. The effect of RAMP1 KO on apoptotic pathways can be investigated 
using a caspase cleavage assay. The principle of such an experiment is to add a 
substrate directly onto cells in culture. The substrate will first lyse the cells and then 
also contains a luminogenic (or colorimetric/fluorimetric) substrate fused with a 
DEVD sequence. This sequence is a recognition site for caspases and any present will 
therefore cleave the substrate which then results in the release of luciferin and 
ultimately leading to a luminescence signal proportional to caspase activity [174, 
175].   
 
 Subsequent to a primary tumour being formed after cancer cells have 
proliferated sufficiently, they may enter the “invasion-metastasis” cascade. This 
term describes the process whereby primary tumour cells undergo epithelial to 
mesenchymal transition (EMT) and begin to invade local tissues through the 
surrounding extracellular matrix (ECM). To do this, cells enter a migratory phenotype 
that can be described as the movement of a cell from one area to another. However, 
in order to penetrate the surrounding tissues, cells must also be capable of invasion 
[176]. EMT can cause pathways within the cell that regulate cell adherence and 
structure to either be activated or deactivated.  In many prostate cancer cell lines 
such as PC3, DU145 and LNCaP it has been reported that treatment of 10-8 M CGRP 
can increase migration of cells by up to 30% across a gradient of fibronectin (an ECM 
protein) [104]. This is known as “haptotactic” migration where cells respond to a 
stimulus e.g. fibronectin which may trigger migration. Invasion of cells can be 
measured by using Matrigel-coated invasion chambers. Matrigel is a substance that 
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was first extracted from a tumour and contains all common ECM proteins such as 
laminin, collagen IV and heparan sulphates [177]. It has been reported that 
treatment with 10-7 M CGRP increases the invasive ability of PC3 and LNCaP cells by 
30% [104, 178]. There are no current studies in the literature which show the 
importance of RAMP1 in migration and invasion of cancer cells of any type. However, 
it could be hypothesised that as RAMP1 is a component of the CGRP receptor, similar 
effects may be observed. 
 
 After cells have successfully located to the metastasis site, colonisation must 
occur. A proposed model of metastasis is the “seed and soil” hypothesis which states 
that only particular subset of cells (the “seeds”) that disseminate from the primary 
tumour landing in the optimal microenvironment (the “soil”) can successfully form 
secondary tumours [179]. In the context of prostate cancer, the “soil” is often the 
bone microenvironment. If only a small group of cells reach the bone 
microenvironment, the ability of these cells to form colonies and progress is 
paramount to tumour formation. Colony-forming assays have been developed to 
test the effect of anti-cancer treatments on the colony-forming ability of cancer cells. 
This can be achieved by sparsely plating cells on soft agar or standard cell culture 
plates and allowing the cells to growth for 2+ weeks to see how many individual cells 
form colonies of 50 cells or more [180]. It has been reported that depletion of RAMP1 
resulted in a 55% reduction in the average number of colonies formed by PC3 cells 
[105]. This indicates RAMP1 is an important factor in the ability of single cells to 
divide into larger populations and therefore may reflect its role in metastatic tumour 
progression.  Cancer cells must also lose their adhesive properties when dissociating 
from the stroma in order to intravasate into the circulation. However, after the 
metastasis site has been reached, cancer cells must reverse this effect in order to 
anchor themselves in the bone microenvironment [181]. This requires the switching 
on or off of different adhesion-associated pathways. In prostate cancer, annexin II 
has been found to be produced in endothelial and osteoblast cells and can promote 
adhesion of cancer cells expressing the annexin II receptor [182]. The effect of 
RAMP1 depletion was not reported on adhesion of PC3 cells, however previous 
 
 
 
112
reports show when stimulated with CGRP, no effect on PC3 cell adhesion was 
observed [178]. 
 
It is vital that future investigations find therapeutic targets that are involved 
in the metastasis of prostate cancer. RAMP1 has been shown to be upregulated in 
prostate cancer patients [140] and genome-wide studies find it to be the significantly 
upregulate in prostate cancer when compared with other solid tumours e.g. breast, 
lung and liver [105]. RAMP1 is therefore a candidate for playing a key role in prostate 
cancer metastasis. By generating successful RAMP1 knockouts in a PC3 cell line, we 
can now test this hypothesis. In vitro assays have been previously reported in the 
literature as useful tools for determining changes in a cell line’s metastatic potential. 
These will be used to compare RAMP1 KO and wild type PC3 cells for their ability to 
proliferate, migrate and invade, adhere and colonise and finally to evade apoptosis.  
It is also important to investigate whether the CGRP (RAMP1:CLR) receptor is 
responsible for the tumorigenic effects seen in wild type PC3 cells. Therefore, by 
using CGRP and CGRP antagonist treatments in in vitro experiments, it can be 
determined whether the CGRP receptor is important for PC3 cell growth and other 
metastatic processes.  
 
 
 Hypotheses  
 
1. Deletion of RAMP1 in PC3 cells will affect:  
a. Cell survival 
b. Processes of metastasis  
c. Downstream signalling pathways  
 
2. The effect of RAMP1 on PC3 cells is mediated by CGRP.  
 
 Research Aims 
 
1. To determine the effect of RAMP1 deletion on cell survival and processes of 
metastasis using in vitro assays.  
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2. To determine the effect of RAMP1 deletion on downstream signalling 
pathways using a multiplex magnetic bead assay 
 
3. To determine the cause of RAMP1’s effect using CGRP stimulation and CGRP 
antagonists in vitro.   
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 Materials and Methods  
 
4.4.1 Viability Assays  
 
Cell viability was measured using the RealTime-GloÔ MT Cell Viability kit (Promega). 
This is a non-lytic bioluminescent method for measuring viability in real time. The 
number of viable cells in culture is determined by measuring the reducing potential 
and metabolism (MT) of the cells (see Fig 4.1). A 1,000X NanoLuc cell-permeable 
substrate was added to cells in culture in combination with a 1,000X NanoLuc 
enzyme (luciferase) to final concentration of 1X. Viable cells then reduced the 
proprietary substrate to generate a second substrate (luciferin) for the Nanoluc 
enzyme (luciferase) which in turn produces a luminescent signal which was then read 
using an Ensight plate reader (Perkin Elmer) using the settings described in Table 4.1.  
 
This assay relies on reduction of the viability substrate by viable cells to produce a 
luciferin substrate for the luciferase enzyme. This produces a luminescent signal 
proportional to the number of viable cells in culture.  
 
 
 A continuous-read format allows the luminescent signal to be monitored 
over an extended period of time, allowing measurements of cell viability in real time. 
Viability assays were typically run for 3 days. PC3 wild type cells were first used to 
optimise cell density for this viability assay (see Fig 4.2). It was found that a seeding 
of 2,000 cells per well produced very dramatic increases in viable cells, due to an 
Figure 4.1 Principle of cell viability assay. 
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increased growth rate. This creates a narrow window of time to perform the 
experiment, limiting the time for any effects on viability to be measured. Cells 
seeded at 1,000 cells per well displayed a continuing linear phase after 72 hours and 
therefore were chosen as the optimal cell density for performing viability 
experiments. Cells were cultured as previously described (see Chapter 2, Section 
2.4.1-3) and seeded at 500 cells per well showed similar linear growth rates but were 
also slow to begin growth and were therefore not selected as the optimal density. 
PC3 wild type and RAMP1 CRISPR cells were seeded at the optimal density of 1,000 
cells per well for all viability experiments. Measurements were taken every 24 hours 
for a total of 3 days. In some cases, cells were treated daily with either calcitonin 
gene related peptide (CGRP) (Sigma) or Telcagepant/MK0974 (MedChem Express). 
Ligand or antagonists were made to concentrations of 1, 3 or 5µM and were diluted 
in PBS to a 50X concentration in a 2µL volume to be added to each well containing 
100µL media.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.1 Plate reader settings for viability assays. 
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Optimisation of PC3 cell density for viability assays. 1,000 cells per well (red) was 
selected as the optimal cell density. All values are mean ± SEM, n=3. 
 
 
4.4.2 Apoptosis Caspase 3/7 Assays  
 
 
 To measure rates of apoptosis in PC3 wild type and RAMP1 KO cells, the 
Caspase-Glo 3/7 assay kit (Promega) was used. This is a homogenous, luminescent 
assay that measures caspase 3 and caspase 7 activity. These are renowned members 
of the cysteine aspartic acid-specific protease (caspase) family and play key roles in 
apoptosis in mammalian cells [183]. Cells were cultured using previously described 
methods (see Chapter 2, Section 2.4.1-3) and then seeded 1,000 cells per well in a 
white opaque 96 well plate and incubated at 37°C for 24 hours. Cells were then 
serum-starved to induce apoptosis and the incubation times were optimised for PC3 
cells. Cells were compared with “unstressed” conditions (complete media) to find 
the most significant difference between stressed and unstressed. After incubation 
with serum-free media 50µL of a luminogenic caspase 3/7 substrate reconstituted in 
2.5mL Caspase-GloÒ 3/7 Buffer was added to each well. This resulted in cell lysis and 
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Figure 4.2 Cell density optimisation for viability assay. 
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cleavage of the substrate by caspase3/7, leading to the release of aminoluciferin and 
causing a reaction with luciferase and production of light (see Fig 4.3). It was found 
that 48 hours of serum starvation yielded the biggest difference in caspase 3/7 
activity between stressed and unstressed conditions (see Fig 4.4). This increases the 
opportunity to see an effect in caspase 3/7 activity between PC3 wild type and 
RAMP1 KO cells. All experiments comparing PC3 wild type and RAMP1 KO cells used 
a serum starvation incubation time of 48 hours. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cleavage of luminogenic substrate by caspase 3/7 results in release of aminoluciferin 
and reaction with luciferase leads to production of light.  
 
 
   
 
 
 
 
Figure 4.3 Caspase 3/7 assay principle. 
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(A) 24 hours incubation showed a 26% increase in caspase 3/7 activity compared with 
unstressed conditions. (B) 32 hours incubation showed a 33% increase in caspase 3/7 
activity. (C) 48 hours showed a 69% increase in caspase 3/7 activity.  All values are 
mean ± SEM, n=4. P<0.05, (Students unpaired t-test). 
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Figure 4.4 Optimisation of incubation time for caspase 3/7 assay. 
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4.4.3 Migration “Scratch” Assays 
 
 To measure migration in PC3 wild type and RAMP1 KO populations, cells were 
cultured as previously described (see Chapter 2, Section 2.4.1-3). 3 x 105 cells were 
seeded in 6 well plates (in triplicates) and were 90% confluent 24 hours later. All cells 
were then treated with 0.5µM Mitomycin C for 2 hours as this has been shown to 
suppress PC3 cell proliferation without causing harmful toxicity [184]. After 
treatment, scratches were made in the cell monolayer using a 200µL pipette tip. Cells 
that became unattached after scratching were removed by washing with 500µL PBS 
three times. Complete media was then added to all wells and images were taken at 
three different regions of interest (ROIs) for each scratch using an EVOS FL Auto 
Imaging System (Thermo Fisher Scientific). Cells were incubated overnight and then 
imaged again at the same ROIs.  Closure of the scratch or “wound” was quantified 
using the MRI Wound Healing Tool macro for Image J.  
(http://dev.mri.cnrs.fr/projects/imagej-macros/wiki/Wound_Healing_Tool )  
 
 
4.4.4 Transwell Invasion Assays  
 
 Invasion and migration of PC3 wild type and RAMP1 CRISPR cells was 
measured using a BD BioCoatÔ MatrigelÔ Invasion Chamber (Corning). Cell density 
was first optimised using PC3 wild type cells which were cultured as previously 
described (see Chapter 2, Section 2.4.1-3) and seeded at 1x105, 5x105 and 1x106 cells 
in Matrigel-coated and control inserts. Prior to seeding cells were incubated in 
serum-free medium for 24 hours.  750µL complete RPMI medium was added to the 
wells beneath the inserts and cell suspensions were made in serum-free media. After 
being seeded in either control or Matrigel inserts, cells were incubated for 24 hours 
at 37°C.  Non-invasive cells were removed from the upper surface of the membrane 
by scrubbing with a cotton swab moistened with serum-free RPMI media. Invasive 
cells on the lower surface of the membrane were then fixed in 500µL methanol for 
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2 minutes and then stained with 1% Toluidine Blue in 1% borax solution (Sigma) for 
another 2 minutes. Inserts were then air dried and image using an EVOS FL Auto 
Imaging System (Thermo Fisher Scientific). Analysis was performed by taking six 
different regions of interest in the well and counting cells manually. It was found that 
1x106 PC3 cells was the optimal density for both control and Matrigel coated 
membranes (see Fig 4.5). Experiments comparing RAMP1 KO and PC3 wild type cells 
were performed using 1x 106 cells for both control and Matrigel inserts. Percentage 
of invaded cells was calculated using the following formula as suggested in the 
manufacturer’s protocol:  
 
% Invasion = Mean number of cells through Matrigel insert membrane 
           Mean number of cells through control insert membrane  x 100 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Different densities of PC3 cells were seeded. Cells were fixed with 100% methanol 
and then stained with 1% toluidine blue in 1% borax solution for visualisation and 
analysis.  
 
 
Figure 4.5 Transwell control and Matrigel-coated membranes 
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4.4.5 Colony Formation Assays  
 
 To measure the ability of PC3 wild type and RAMP1 KO cells to form colonies 
in culture, colony formation assays were performed. PC3 and RAMP1 KO cells were 
cultured as previously described (see Chapter 2, Section 2.4.1-3) and cell density was 
first optimised for colony formation by seeding 25, 50 and 100 cells in single wells of 
a 6 well plate. This was performed in triplicates using RAMP1 CRISPR clone “D5” and 
PC3 wild type cells to determine the optimal density to form colonies that could be 
visualised. (see Fig 4.6). After cells were seeded, plates were incubated at 37°C for 
14 days and the media was changed on all wells every 3 days. The media was then 
removed and the cells were fixed with ice cold 100% methanol for 15 minutes. Cells 
were then stained with 0.25g crystal violet diluted with 25% methanol-PBS for 10 
minutes. The stain was then removed with distilled water and  
 
Density was optimised using both PC3 wild type and RAMP1 KO clone “D5” cells. The 
optimal density was determined as 100 cells as this yielded quantifiable colonies after 
14 days of growth.  
 
plates were air dried before imaging with a Pixera Professional High-Resolution 
Digital Camera (Pixera). Colonies were then quantified using GeneTools 4.01 
Figure 4.6 Optimisation of cell density for colony formation assay. 
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software (SynGene). It was determined that seeding of 100 cells was the optimal 
density for colony formation and subsequent analysis. Subsequent experiments 
were performed by seeding 100 cells in each well of all cell types. 
 
4.4.6 Adhesion Assays  
 
 To measure the ability of PC3 wild type and RAMP1 KO cells to adhere to 
extracellular matrix proteins, adhesion assays were performed. Cells were cultured 
as previously described (see Chapter 2, Section 2.4.1-3). Cells were counted and then 
resuspended at 2x105/mL in serum-free media and stained with 1uM Calcein AM for 
30 minutes at 37°C. Cell suspensions were then washed twice with 1mL serum-free 
medium and centrifuged at 1,000 x G. Cells were finally suspended in 1mL complete 
media and 100uL was added per well to BioCoatÔ 3-5µg/cm2 Fibronectin-coated 96 
well plates (Corning). Cells were left to adhere at 37°C for 30 minutes and then 
selected wells were washed three times with 100µL PBS and then 200µL PBS was 
added to the wells. Washed wells were chosen to represent “adherent cells” 
whereas unwashed cells represented the “total population of cells”. Adherence was 
then calculated as the percentage of adherent cells to the total population of cells. 
This calculation was account for any differences in seeding. Fluorescence intensity 
of each well was then measured using an Ensight plate reader (Perkin Elmer) at an 
emission/excitation wavelength of 485/ 520nm.  
 
 
4.4.7 Multiplex Magnetic Bead Assay 
 
 A multi-pathway 9-plex magnetic bead kit (Merck) was used to detect 
phosphorylated proteins from different signaling pathways in PC3 wild type and 
RAMP1 KO cell lysates. This assay is an immunoassay combined with magnetic beads 
and the principle is very similar to a sandwich ELISA (see Fig 4.6). Capture antibodies 
specific to a protein of interest are covalently bound to the beads. The coupled beads 
react with proteins within the cell lysate sample, and a Bio-Plex Proä Wash Station 
(BioRad) was then used to remove unbound protein. A biotinylated detection 
antibody was then added to create a sandwich complex. A final complex was then 
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formed with a streptavidin-phycoerythrin (SA-PE) conjugate and a fluorescent signal 
was then read using a Luminex MAGPIX Instrument (Biorad). Magnetic beads contain 
internal specific fluorescent dyes allowing multiplexing of different beads and 
antibodies targeting different proteins within the same sample.  
 
 
 
 
Figure 4.7 Schematic diagram of multiplex magnetic bead immunoassay. 
Magnetic beads are bound to antibodies specific to a protein of interest. Biotinylated 
detection antibody is also specific to protein of interest and conjugated to a 
streptavidin-phycoerythrin (SA-PE) complex which acts as a fluorescent reporter.  
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Phosphorylated proteins from different interacting signaling pathways (highlighted 
red) were targeted by magnetic beads bound to specific antibodies.  
 
 
 
4.4.7.1 Preparation of Cell Lysates 
 
 PC3 and RAMP1 KO cells were cultured as previously described (see Chapter 
2, Section 2.4.1-3). 2 x 105 wild type PC3 or RAMP1 KO cells were then seeded in 6 
well plates and incubated at 37°C overnight in complete media. Cells were then 
washed once with PBS and then 1% RPMI media was added and cells were incubated 
at 37°C overnight. Cells were washed with 500µL ice cold PBS and then 500µL ice 
cold 1X MILLPLEXÒ lysis buffer with protease inhibitor cocktail set III (Calbiochem) 
diluted 1:200 was added to the cells. A cell scraper was used to remove adherent 
cells and the cell suspension was transferred to a 1.5mL Eppendorf tube. Samples 
were then gently rocked for 15 minutes at 4°C. Samples were then transferred to a 
0.5mL filter column (Merck) and centrifuged for 4 minutes at 4°C. Samples were then 
Figure 4.8 Schematic diagram of multiple pathways targeted in multiplex bead assay. 
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aliquoted and stored at -80°C. Quantification of protein concentration was 
performed using a BCA assay as previously described (see Chapter 2, Section 2.4.10).   
 
4.4.7.2 Immunoassay Protocol 
 
 An opaque black 96 well plate was used for multiplex magnetic bead assays 
and all wells were first washed with 50µL assay buffer (Merck). 25µL magnetic beads 
were added to all wells and 25uL assay buffer was added to blank negative controls. 
Samples and positive controls were added at 25µL in triplicate wells. Positive 
controls included cell lysates provided in the kit and included a HeLa cell lysate 
(unstimulated), a A431 cell lysate (EGF stimulated), a MCF7 cell lysate (IGF-1 
stimulated) and a HeLa cell lysate (TNFa/Calyculin A stimulated). PC3 wild type and 
RAMP1 KO cell lysates were added at a concentration of 0.5mg/mL and positive 
controls were added at a concentration of 0.8mg/mL. All incubation steps were 
performed on a plate shaker at 800 rpm. All samples and magnetic beads were left 
to incubate overnight in the dark at 4°C. The plate was then placed on a magnetic 
block for 1 minute to allow beads to settle and washed with 100µL assay buffer 
twice. 25µL detection antibody was added to each well and the plate was incubated 
in the dark at room temperature for 1 hour. The detection antibody was then 
removed by placing the plate on a magnetic block and removing the detection 
antibody by pipetting. 25µL streptavidin-PE was added to each well and the plate 
was incubated in the dark at room temperature for 15 minutes. The SA-PE was not 
removed and 25µL amplification buffer was added to each well. The plate was then 
incubated in the dark at room temperature for 15 minutes. All liquid was removed 
from each well using the magnetic block and beads were then suspended in 150µL 
assay buffer before the plate was read using a Luminex MAGPIX instrument (BioRad). 
Fluorescent signal for blank wells was subtracted from sample values and positive 
controls were checked as a quality control for the assay.   
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4.4.8 Statistical Analysis  
 
 All data are expressed as mean ±SEM. Statistical significance was tested for 
(unless otherwise stated) using an unpaired Student’s t-test and F-test with Prism 7 
software (GraphPad). P <0.05 was considered significant.  
 
 
 Results 
 
4.5.1 Viability Assays 
 
 RAMP1 KO cells were tested for differences in cell viability compared with 
PC3 wild type cells. Measurements were taken every 24 hours for a total of 3 days. 
All clones that were validated with qPCR were selected for viability experiments. 
After four experimental repeats, it was found that three clones (A7, C1 and D5) 
showed significant reductions in viability compared with PC3 wild type cells on days 
1-3. A7 showed a 32% reduction, C1 a 31% reduction and D5 displayed reduced 
viability by 41% compared with PC3 wild type cells. CRISPR clones B5, D4 and B12 
did not show significant differences in viability on days 1 and 2. B5 and D4 showed 
reduced viability by 20% and 23% respectively on day 3, but B12 did not show any 
significant differences from days 1-3 (see Fig 4.9). 
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Measurements were taken every 24 hours for 3 days. A) A7 showed 32% reduced 
viability compared with PC3 controls after 3 days growth (P = 0.0001). (B) C1 showed 
31% reduced viability (P = <0.0001.) (C) D5 showed 41% reduced viability (P = 
<0.0001). (D) B5 showed 20% reduced viability (P = 0.834). (E) D4 showed 23% 
reduced viability (P = <0.0001). (F) B12 showed no significant difference in viability 
compared with PC3 wild type controls. All values are mean ± SEM, n=4. (Students 
unpaired t-test). 
 
 
 
 
 
 
 
 
Figure 4.9 Viability assays comparing PC3 wild type and RAMP1 KO cells. 
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Table 4.2 Percentage differences in cell viability. 
Reductions in viability at Day 3 of different CRISPR clones compared with PC3 wild 
type cells. 
 
 
 
 Viability assays were performed on wild type PC3 cells in combination with 
treatment of 1, 3 or 5µM CGRP or Telcagepant (a CGRP antagonist). Viability assays 
were continued for 5 days and repeated three times resulting in no significant 
differences in viability between untreated cells and those treated with CGRP or 
Telcagepant (see Fig 4.10).   
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Viability assays performed using wild type PC3 cells. Treatment of CGRP or 
Telcagepant had no significant effect on PC3 cell viability at any time point.  All values 
are mean ± SEM, n=3. P>0.05, (Students unpaired t-test). 
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Figure 4.10 CGRP and antagonist cell viability. 
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4.5.2 Migration “Scratch” Assays 
 
The ability of RAMP1 KO cells compared with PC3 wild type cells to migrate 
in culture was measured using a migration “scratch” or “wound healing” assay. All 
cells were plated in 6 well plates and treated with Mitomycin C for 2 hours to halt 
proliferation. Scratches were made in the cell monolayer and then images taken at 
0 hr and 22 hr time points. These images were analysed using ImageJ MRI Wound 
Healing tool to calculate the percentage of wound closure in each cell type (see Fig 
4.12). After three experimental repeats, it was found that RAMP1 KO clones A7 and 
C1 appeared to migrate 94% and 54% faster than PC3 wild type cells however RAMP1 
KO clone D5 showed no significant difference (see Fig 4.11).  
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Images were taken of “scratches” for PC3 wild type cells and RAMP1 KO clones A7, C1 and D5 at 0 hour and 22 hour time points.   
Figure 4.11 Migration (scratch) assay. 
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ImageJ analysis using MRI Would Healing software indicates that both RAMP1 KO 
clones A7 and C1 have an increased rate of wound closure of 94% and 58% 
respectively compared with PC3 wild type cells (P = <0.0001). All values are mean ± 
SEM, n=3. P<0.05, (Students unpaired t-test). 
 
 
 
Percentage of increased migration of different CRISPR clones compared with PC3 wild 
type cells. 
 
Figure 4.12 ImageJ analysis of migration assay. 
Table 4.3 Percentage differences in migration. 
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4.5.3 Transwell Invasion Assays 
 
The invasive potential of RAMP1 KO cells was compared with PC3 wild type 
cells using a Transwell invasion assay. Cells were seeded in Transwell inserts coated 
with or without Matrigel. Control inserts had no coating and represented the 
migration of cells over a period of 24 hours. After three experimental repeats, it was 
found that migration was higher in RAMP1 KO cells when compared with PC3 wild 
type cells. RAMP1 clones A7, C1 and D5 showed an increase in 4-fold or more in the 
number of migrated cells compared with PC3 wild type cells (see Fig 4.13). The 
percentage of invaded cells was calculated from the number of migrated cells 
through the control insert membrane. This indicated a decrease in invasion in 
RAMP1 KO cell clones A7, C1 and D5 of 51%, 83% and 83% respectively (see Fig 4.14)  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Analysis of number of cells migrating through control Transwell insert membrane 
shows a four-fold increase in RAMP1 KO clone A7 (P = 0.003), a four-fold increase in 
C1 (P = 0.03) and a five-fold increase in clone D5 compared with PC3 wild type cells 
(P = 0.009). All values are mean ± SEM, n=3. (Students unpaired t-test). 
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Figure 4.13 Transwell migration assay. 
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Percentage of invaded cells was calculated by comparing with number of migrated 
cells. RAMP1 KO clone A7 showed a 51% decrease in invasion compared with PC3 
wild type cells (P = 0.09). C1 showed an 83% decrease (P <0.0001) and D5 a 83% 
decrease compared with PC3 wild type cells (P = 0.015). All values are mean ± SEM, 
n=3. (Mann-Whitney test). 
 
 
 
Percentage increases in migration and decreases in invasion of different CRISPR 
clones compared with PC3 wild type cells. 
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Figure 4.14 Transwell invasion assay. 
Table 4.4 Percentage differences in migration and invasion. 
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4.5.4 Colony Formation Assays  
 
The ability of RAMP1 KO cells to form colonies in culture was compared with 
PC3 wild type cells. Cells were plated in 6 well plates and left to form colonies for 14 
days. After fixation and staining (see Fig 4.15) the number of colonies was counted. 
In case the software miscounted or ignored small colonies the percentage of total 
area that was positively stained was also calculated. RAMP1 CRISPR clones that 
showed reduced viability (A7, C1 and D5) were selected for colony formation 
experiments.   After three experimental repeats, it was found that the number of 
colonies was reduced 44% for A7, 89% for C1 and a 54% reduction was seen in D5 
(see Fig 4.16). These reductions were also reflected when measuring the percentage 
of total area that was positively stained compared with the total area of the well 
(70% for A7, 96% C1 and D5 78%) (see Fig 4.17). 
 
 
Scanned images of cells stained with crystal violet to show visible differences in 
colony formation in RAMP1 KO clones (A7, C1, D5) and PC3 wild type cells.  
 
 
 
 
 
Figure 4.15 Colony formation images 
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Quantification of the total number of colonies indicates that RAMP1 KO clone A7 
showed a 44% reduction compared with PC3 wild type cells (P = 0.02). 89% reduction 
was seen in C1 (P = <0.0001) and 54% reduction in D5 (P = 0.015). All values are mean 
± SEM, n=3. (Students unpaired t-test). 
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Figure 4.16 Number of colonies in colony formation assay. 
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Percentage of total area that was positively stained indicates a 70% reduction in A7, 
a 96% reduction in C1 and a 78% reduction in D5 compared with PC3 wild type cells 
(P = <0.0001). All values are mean ± SEM, n=3. (Students unpaired t-test). 
 
 
 
Reduction in number of colonies and percentage of total area covered by colonies of 
different CRISPR clones compared with PC3 wild type cells. 
 
Figure 4.17 Percentage area of colonies in colony formation assay. 
Table 4.5 Percentage differences in colony formation. 
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4.5.5 Adhesion Assays  
 
To measure the ability of RAMP1 KO cells to adhere in culture compared with 
PC3 wild type cells, adhesion assays were performed using fibronectin-coated 96 
well plates. Cells were stained with calcein AM prior to adhering. After allowing cells 
to adhere for 30 minutes, fluorescence was measured. For analysis, wells containing 
cells that were washed three times (adherent population) were then compared with 
wells that were not washed (total population) to calculate percentage of adherent 
cells from the total amount seeded. After three experimental repeats, it was found 
that there was a 33% reduction in the percentage of adherent cells in RAMP1 CRISPR 
clone A7 compared with PC3 wild type cells. A 75% reduction was seen in C1 and 
40% in D5 (see Fig 4.18).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adhesion assay was performed using 3-5µg/cm2 fibronectin-coated 96 well plates. A 
33% reduction in percentage of adherent cells was seen in RAMP1 CRISPR clone A7 
compared with PC3 wild type (P = 0.117). A 75% reduction was seen in C1 (P = 0.0015) 
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Figure 4.18 Adhesion assay. 
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and a 40% reduction was seen in D5 (P = 0.02). All values are mean ± SEM, n=3. 
(Students unpaired t-test). 
 
 
 
  
 
 
 
 
 
Reductions in adhesion to fibronectin-coated culture plates of different CRISPR clones 
compared with PC3 wild type cells. 
 
4.5.6 Apoptosis Assays  
 
To determine apoptosis activity in RAMP1 KO cells compared with PC3 wild 
type cells, caspase 3/7 activity was measured. To induce apoptosis, cells were serum 
starved for 48 hours and then caspase 3/7 activity was measured. This was compared 
with measurements from cells in “unstressed” conditions, grown in complete media. 
After three experimental repeats, PC3 wild type cells displayed a 70% increase in 
caspase 3/7 activity after serum starvation. However, no increases in caspase 3/7 
activity were seen in RAMP1 KO cells after serum starvation (see Fig 4.19). In 
unstressed conditions, RAMP1 KO clones A7 and D5 showed increased caspase 3/7 
activity of 83% and 88% respectively compared with PC3 wild type cells. RAMP1 KO 
clone C1 did not show any increases in caspase 3/7 activity in both unstressed and 
stressed conditions (see Fig 4.19). 
Table 4.6 Percentage differences in adhesion. 
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Caspase 3/7 activity in PC3 wild type cells showed a 70% increase after 48 serum 
starvation (P = 0.09). RAMP1 KO clones A7, C1 and D5 showed no difference in 
activity after serum starvation. In unstressed conditions RAMP1 KO clone A7 showed 
an 83% increase (P = 0.06) and D5 an 88% increase (P = 0.03) compared with PC3 
wild type controls. CRISPR KO clone C1 showed no significant difference in caspase 
activity with PC3 wild type cells in unstressed conditions and did not show any 
increases after serum starvation. All values are mean ± SEM, n=3. (Students unpaired 
t-test). 
 
PC
3 W
T A7 C1 D5
0
50000
100000
150000
200000
Caspase 3/7 Activity In 0% RPMI
R
LU
PC
3 W
T A7 C1 D5
0
50000
100000
150000
200000
Caspase 3/7 Activity in 10% RPMI 
R
LU
*
Figure 4.19 Caspase 3/7 activity. 
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Table 4.7 Percentage differences in caspase 3/7 activity. 
Percentage differences in caspase activity in both unstressed (10% RPMI) and 
stressed (serum starvation, 0% RPMI) conditions in different CRISPR clones compared 
with PC3 wild type cells. 
 
 
4.5.7 Multiplex Magnetic Bead Assay: Multi-Pathway 9 Plex 
 
Cell lysates for both PC3 wild type and RAMP1 KO clone D5 were tested for 
the presence of phosphorylated proteins from different signaling ERK1/2 
(Thr185/Tyr187), Akt (Ser473), STAT3 (Ser727), JNK (Thr183/Tyr185), p70 S6 kinase 
(Thr412), NF-kB (Ser536), STAT5A/B (Tyr694/699), CREB (Ser133), and p38 
(Thr180/Tyr182). In all experiments, positive control lysates (unstimulated or 
stimulated) were used as a quality control for the assay. Three separate protein 
extractions were performed on each cell type and assayed in triplicate. Significant 
differences were found in the amount of phosphorylated Akt which was increased 
in PC3 wild type cell lysates compared to RAMP1 KO (see Fig 4.20.A) (P = 0.003). A 
significant reduction in phosphorylated STAT3 was also found in RAMP1 KO samples 
compared with PC3 wild type (P = 0.03) (see Fig 4.20.B). No significant differences 
were found in the remaining targets (see Fig 4.21.C-I). 
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Figure 4.20 Multiplex multi-pathway magnetic bead assay A-D 
Multiplex multi-pathway magnetic bead assay. PC3 wild type and RAMP1 KO (clone 
D5) cell lysates were assayed for different phosphorylated proteins (A) Akt was found 
to be significantly downregulated in RAMP1 KO samples (P = 0.003). (B) STAT3 was 
also found to be significantly downregulated in RAMP1 KO samples (P = 0.03). All 
values are mean ±SEM, n=3. (Students unpaired t-test). 
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 Multiplex multi-pathway magnetic bead assay. PC3 wild type and RAMP1 KO (clone 
D5) cell lysates were assayed for different phosphorylated proteins (C-I) STAT5, CREB, 
NF-kB, p38, ERK1/2, JNK and p70S6K were not found to significantly different.  All 
values are mean ±SEM, n=3. (Students unpaired t-test). 
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Figure 4.21 Multiplex multi-pathway magnetic bead assay (E-I). 
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 Discussion 
 
 On the whole, the results of these in vitro experiments implicate RAMP1 as 
an important factor in many processes of prostate cancer metastasis including, cell 
viability/proliferation, evasion of apoptosis, invasion across the ECM and cell 
colonisation. To assess cell growth and viability, RAMP1 KO and PC3 wild type cells 
were grown for 3 days and the number of viable cells was counted every 24 hours.  
RAMP1 deletion appears to affect PC3 cell viability and consequently reduced cell 
growth over 3 days when compared with wild type cells. The RealTime-GloÔ MT Cell 
Viability assay allows real-time luminescent measurements of cell viability. This has 
advantages over standard endpoint proliferation assays which can be time 
consuming requiring numerous cell counts which can often lead to human error and 
inaccurate results. Nevertheless, this assay measures the reducing potential of cells 
which represents the metabolism of the cell. Cellular metabolism has been found to 
be quite varied and this is therefore a limiting factor of this particular viability assay 
[185].  
 
 Optimisation of the cell viability assay was achieved using PC3 wild type cells 
as this was also a positive control cell line to compare RAMP1 KO cell viability. All 
clones tested for cell viability had been previously validated for RAMP1 KO using 
endpoint and qPCR.  Measurements indicated exponential cell growth over three 
days however, when comparing results of PC3 wild type cells with each RAMP1 KO 
clone, it was found that three clones showed reduced viability on all time points 
across days 1-3. This reflected a decreased growth rate in RAMP1 KO clones A7, C1 
and D5. RAMP1 KO clones B5, D4 and B12 did not show any significant differences in 
cell viability apart from B5 and D4 on Day 3. RAMP1 KO clone B12 did not show any 
significant differences in viability throughout the experiment.  
 
A possible explanation for the differences in viability between these clones 
could be the editing that has occurred. Editing events may not be identical in each 
cell and therefore this could lead to differences in cell viability. Efforts were made to 
investigate differences in gene editing between each clone using Sanger sequencing, 
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however this technique has a capacity of less than 1,000 base pairs and therefore 
sequencing the entire RAMP1 gene was impossible. PCR primers were designed to 
amplify a region targeted by 2 of the 3 guide RNA sequences and these products 
were sequences (See previous chapter). The last guide RNA sequence was targeted 
by PCR primers but these could not be optimised possible due to the GC-rich 
amplicons. Next generation sequencing has the capacity to sequence entire genes 
however this is an expensive technique but may be used in the future for further 
investigations. qPCR analysis showed that B5, D4 and B12 had slightly higher relative 
expression of 10-30% compared with other CRISPR clones, even though CT values 
were consistently >35 (see Chapter 3, Section 3.5.5, Table 3.9). This may mean that 
a RAMP1 expression has been reduced but not completely deleted and therefore 
cells may retain viability through a knockdown phenotype. Reports of RAMP1 
knockdown in both PC3 and LNCaP cells show that cell proliferation was not reduced 
significantly until day 6 [105]. Experiments could have been run for longer and may 
have revealed differences in these CRISPR clones at a later time point.  
 
An alternative explanation for the variance seen between different CRISPR 
clones is that these are simply different cells. Many genetic changes occur in cancer 
cells and this leads to heterogeneity in tumours which are often described as 
polyclonal in nature. This means that one population of tumour cells may have 
different genetic changes compared with host cells and also other cancer cells within 
the same tumour. This intratumour plasticity is why single biopsies in the clinic can 
often neglect to reveal the complete tumour heterogeneity and this failure to detect 
all variants can often lead to drug-resistant populations of cancer cells [186]. It may 
therefore be argued that in vitro study of single cells isolated from a cancer cell line 
has equal disadvantages when investigating the role of RAMP1 deletion in prostate 
cancer. This is why multiple CRISPR clones were selected for functional testing in 
order to eliminate the possibility of “clonal” effects disguising the true effect of 
RAMP1 deletion. The selected CRISPR clones may not harbour the heterogeneity of 
a PC3 cell line but single cell analysis has become a popular technique in cancer 
research due to the interest in “cancer stem” or “tumour-initiating” cells. Prostate 
cancer tumours can often derive from single cell clones that have reached secondary 
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sites of metastasis as stated in the “seed and soil” hypothesis [179]. There is further 
evidence of prostate tumours originating from a small number of “tumour-initiating” 
stem-like cells [187]. It has been hypothesised that these clones give rise to cancer 
cells that undergo further genetic mutations ultimately forming a heterogenetic 
tumour population [188]. Although cancer cell lines are often described as poor 
models of cancer as they fail to represent the true characteristics of an in vivo 
tumour, they are nonetheless an important tool in identifying key targets in a 
disease. Heterogeneity is also seen in prostate cancer cell lines and this may also 
explain the differences in viability seen in different clonal populations. In conclusion, 
CRISPR clones A7, C1 and D5 all had below 10% expression after qPCR analysis and 
consistently showed reduced viability. These were selected as RAMP1 KO clones to 
be further tested for the effect of RAMP1 deletion in vitro.  
 
RAMP1 deletion appears to affect PC3 cell viability and also the growth rate 
of cells over a period of three days however the mechanism by which RAMP1 may 
be acting remains unknown. In attempt to determine this, wild type PC3 cells were 
assayed for viability over a course of five days and were treated with either CGRP or 
Telcagepant (a CGRP antagonist). Previous reports have claimed treatment of CGRP 
to influence PC3 cell growth at 1µM concentrations however this effect was very 
slight [103]. Experiments here show no significant effect of either CGRP or 
Telcagepant on PC3 cell viability on any time point measured. This may indicate that 
CGRP is not responsible for the effect seen in RAMP1 KO cells and their viability.  
 
 After a primary tumour has been established, the first step in metastasis will 
be migration of the cells. In the case of prostate cancer, this is often towards the 
bone microenvironment and this is reflected in prostate cancer patients where 
around 90% have incurable bone metastases [189]. To test the effect of RAMP1 
deletion on the migratory capacity of PC3 cells, wound healing or “scratch” assays 
were performed. Interestingly, results show that two different RAMP1 KO clones 
were migrating (up to 94%) faster than PC3 wild types, whereas one clone showed 
no significant differences. When migration was measured using a Transwell 
migration chamber, all RAMP1 KO clones showed faster migration rates when 
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compared with PC3 wild type cells. It is unclear why deletion of RAMP1 results in 
increased migration rates however previous studies have found a relationship 
between RAMP1 and NF-kB in vascular smooth muscle cell (VSMC) migration. It was 
found that RAMP1 inhibits migration of these cells through NF-kB signal pathways 
[190]. It could be hypothesised that deletion of RAMP1 would remove this inhibitory 
effect leading to increases in migration in VSMCs and possibly also in PC3 cells but 
this has not been investigated. Cells are pre-treated with Mitomycin C, a DNA cross-
linker which stops cell proliferation and ensures only migration is measured during 
in vitro assays. The dose of mitomycin C was taken from the literature from studies 
on PC3 cells [184],  however it is possible that RAMP1 KO cells were not responsive 
to this dose and so the proliferation of these cells has been mistaken as migration.  
 
 The process of prostate cancer cells migrating away from the primary tumour 
also requires their invasion into the stroma. Triggering of signalling pathways that 
control cytoskeletal dynamics allows invading tumour cells to penetrate basement 
membranes and endothelial walls of vessels to enter the blood stream and 
metastasise to distant sites [191].  To determine the effect of RAMP1 deletion on 
PC3 cell invasion, Transwell Matrigel-coated invasion chambers were used in vitro. 
Basement membranes contain extracellular matrix which is composed structural 
proteins such as laminin, collagen IV and heparin sulphate proteoglycan [177]. 
Matrigel is an extract taken from a tumour found to contain all of these components 
and can be used to culture cells and to test the invasive potential of cells [192]. 
Invasion data was expressed as a percentage of cells invading through the Matrigel-
coated membrane relative to cells migrating through the control membrane. Using 
this recommended calculation, it was found that RAMP1 KO cells had 70-90% 
reduced invasion compared with PC3 wild type cells. This is an interesting result as 
migration was not found to be reduced, a process that is often associated with 
invasion. In order to acquire this ability of invasion, cancer cells must enter epithelial-
to-mesenchymal transition (EMT). In many cases this increase in invasion has been 
coupled with increased migration [193], however recent findings have suggested 
that migration is not always a characteristic of EMT and that migration and invasion 
can act separately in EMT-cancer cells in vitro and in vivo [176].  
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 The next step in metastasis for prostate cancer cells is to colonise distant sites 
to form secondary tumours. RAMP1 KO cells were tested for the ability of single cells 
to proliferate into colonies using clonogenic or colony formation assays [194]. 
Results showed decreases in both number of colonies and the average size of 
colonies. The latter result may not be surprising as these cells had already shown 
reduced viability and growth rates. However, RAMP1 KO clearly resulted in fewer 
cells growing successfully into colonies. This in vitro study suggests that the 
colonisation of PC3 cells is altered by the deletion of RAMP1. An important property 
of cancer cells during colonisation of secondary sites, is the ability to adhere to 
extracellular matrix. It was important to also test the adherence of RAMP1 KO cells 
to more accurately measure the ability of the KO cells to colonise during metastasis. 
Fibronectin is an extracellular matrix protein that plays a major role in the adhesion 
of many different cell types [195]. Adhesion was measured by counting the amount 
of PC3 wild type and RAMP1 KO cells that could adhere to fibronectin-coated culture 
plates.  The percentage of adherent cells was found to be significantly reduced in 
RAMP1 KO cells by up to 75%. This indicates RAMP1 as an important factor in PC3 
cell adherence and colonisation.  
 
 Once cancer cells have successfully metastasised and formed secondary 
tumours they must evade apoptosis. This is described as the third hallmark of cancer 
[5] and is a characteristic of cancer cells that permits uncontrollable division by 
“hijacking” cell growth pathways and evade cell death by loss-of-function mutations, 
most commonly in p53 a prominent regulator of cell death [196] or by upregulating 
anti-apoptosis proteins such as Bcl-2 and downregulating pro-apoptosis proteins 
such as Bax and Bak [197]. Caspases are regulators of the apoptosis pathway and 
often execute cell death. These regulatory factors are often indicative of levels of 
apoptosis within a cell population [172]. Caspase 3/7 are part of the downstream 
caspase pathway and are known as effectors or “executioners”. The caspase 3/7 
activity was measured in RAMP1 KO cells to see the effect of RAMP1 deletion on cell 
death. Interestingly, it was found in PC3 wild type cells that caspase 3/7 activity was 
relatively low until apoptosis was “induced” with a period of serum starvation. This 
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effect however was not seen in RAMP1 KO cells. In normal conditions, RAMP1 KO 
clones A7 and D5 showed high caspase levels indicating the number of cells 
undergoing apoptosis is always relatively high compared with PC3 wild type cells. 
This high amount of activity did not further increase after a period of serum 
starvation. A possible explanation is that cells had produced the maximum amount 
of caspase 3/7 possible during normal conditions as an effect of RAMP1 deletion. 
RAMP1 KO clone C1, did not show significant differences in caspase 3/7 activity 
between PC3 wild types in normal conditions, nor any increases in caspase activity 
after serum starvation. It is unclear why this was found, however if apoptosis is 
occurring but at an earlier stage, the activity of different caspases may increase (such 
as caspase 8.) Experiments were attempted to measure early caspase “apoptosis 
initiators” levels but could not be successfully optimised. Future work may 
determine the activity of these markers in RAMP1 KO and PC3 wild type cells.  
 
 These findings are typically concomitant with the current literature. Studies 
have used RAMP1 shRNA knockdown to show this decreases proliferation in 
prostate cancer cells and disrupts the ability of cells to form colonies in vitro. 
However, knockdown of RAMP1 did not, in this case, influence caspase 3 activity 
[105]. It is therefore possible that complete deletion of RAMP1 is required to alter 
pro-apoptotic factors in prostate cancer cell lines such as PC3. CGRP has been used 
to treat prostate cancer cells and increases in migration and invasion have been 
reported [178, 198]. This sets a precedent for reduced migration or invasion after 
RAMP1 deletion, however only reductions in invasion were observed in PC3 cells. 
The increased migration in RAMP1 KO cells confounds previous reports on CGRP as 
RAMP1 is a key receptor component of CGRP. However, the same studies found no 
significant effect of CGRP treatment of prostate cancer cell adherence. Therefore, it 
is possible that RAMP1 may be acting separately from CGRP or through another 
ligand.  In cardiomyocytes, RAMP1 has been reported to exert anti-apoptotic effects 
during oxidative stress by increasing expression of Bcl-2 [173]. This mechanism was 
contributed to a CLR-RAMP1 complex and therefore attributed to CGRP. Another 
hallmark of cancer is the resistance of cancer cells to hypoxia, a condition that can 
trigger oxidative stress [5]. It is therefore interesting that RAMP1 should be 
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implicated in inhibiting apoptosis during oxidative stress and the understanding of 
this role may benefit from further investigations into the effect of RAMP1 in hypoxic 
conditions.  
 
 It is also important to consider the effect of RAMP1 deletion on downstream 
signalling in prostate cancer cells. Magnetic bead assays have been developed to 
allow the targeting of multiple analytes within cell lysates. A multi-pathway 9-plex 
assay was used to investigate which signalling pathways may be regulated by 
RAMP1. Results showed significant downregulation in Akt and STAT3 
phosphorylation in RAMP1 KO samples compared with PC3 wild type. Akt promotes 
cell survival and is often mutated in cancers, prostate cancer included. PTEN, a 
negative regulator of Akt signalling is mutated in 60% prostate cancer patients and 
the PI3K/Akt pathway is associated with androgen signalling too [199, 200]. Previous 
studies have also shown that depletion of RAMP1 results in downregulation of IL-6 
signalling which is known to activate Akt in LNCaP cells [105, 201]. Interestingly, IL-6 
is expressed predominantly in androgen insensitive cell lines such as DU145 and PC3 
suggesting a link with androgen independence. LNCaP cells do not express IL-6 but 
do possess IL-6 receptor. Transfection of IL-6 into LNCaP cells results in increased 
proliferation (P = <0.05) and activates STAT3 binding [202]. Results showing that 
RAMP1 KO in a PC3 cell line cause downregulation of Akt and STAT3 may therefore 
be due to IL-6 downregulation in RAMP1 KO cells. This should be further investigated 
as it is clinically relevant to advanced prostate cancer patients. Serum levels of IL-6 
are found to be higher in patients with bone metastasis compared with those 
without [203]. Although no significant differences were found in levels of other 
phosphorylated protein the data was observed to be slightly different between each 
extraction of cell lysates. Therefore, further repeats may reveal smaller changes in 
protein levels between PC3 wild type and RAMP1 KO cells that are not currently 
significant.  
 
 Taken together these findings implicate RAMP1 as an important factor in 
prostate cancer metastasis at each sequential step, including downstream molecular 
interactions. Results show that in PC3 cells RAMP1 is required for proliferation and 
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viability, invasion into the ECM, adhering to the surrounding stroma and promoting 
the colonisation of individual cells. These findings will be tested in vivo to determine 
the role of RAMP1 in the growth of xenograft tumours and metastatic tumours in 
the bone microenvironment.  
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 CHAPTER 5: FUNCTIONAL EFFECT OF 
RAMP1 DELETION IN VIVO. 
 
 
 
 Introduction  
 
Despite continuing advances in the field of prostate cancer research, this 
disease remains the most common cancer to affect men in the western world [204]. 
In the UK, 1 in 8 men will be diagnosed with prostate cancer at some point in their 
lifetime and 54% of those patients will be aged 70 or over [1]. Although prostate 
cancer is often considered an age-related disease due to these statistics, over 10% 
of new cases in the US occur in men aged 55 or less [205].  This early onset of prostate 
cancer is also often associated with a poorer prognosis compared with older patients 
[206].  
 
Further investigation into the progression of prostate cancer in both young 
and old patients relies on realistic models of the disease. There is a limited 
availability of prostate cancer cell lines that have been successfully immortalised to 
allow in vitro studies of the intracellular mechanisms promoting tumorigenesis [207]. 
Unfortunately, in vitro studies may not reveal useful information on the effect 
prostate cancer cells have on the tumour microenvironment.  To study this 
mechanism, in vivo prostate cancer models are required. Models must have both 
pathological and physiological relevance to the human disease studied, presenting a 
challenge in prostate cancer as this disease does not naturally occur in mice (the 
most frequently used animals for in vivo studies) [125]. A tractable method that 
utilises prostate cancer cell lines in an in vivo environment, is the subcutaneous 
xenograft mouse model. Over 25 years ago this model was developed to use 
immortalised human cancer cell lines that can be injected subcutaneously into 
athymic (and therefore immunocompromised) mice. These cells, when injected in 
combination with reconstituted basement membrane matrix (also known as 
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Matrigel), can quickly establish subcutaneous tumours that often result in rapid 
proliferation [208]. 
 
Cell lines named LNCaP, PC3 and DU145 have all been previously used for 
prostate xenograft models, but the PC3 cell line has been described to have a higher 
metastatic potential than the DU145 and is androgen-independent, unlike LNCaP 
cells [126, 209].  PC3 cells may therefore best represent the most aggressive stages 
of prostate cancer where cells lose their androgen dependence and become 
metastatic [210]. Subcutaneous xenograft models may not mimic prostate cancer in 
humans very accurately, but they have been previously described as a “first port-of-
call” for initial studies that may lead to more advanced in vivo models which often 
have longer time frames and higher costs [138]. Recent uses of subcutaneous PC3 
xenograft models have led to important findings, for example treatment with 
simvastatin has been found to reduce tumour growth and to decrease Akt activity 
and prostate serum antigen (PSA) levels [211]. This groundwork allows for more in-
depth studies into a treatment as a potential therapy in prostate cancer. In addition, 
a comprehensive review of this technique found that xenograft models can be highly 
predictive of drug efficacy and activity in humans. Therefore they are important tools 
for screening cytotoxic chemotherapeutic drugs and can often reveal information 
regarding pharmacokinetics or drug doses that are clinically relevant [212]. 
 
The most common site for xenograft in prostate cancer is a subcutaneous 
site, usually on the flank. The advantage of this is that injected cancer cells are grown 
in a site containing nutrients and other circulating factors which are physiologically 
relevant. Tumour cells are therefore given the opportunity to influence their local 
environment by acting on host stromal cells and tissue to promote tumour growth. 
An example of this is the cells ability to promote the production of new blood vessels 
at the site of injection.  Tumours in this location are easy to measure/monitor and 
the method is generally very reproducible [138]. Nevertheless a key disadvantage of 
subcutaneous xenograft is that this does not represent the true prostate 
microenvironment and metastasis is rarely observed, even with highly aggressive cell 
lines such as PC3 [212]. Nonetheless, prostate cancer is a metastatic disease which 
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has the capacity to metastasise to bone in more than 80% of prostate cancer cases 
[213]. Therefore, understanding of disease progression is limited without models 
that mimic that characteristic in vivo.  
 
Orthotopic xenografts of human prostate cancer cell lines such as LNCaP and 
PC3 result in lymph node, lung and bone metastases when tested in male athymic 
(nude) mice [135, 136]. This not only permits the study of metastasis of cells from 
the prostate to distant sites, but also may reveal the behaviour of these cells in a 
new metastatic niche.  A limitation of orthotopic models of prostate cancer 
metastasis is that the mouse prostate gland differs from human both in structure 
and composition. The mouse prostate is composed of four distinct lobes unlike the 
human which is described as having central, peripheral and transitional “zones” 
which are not clearly demarcated [214]. Mouse prostate glands also have differences 
in the proportion of basal and neuroendocrine cells with reduced fibromuscular 
stromal populations [215]. These variations also reflect differing genetic 
backgrounds of the prostate gland compared with humans and require that care is 
taken in interpretation of data from mouse orthotopic studies. Orthotopic models 
are also predominantly relevant to advanced/late stages of human disease therefore 
restricting what can be learned about prostate cancer as a progressive disease [216].  
 
Alternative mouse models have been developed in attempts to overcome the 
limitations of xenograft experiments and to improve understanding of mechanisms 
of metastasis in prostate cancer. Injection of prostate cancer cell lines into the left 
ventricle of the heart allows cells to circulate with oxygen-rich blood around the 
body. Targeting the left ventricle, minimises the risk of cells clumping in the lung 
capillary bed. Intracardiac injection models mimic the later stages of metastasis 
when tumour cells have left the primary site and are circulating to distant sites to 
form secondary tumours. The cells can also be labelled with luminescent markers 
such as luciferase, allowing detection of metastasis in real time compared with 
previous results solely based on endpoint microdissection of distant metastases 
[217, 218]. Following intracardiac injection of luciferase-labelled PC3 cells, skeletal 
metastases can be observed after 1 week and using bioluminescent imaging 
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techniques, hind limb and craniofacial metastases can be seen to develop 
progressively [218, 219]. Information potential therapeutic treatments can be 
achieved by treating at the time of intracardiac injection. This will show how 
effective the treatment may be at preventing cells from homing to the site of 
metastasis. Alternatively, treatments that are started after 1 week may show the 
effect on metastatic growth and the ability of cells to contribute to the metastatic 
niche.  
 
Results of such experiments are both highly informative and clinically 
relevant. The intracardiac xenograft model allows the study of prostate cancer cells 
and their interaction with the bone microenvironment. This complicated 
relationship can therefore be more deeply explored when compared with in vitro 
studies or modest subcutaneous and orthotopic xenografts. To recapitulate human 
prostate cancer in a mouse model, transgenic mice can be genetically engineered to 
present with prostate cancer in the later stages of life. For example, the disruption 
of target genes such as Nkx3.1 or PTEN results in transgenic mice developing defects 
that resemble prostate intra-epithelial neoplasia [220, 221]. These mice can then be 
studied for specific changes or deregulation of genetic pathways that may also be 
key to prostate cancer progression in humans. Transgenic models still only represent 
a single mutation contrasting with the true disease which will harbour many 
different genetic alterations. Practically, this method can also be time-consuming 
and costly and therefore can be described as a more high-end, complex and involved 
in vivo model.   
 
In an attempt to better represent the genetic landscape of prostate cancer, 
patient derived xenograft (PDX) are considered a good preclinical model highlighting 
histological compatibility and harbouring similar gene expression and variants found 
in prostate tumours [222-224]. Practically, PDX models can be difficult to successfully 
establish as implantation of patient derived tissues can often be hard to do, 
especially when orthotopic. The site of implantation must ensure a good vascular 
supply and production of cytokines or growth factors required for tumour growth 
[225, 226]. Aggressive tumours are more likely to be engrafted successfully, limiting 
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PDX models to investigations of late stage disease rather than the early development 
of prostate cancer [222, 224].  Recent studies have also found that when generating 
human prostate cancer xenograft models, only 2% of biopsies result in a stable cell 
line that resembles prostate cancer. The remaining xenografts were found to be B 
cell lymphomas due to injection of xenografts inadvertently infected with the 
Epstein Barr virus (EBV) into immunocompromised mice [227]. EBV infects over 90% 
of humans often lying dormant and asymptomatic in immunocompetent individuals 
in their B-lymphocytes population. Therefore, care must be taken when selecting 
patient samples for PDX models. 
 
Recent research into the role of RAMP1 in prostate tumour progression using 
in vivo models is limited but there have been studies using subcutaneous xenografts 
and the PC3 cell line. Knockdown of RAMP1 was achieved using shRNA in a PC3 cell 
line and these cells were then injected into male athymic (nude) mice. RAMP1 
knockdown tumours were then compared with PC3 cells transfected with a control 
shRNA which were also injected subcutaneously. After 25 days of tumour growth, 
reductions of 20-30% in growth were seen in RAMP1 knockdown tumours and after 
the mice were sacrificed, this reduction was also seen in final tumour weight and 
size.  Subsequent immunohistological staining of the tumour tissues found Ki67 and 
pHH3 to be decreased in the RAMP1 knockdown tumours [105]. These are markers 
of proliferation and have been argued to be clinically relevant prognostic markers 
[167].  
 
There is a gap in the literature with regards to the mechanism by which 
RAMP1 may promote prostate cancer. RAMP1 is a subcomponent of G protein-
coupled receptors for different ligands, one of which is the calcitonin gene-related 
peptide (CGRP). CGRP has been previously found to be elevated in the sera of 
prostate cancer patients and can promote migration/invasion of prostate cancer cell 
lines including PC3 in vitro [101, 103].  It would therefore be beneficial to investigate 
the possible recruitment of CGRP by RAMP1 in the effort of promoting prostate 
tumour growth in vivo. This can be achieved by the use of CGRP antagonists such as 
Telcagepant (MK-0974) which have been incidentally clinically approved to treat 
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migraine [228, 229]. Reports have used the crystal structure of the RAMP1/CLR 
complex to show how Telcagepant can block access to the peptide-binding cleft at 
the CLR and RAMP1 interface [230]. Although there is a lack of data regarding 
telcagepant treatment in mice, a dose response of the antagonist will be tested on 
a mouse cell line to determine whether Telcagepant (or other available CGRP 
antagonists such as MK-3027 and Olcegepant) are potent on mouse CGRP receptors. 
This can be achieved using cAMP TR-FRET assays and will also indicate IC50 of the 
antagonist when inhibiting CGRP, also demonstrating appropriate doses to use for 
treatments in vivo.  
 If a link exists between CGRP and RAMP1 in prostate tumour growth in vivo, 
then the treatment of Telcagepant may reduce growth of subcutaneous tumours in 
PC3 wild type xenografts. Subcutaneous xenograft of RAMP1 KO cells will answer the 
null hypothesis that RAMP1 is not involved in the growth of prostate tumours in vivo. 
RAMP1 KO cells will therefore be subcutaneously injected with Matrigel into male 
athymic (nude) mice and compared with PC3 wild type xenografts. Treatment with 
Telcagepant will also aid to elucidate the mechanism by which RAMP1 is affecting 
tumour growth. Results of this in vivo experiment will either validate or repute 
previous in vitro findings. 
 
Histological analysis of tumour sections can be undertaken after the 
experiment to determine any changes in the expression of proliferative markers. 
Ki67 is a proliferative marker than can be targeted with immunohistochemistry and 
will reveal any differences in the number of proliferating cells in tumours from the 
different experimental groups. CD31 staining can also be used to measure 
differences in the number of blood vessels as this is an endothelial cell marker.  
 
 Hypothesis: 
 
1. Deletion of RAMP1 in a PC3 cell line reduces subcutaneous tumour growth in 
male athymic (nude) mice. 
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2. CGRP is signalling through the RAMP1:CLR complex to promote prostate 
tumour growth 
 
 Research Aims: 
 
1. To determine if RAMP1 knockout in a PC3 cell line results in reduced tumour 
growth in a subcutaneous xenograft model. 
 
2. To determine if CGRP is promoting prostate tumour growth in vivo via the 
RAMP1:CLR complex by treating mice with CGRP antagonist Telcagepant 
(MK-0974) and observing the effects of tumour growth compared with 
vehicle treated mice. 
 
 
 Methods and Materials  
 
5.4.1 Mice 
 
Xenograft subcutaneous studies were performed using 6-week-old male BALB/c 
immunocompromised (athymic nude) mice (Envigo). All procedures complied with 
the UK Animals (Scientific Procedures) Act 1986 and were reviewed and approved 
by local Research Ethics Committees of the University of Sheffield under Home Office 
project licence PF61050A3. 
 
5.4.2 CGRP Antagonist Preparation  
 
Telcagepant (MK-0974) was purchased from MedChem Express. The compound was 
reconstituted to 10mM in 1mL DMSO and then further diluted with Kolliphor® HS 
15: Kollisolv® PEG E 400: dH2O=1:3:6. 10mg/kg of Telcagepant was used to treat each 
mouse in 100uL Kolliphor® HS 15: Kollisolv® PEG E 400: dH2O=1:3:6.  
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5.4.3 Preparation of Cells for Subcutaneous Injection 
 
 PC3 wild type and RAMP1 KO (clone D5) cells were grown in triple layered 
cell culture flasks (Thermo Fisher) as previously described (see Chapter 2, Section 
2.4.1-3).  When cells had been grown to 70% confluence, all cells were washed with 
100mL PBS (Gibco) per flask once. 10mL TrypLE (Thermo Fisher) was diluted with 
10mL PBS and added to each flask, cells were then incubated at 37°C for 5-10 
minutes. Cell detachment was then confirmed using an inverted microscope 
(model?). 20mL PBS was then added to wash cells and the total cell suspension was 
transferred to a 50mL Falcon tube. Cells were then centrifuged at 1,000 x pm for 5 
minutes. Cell pellets were resuspended in 2mL PBS and combined together for cell 
counting using methods previously described (See Chapter 2, Section 2.4.3). Twice 
the needed number of cells were resuspended in 50% PBS – 50% Matrigel solution 
to account for human error.  Matrigel solution (Corning) was thawed on ice at 4°C 
overnight before being used to resuspend cells.  
 
5.4.4 Subcutaneous Injection of Cells 
 
 1.5 x 108 PC3 wild type or RAMP1 KO cells were suspended in 50% PBS and 
50% Matrigel and kept on ice in 1.5mL eppendorf tubes. 40 mice were divided into 
four groups. The experimental group contained 20 mice subcutaneously injected 
with 100µL of either PC3 wildtype or RAMP1 KO cell suspension. These two groups 
of mice were then treated daily with intraperitoneal injections of 10mg/kg 100µL 
Telcagepant (in Kolliphor® HS 15: Kollisolv® PEG E 400: dH2O=1:3:6). The vehicle 
control group contained 20 mice that were also subcutaneously injected with 100µL 
of either PC3 wildtype or RAMP1 KO cell suspensions (5x106 in 50% PBS and 50% 
Matrigel) and these mice were treated daily with intraperitoneal injections of 100µL 
Kolliphor® HS 15: Kollisolv® PEG E 400: dH2O=1:3:6.  
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5.4.5 Measurement of Tumour Growth 
 
 After cells had been subcutaneously injected into the mice, tumour growth 
was monitored twice a week by measuring with vernier callipers (LOUISWARE). 
Length and width of each tumour was recorded and then volume was calculated as 
a cylinder using the following formula based upon the assumption that they are 
cylindrical: 
V =hp(r2) 
 
V = Volume 
r = width of tumour ÷ 2 
h = length of tumour  
Weights were also recorded for each mouse twice a week and monitored for any 
weight loss of >10%.  
 
 
5.4.6 Experiment Endpoint 
 
 After 2 weeks, the mice were euthanased using Schedule 1 method of 
concussion and cervical dislocation and then blood was collected. Collection of 
subcutaneous tumours, liver, spleen, kidneys, heart and lungs was performed and 
these organs were then weighed and stored in 100% formalin for histological 
processing by the Skeletal Analysis Laboratory (University of Sheffield.)  
 
5.4.7 Immunohistochemistry Staining of Tumour Tissues 
 
 Tumour tissues were sectioned and embedded in paraffin wax and then 
select slides were stained for haematoxylin and eosin by Mark Kinch from the 
Skeletal Analysis Laboratory (University of Sheffield).  
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5.4.8 Ki67 Immunohistochemistry Staining 
 
Slides were first dewaxed by immersion in xylene for 5 minutes twice and then 
rehydrated for two minutes through a gradient of concentrated ethanol (from 100% 
to 70%) before being left to rest in distilled water for a minimum of 5 minutes. 
Antigen retrieval was performed by incubating slides in TE (10mM Tris, 1mM EDTA, 
PBS pH 8.0) buffer with 0.05% Tween-20 (Fisher Scientific) for 25 minutes in a food 
steamer (Tesco). Slides were left to cool to room temperature for 20 minutes and 
were then washed once with TE buffer quickly and then twice for 10 minutes on a 
plate shaker at 650rpm. Sections were then blocked using 15% goat serum (Vector 
Laboratories) in TBS-T (50mM Tris, 150mM NaCl, 0.05% Tween-20, PBS, pH 7.6) 
buffer for 1 hour at room temperature in an immunotray. Slides were then incubated 
with Ki67 anti-human rabbit monoclonal antibody (AbCam) diluted in blocking buffer 
1:250 for one hour at room temperature in an immunotray.  
 
 Slides where then washed three times in TBS buffer for 5 minutes each on a 
plate shaker at 650rpm. Slides were next incubated with a goat anti-rabbit IgG HRP 
conjugated secondary antibody (Dako) diluted in blocking serum 1:150 for 30 
minutes at room temperature in an immunotray. Slides were then washed in TBS 
buffer three times for 5 minutes each on a plate shaker at 650rpm. Slides were then 
incubated in an avidin-biotin substrate diluted in TBS buffer (Vector Laboratories) 
for 30 minutes at room temperature in an immunotray. Slides were then washed 
three times in TBS buffer for 5 minutes each on a plate shaker at 650rpm. Slides 
where then incubated with a DAB solution (Vector Laboratories) for 2 minutes each 
and then DAB was inactivated by washing the slides with distilled water. Slides were 
continually rinsed in distilled water for a minimum of 5 minutes and then 
counterstained with haematoxylin for 20 seconds. Slides were dehydrated through 
increasing concentrations of ethanol (from 70% to 100%) for 2 minutes and then 
incubated in xylene twice for 5 minutes. Slides were then mounted with coverslips 
using DPX mounting medium. Slides were scanned using a Panoramic 250 Flash III 
 162
slide scanning system (3DHISTECH) and percentage of positively stained cells was 
calculated and analysed using QuPath v0.1.2 software [231].  
 
5.4.9 CD31 Immunohistochemistry Staining 
 
 Slides were first dewaxed by immersion in xylene for 5 minutes twice and 
then rehydrated for 30 seconds through a gradient of concentrated ethanol (from 
100% to 70%) before being left to rest in distilled water for a minimum of 5 minutes. 
Antigen retrieval was achieved by heating 1X citrate buffer (AbCam) pH 6.0 to 80°C 
in a PT module (Thermo Scientific). Slides were then added to the citrate buffer and 
incubated for 25 minutes at 95°C. After cooling slides were rinsed in distilled water 
for a minimum of five minutes. Slides were then blocked for endogenous 
peroxidases using 3% hydrogen peroxidase in distilled water (Sigma) for 20 minutes. 
Slides were then rinsed with distilled water for five minutes on a shaker at 550 rpm. 
Sections were outlined using a PAP pen and blocked with 15% rabbit serum in T-BST 
(Vector Laboratories) for 30 minutes at room temperature in an immunotray. A 
monoclonal rat anti-mouse CD31 primary antibody (Stratech) was diluted 1:50 in TBS 
and slides were incubated overnight at 4°C in an immunotray.  
 
Slides were then washed three times on a shaker at 550 rpm in TBS-T before 
being incubated with a biotinylated anti-rat secondary antibody diluted 1:400 in 
block for 30 minutes at room temperature in an immunotray. Slides were then 
washed for 10 minutes in PBS on a shaker at 550 rpm and then incubated with an 
avidin-biotin substrate (Vector Laboratories) diluted in TBS for 30 minutes at room 
temperature in an immunotray. Slides were then washed again in PBS for 5 minutes 
on a shaker at 550 rpm. Immpact DAB Eq (Vector Laboratories) was then added to 
the slides and incubated at room temperature for 10 minutes in the dark. Slides were 
then washed twice in PBS for 5 minutes on a shaker at 550 rpm. Slides were 
counterstained with haematoxylin for 30 seconds and rinsed with distilled water. 
Slides were dehydrated through increasing concentrations of ethanol (from 70% to 
100%) for 2 minutes and then incubated in xylene twice for 5 minutes. Slides were 
then mounted with coverslips using DPX mounting medium. Slides were scanned 
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using a Panoramic 250 Flash III slide scanning system (3DHISTECH) and analysed 
using ImageJ software.  
 
5.4.10 ImageJ Analysis of CD31 Staining 
  
 Slide images were opened in QuPath v0.1.2 software and regions of interest 
(ROIs) were chosen at random for each tumour at a magnification of 3.5x. Due to 
large differences in tumour size only one or two ROIs were required for RAMP1 KO 
tumours to include the entire section. Six different ROIs were drawn for larger wild 
type PC3 tumours. These were then exported as TIFF files to ImageJ for analysis. 
Colour thresholds were set to exclude all blue (haematoxylin staining) sections and 
highlight brown staining. Thresholds were adjusted to exclude non-specific staining 
using a section with the highest amount of background and then these thresholds 
were used for all tumours sections (see Fig 5.2).  Images were then converted to 8-
bit and the Analyse Particles function was used with the following settings (see Fig 
5.1.) to generate “masks” of areas of staining.  
 
Mask images were then saved for all ROIs for each tumour and compressed 
into a stack of images for analysis. All slides in the stack were then measured for area 
fraction, giving a percentage value for the area of positive staining for each ROI. 
These values were then compiled using Graphpad Prism.  
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Screenshot of settings used to analyse particles. Pixel size was increased to 30 to 
exclude small particles resulting from background non-specific staining.  
  
Figure 5.1 ImageJ analysis settings 
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ImageJ analysis of CD31 positive staining. TIFF files of ROI were exported to Image J 
for wild type PC3 (A-C) and RAMP1 KO (D-E). Colour thresholds were set and a region 
for analysis was drawn to exclude scale bars (B & E). 8-bit images were then analysed 
for particles larger than 30 pixels and these images were measured for percentage 
area of staining.   
Figure 5.2 ImageJ analysis for CD31 IHC staining. 
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5.4.11 cAMP LANCE TR-FRET Assays 
 
 
 Measurements of cAMP activity were performed using methods as 
previously described (see Chapter 2, Section 2.4.15). Forskolin dose response curves 
were generated to optimize cell density of cell lines. Panc02 cells were found to 
result in the largest linear range when adding 500 cells to each well (see Fig 5.3). A 
dose response of CGRP was then performed (see Fig 5.4) to calculate the IC50 and 
this dose was used for assays testing the inhibitory effect of CGRP antagonists: 
Telcagepant, MK-3207 and Olcegepant. CGRP antagonist dose responses were 
performed using concentrations ranging from 10µM to 10pM at every log.  Data was 
plotted using Graphpad Prism 7 software in a non-linear four parametric curve.  
 
 
Figure 5.3 Forskolin dose response on Panc02 cells. 
Dose response of forskolin using different densities of Panc02 cells. 500 cells per well 
(blue) was chosen as the optimal density giving the widest linear range. All values are 
mean ±SEM, n=3. 
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Table 5.1 Best fit values for forskolin curves. 
Best fit values for each cell density show that 500 cells per well gives that highest 
“span” compared to other cell densities and therefore the widest linear range.  
 
 
 
Figure 5.4 CGRP dose response on Panc02 cells 
Dose response of CGRP on Panc02 cells shows a dose-dependent production of cAMP. 
All values are mean ±SEM, n=3. 
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Best fit values for CGRP dose response shows a low linear range compared with 
forskolin dose responses and an IC50 of 12nM.  
 
 
5.4.12 Statistical Analysis  
 
 All data are expressed as mean ±SEM. Statistical significance was tested for 
(unless otherwise stated) using an unpaired Student’s t-test and F-test with Prism 7 
software (GraphPad). P <0.05 was considered significant. Values of best fit were 
generated for dose response curves (see Tables 5.1 & 5.2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5.2 Best fit values for CGRP curve. 
 169 
 Results 
 
5.5.1 Tumour Development 
 
 Measurements of tumour volume were performed twice weekly using 
callipers and were then plotted for each time point to see the growth of tumours 
from 72 hours post-injection (to allow tumours time to establish and Matrigel to 
dissolve) until the last day of measurement before the. RAMP1 KO tumours were 
found to be significantly smaller than PC3 wild type tumours at all time points (see 
Fig 5.5.) This result was also reflected in tumour mass, measured at the end of the 
experiment. There were significant reductions in the size and weight of the RAMP1 
KO tumours compared with PC3 wild type (see Fig 5.6). 
 
 
Tumour volume of PC3 wild type and RAMP1 KO tumours. RAMP1 KO tumours 
showed significant decreases in tumour volume across all time points (P = <0.0001). 
All values are mean ±SEM, WT n=8, KO n=10. (Students unpaired t-test). 
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Figure 5.5 Tumour volume measurements. 
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Figure 5.6 Tumour mass measurements. 
Tumour mass was calculated after dissection of tumours at the end of the 
experiment. A significant reduction in tumour mass was seen in RAMP1 KO tumours 
compared with PC3 wild type. All values are mean ±SEM, WT n=8, KO n=10. (Students 
unpaired t-test). 
 
 
 
Comparison of tumour volumes between groups treated with 10mg/kg 
Telcagepant and groups treated with a vehicle control showed no significant 
differences in both PC3 wild type and RAMP1 KO tumours (see Fig 5.7). However, on 
Day 17, a slight separation of tumour growth could be observed between PC3 wild 
type treatment and vehicle control groups. This was also reflected in tumour mass 
which was calculated after dissection of tumours at the end of the experiment (see 
Fig 5.8). Endpoint liver mass was also measured in all groups and was seen to be 
significantly decreased in both treatment and control PC3 wild type groups 
compared with treatment and control RAMP1 KO groups (see Fig 5.9). However, 
differences in liver mass were also reflected in the total weight of the mice (see Fig 
5.10).  
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Tumour volume of treatment and vehicle control groups for both PC3 wild type and 
RAMP1 KO tumours. No significant differences were found in tumour volume 
between treatment and control groups for either PC3 wild type or RAMP1 KO. A slight 
separation of PC3 treated and control groups was observed on Day 17. All values are 
mean ±SEM, WT control n=8, KO control n=10 WT treatment n=8, KO treatment n=9. 
(Students unpaired t-test). 
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Figure 5.7 Tumour volume measurements for all experimental groups. 
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Tumour mass of treatment and vehicle control groups for both PC3 wild type and 
RAMP1 KO tumours. No significant differences were found in tumour mass between 
treatment and control groups for either PC3 wild type or RAMP1 KO.  
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Figure 5.8 Tumour mass measurements for all experimental groups. 
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Liver mass for treatment and vehicle control groups for both PC3 wild type and 
RAMP1 KO tumours. Significant decreases in liver mass was seen for PC3 wild type 
tumours (both treatment and control groups) when compared with RAMP1 KO (P 
<0.0001). All values are mean ±SEM, WT control n=8, KO control n=10 WT treatment 
n=8, KO treatment n=9. (Students unpaired t-test). 
 
 
 
Figure 5.10 Endpoint total mice weights for all experimental groups 
Total mouse weights for treatment and vehicle control groups for both mice injected 
with PC3 wild type and RAMP1 KO cells. Significant decreases in weight were seen 
between PC3 wild type and RAMP1 KO groups (P <0.0001). All values are mean ±SEM, 
WT control n=8, KO control n=10 WT treatment n=8, KO treatment n=9. (Students 
unpaired t-test). 
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Figure 5.9 Endpoint liver mass measurements for all experimental groups. 
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5.5.2 Immunohistochemistry 
 
 
 Staining of tumour sections with haematoxylin and eosin resulted in 
observed differences in structure between PC3 wild type and RAMP1 KO tumours. 
PC3 wild type tumours were much larger than RAMP1 KO and showed evidence of 
necrotic lesions in the largest tumours (see Fig 5.11 & 5.12.) These lesions were not 
found in any RAMP1 KO tumours, which appeared much less dense in structure and 
sections showed variation in tissue types including fat and muscle whereas PC3 wild 
type tumours were much more homogenous. Many PC3 wild type tumours showed 
increased development of blood vessels both within the tumour tissue and towards 
the surface of the dermis. Blood vessels were also observed in RAMP1 KO tumours 
but not as often and in lower numbers (see Fig 5.13), however quantification with 
CD31 marker showed this not to be the case.  Tumour sections were also stained to 
target Ki67, a proliferative marker (see Fig 5.14). No significant differences in the 
positivity of Ki67 stained cells were observed between PC3 wild type and RAMP1 KO 
tumours (see Fig 5.15).   
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Figure 5.11 Images of H&E staining of PC3 WT tumour. 
Haematoxylin and eosin staining of a wild type PC3 tumour. Multiple PC3 wild type 
tumours showed necrotic lesions (yellow arrows) identified by the damaged cell 
structure and an increased presence of extracellular matrix.  
  
A 
B 
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Figure 5.12 Image of H&E staining for RAMP1 KO tumour. 
Haematoxylin and eosin staining of RAMP1 KO tumour. Structural differences were 
observed in RAMP1 KO tumours compared with PC3 wild type including reduced 
density of the tumour tissue and more variation in cell types (yellow arrows) .  
  
A 
B 
 177 
 
 
 
 
Haematoxylin and eosin staining of PC3 wild type and RAMP1 KO tumour tissue. An 
increased number of blood vessels (yellow arrows) were observed in PC3 wild type 
(A) tumours when compared with RAMP1 KO (B). This was quantified using CD31 IHC 
(see Fig 5.17.) 
  
Figure 5.13 Images of H&E staining for wild type and RAMP1 KO PC3 tumours. 
A 
B 
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Figure 5.14 Image of Ki67 staining for wild type and RAMP1 KO PC3 tumours. 
Immunohistochemistry staining for Ki67 (brown) in PC3 wild type (A) and RAMP1 KO 
(B) tumour sections. No obvious differences were observed between wild type and 
knockout sections. Intensity of staining (brown) appears slightly more pronounced in 
RAMP1 KO tumours.  
  
A 
B 
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No significant differences were seen in the number of positive cells stained for Ki67 
between PC3 wild type and RAMP1 KO tumours. All values are mean ±SEM, WT n=6, 
KO n=8. (Students unpaired t-test). 
 
 
 CD31 staining was also performed on both PC3 wild type and RAMP1 KO 
control tumour sections. In wild type tumours, staining was very specific and 
highlighted endothelial cells situated in small blood vessels through the tumour 
structure and collections of larger vessels were often found near the surface of 
tumours (see Fig 5.15). CD31 staining in RAMP1 KO tumours had a very different 
appearance. Staining appeared more non-specific in areas of the tumour with a less 
dense structure and in the presence of stroma. These results are also reflected when 
observing haematoxylin and eosin staining which shows clear differences in tumour 
structure in RAMP1 KO and PC3 wild type groups. Some RAMP1 KO tumours had a 
more similar and dense tumour structure compared with PC3 wild types with blood 
vessels appearing through the tumour. Quantitative found that RAMP1 KO tumours 
had a higher percentage of tumour area stained positive (P = 0.001), indicating that 
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Figure 5.15 Analysis of Ki67 positive cells. 
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these tumours had an increased number of blood vessels compared with PC3 wild 
type tumours (see Fig 5.16).  
 
 
 
CD31 immunohistological staining (brown) of PC3 wild type (A) and RAMP1 KO (B) 
tumour sections from untreated control groups. (A) CD31 positive staining in PC3 wild 
type tumours indicates small blood vessels are situated throughout the dense 
tumours structure and collections of larger vessels can be found at the tumour 
surface. (B) RAMP1 KO tumours show more non-specific staining compared with PC3 
wild type tumours however small blood vessels can be identified throughout the 
tumour.  
 
Figure 5.16 Images of CD31 staining of wild type and RAMP1 KO PC3 tumours. 
A 
B 
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Figure 5.17 Quantification of CD31 analysis. 
Quantification of CD31 analysis was achieved using ImageJ software and analysing 
the percentage of CD31 positive staining for each region of interest (ROI). A 
significant increase in the amount of CD31 staining was found in RAMP1 KO tumours 
when compared with wild type PC3 (P = 0.001), indicating a higher prevalence of 
blood vessels.              
 
5.5.3 cAMP LANCE TR-FRET             
 
 Dose responses of Telcagepant and other CGRP antagonists such as MK-3207 
and Olcegepant were performed on a mouse Panc02 cell line using a cAMP LANCE 
TR-FRET assay. Using a 25nM dose of CGRP, inhibitory effects of CGRP antagonists 
were seen in higher doses (see Fig 5.18). Olcegepant was observed to have the most 
potent effect with an IC50 of 771nM and MK-3207 was much less potent with an 
IC50 of 22nM. Although Telcagepant was the least potent of the CGRP antagonists 
tested it showed an IC150 of 1.2µM and maintained an inhibitory effect at a 10µM 
dose (see Table 5.3) The span of the Telcagepant dose response curve was the 
highest of the three CGRP antagonist indicating that at higher doses, the inhibitory 
effect was greater than MK-3207 and Olcegepant.  
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Dose response of CGRP antagonists (A) Telcagepant, (B) MK-3207 and (C) Olcegepant 
on Panc02 cells stimulated with 25nM CGRP. All values are mean ±SEM, n=3. 
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Figure 5.18 cAMP dose response curves for CGRP antagonists. 
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Table 5.3 Best fit values for CGRP antagonist curves. 
Best fit values for dose response curves generated for CGRP antagonists Telcagepant, 
MK-3207 and Olcegepant.  
 
 
 Discussion 
 
 This in vivo study demonstrates that PC3 cells lacking RAMP1 expression have 
a gross reduction in their ability to form tumours in a subcutaneous xenograft model. 
Results show that RAMP1 KO tumours were significantly reduced in tumour growth 
across all time point measurements. In fact, it appears that after tumours were 
established they did not increase in size at all (see Fig 5.5). In vitro data shows that 
the RAMP1 KO clone D5 has 41% decreased viability after three days of growth 
compared with PC3 wild type cells. This clone was selected for in vivo study as it 
shared typical characteristics with other RAMP1 KO clones (for example A7 and C1) 
(see Chapter 4, Section 4.5.1). It was therefore expected that tumour growth would 
also be reduced, however the complete cessation of tumour development in RAMP1 
KO tumours was unprecedented. Endpoint analysis of dissected tumour also 
revealed reduced tumour mass in RAMP1 KO tumours compared with PC3 wild type 
(see Fig 5.6). In many cases, dissection of RAMP1 KO tumours was difficult as they 
were so small that they were hard to locate. In these cases, sections of skin were 
taken at the injection site to be analysed after histological staining for the presence 
of tumour cells. Interestingly, differences in liver mass were significant between PC3 
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wild type and RAMP1 KO tumours. Liver mass was decreased in PC3 wild type 
tumours (in both treatment and control groups) which were incidentally much larger 
in both tumour volume and size. This therefore may be an effect of tumour burden 
in the mouse, the strain of subcutaneous xenograft may focus physiological 
processes and reduce energy spent on other vital organs. It also possible that PC3 
wild type tumours are secreting factors that cause liver shrinkage and that deletion 
of RAMP1 results in deregulation of these factors. Further analysis is required to test 
this hypothesis however a lack of difference between treatment and control groups 
suggest that this reduction in liver mass is not treatment-related. No other side 
effects were seen in any of the treatment or control groups.  
 
 No significant differences were found in tumour volume or mass between 
treatment and control groups for both PC3 wild type and RAMP1 KO tumours. 
However, a slight separation was observed in tumour volume on Day 17 between 
PC3 wild type treatment and vehicle control groups. Although this was not a 
significant difference it could be the continuation of the experiment may have 
revealed a Telcagepant effect. Due to the aggressiveness of the PC3 cell line, this 
experiment had to be finished to abide by Home Office laws as tumours may not be 
grown about 1cm3. Telcagepant has been previously reported to have been used in 
humans and rats [228, 232]. However, there is no current literature on the use of 
Telcagepant in mouse models. It is possible therefore that the absence of effect on 
tumour growth in treated mice was due to incorrect dosing of Telcagepant.  The dose 
for Telcagepant to be administered in mice was calculated from current successful 
doses in humans. Administration of 400mg in humans results in potent effects of 
Telcagepant with a half-life of 6 hours, this would translate approximately to 5mg 
per kilogram (mg/kg) [233]. To increase the half-life and allow daily treatments to be 
successfully potent, this drug was administered to mice at 10mg/kg via daily 
subcutaneous injections. Telcagepant was prepared in Kolliphor® HS 15: Kollisolv® 
PEG E 400: dH2O=1:3:6, as it is not very soluble in more aqueous solutions such as 
PBS or water.  
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The effect of Telcagepant was tested on a mouse cell line in vitro using cAMP 
LANCE TR-FRET assays. When activated, GPCRs can often stimulate the production 
of cAMP and therefore the effect of ligands or antagonists can be measured as a 
proportional differences in cAMP production [234]. Other CGRP antagonists were 
also tested for their effect to determine if Telcagepant stocks were inactive.  Results 
show that all CGRP antagonists have an inhibitory effect on CGRP-stimulated Panc02 
mouse cells, with Olcegepant having the highest affinity. This is concurrent with the 
literature which ranks Olcegepant higher in potency compared with Telcagepant in 
humans and rats [235]. Telcagepant was administered at a dose of 10mg/kg which 
is equal to approximately 3mM. This can be considered a very high dose of 
Telcagepant and therefore, according to cAMP data should have an inhibitory effect 
on CGRP in mouse cells.  
 
Panc02 cells are derived from C57/B6 mice and originate from pancreatic 
adenocarcinomas. These cells may be genetically different from a Balb/c nude 
mouse and are also cancerous. Future experiments may identify the effect of 
Telcagepant on primary mouse cells derived from a Balb/c nude strain. Nevertheless, 
it is possible that Telcagepant had no effect in treatment groups because 
subcutaneous tumours were not driven by CGRP but another factor may be 
responsible. RAMP1 has been reported to traffic other receptors to the cell surface 
including the calcium sensing receptor (CaSR) [58] and also GPRC6A [60]. These 
peptide hormones have also been implicated in prostate cancer and therefore the 
deletion of RAMP1 may be also affecting these GPCRs which can now no longer 
traffic to the surface of PC3 cells, thereby removing their tumorigenic potential [107, 
236]. This hypothesis can be explored in the future by measuring the expression 
levels of CaSR and GPRC6A in both wild type and RAMP1 KO PC3 cells.  
  
 Haematoxylin and eosin (H&E) staining of tumour sections was performed to 
investigate possible differences in structure and histological architecture between 
tumours. Observations of histological staining reflected results seen in tumour 
development, no differences were seen between treatment and control groups in 
both PC3 and RAMP1 KO tumours. The first observation that was made when 
 186
comparing tumours types was the presence of necrotic lesions (see Fig 5.10 & 5.11) 
in PC3 wild type sections. This is characterised by a lack of cell structure and an 
increased presence of extracellular matrix. Necrotic lesions can often occur in 
subcutaneous tumours that are so large, the tumour cells situated in the centre of 
the tumour are “cut off” from nutrients and blood supply feeding the tumour. These 
cells are outcompeted by the surrounding tumour and this ultimately leads to death. 
Necrotic lesions were not found in any RAMP1 KO tumours, which were much 
smaller in size and had a far less dense structure with more variation in tissue type 
e.g. tumour, fat, muscle.     
Analysis of H&E staining also revealed a high number of blood vessels in PC3 
wild type tumours when compared with RAMP1 KO. However, after staining with 
CD31 quantitative analysis did not confirm this observation. CD31 staining of RAMP1 
KO control tumours was significantly increased after ImageJ analysis compared with 
PC3 wild type tumours. However, it was observed that staining on RAMP1 KO 
tumours appeared to have increased amounts of non-specific staining and this may 
have effected quantification of positive staining. General observation of the stained 
slides did not show clear differences in the RAMP1 KO and PC3 wild type tumours. 
This suggests that the number of blood vessels which are composed of endothelial 
cells expressing CD31 is not affected by deletion of RAMP1. It also indicates that the 
difference in tumour growth and size is not due to a lack of blood supply or 
angiogenesis. Immunohistochemistry results therefore show that aside from 
proliferation and angiogenesis/vascular structure, alternative factors are 
responsible for the reduction in tumour growth in the absence of RAMP1 
 
 Histological staining for Ki67, a proliferative marker, showed no differences 
in the percentage of positive cells when comparing PC3 wild type and RAMP1 KO 
(treatment and control) tumours. It was observed that staining in the RAMP1 KO 
tumour sections had a higher intensity but this is most likely due to the differences 
in the size of tumours that are stained with the same amount of anti-Ki67 antibody 
and DAB. Ki67 has been described as a prognostic marker for prostate cancer and is 
often used to label tumour cells which are commonly hyper proliferative [167]. 
Previous studies using RAMP1 knockdown subcutaneous xenografts have reported 
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a reduction in the number of Ki67 positive cells in RAMP1 knockdown tumours [105]. 
Differences seen are not highly significant (P = <0.05) and quantification was 
achieved by selected just five regions of interest (ROI) per section at a high-power 
magnification and manually counting positively stained cells. Tumour sizes in wild 
type PC3 cells were reported at up to 650mm3 and therefore five high-power ROIs 
may not be sufficient for such large sections. Quantification of Ki67 staining in this 
study was achieved using QuPath software, allowing quantification of entire tumour 
sections and minimising the risk of bias ROI selection. The lack of difference may 
suggest that the deletion of RAMP1 does not merely reduce proliferation in PC3 cells 
but also affects other processes that are vital for prostate tumour development. 
Further histological analysis for alternative markers of tumour development may 
provide key insights into the mechanisms behind the reduced growth of 
subcutaneous xenografts in RAMP1 KO cells.  
 
 These results suggest a very important role for RAMP1 in prostate tumour 
development. The effect seen in this in vivo study is much greater than previously 
published data (Logan et al.) Knockdown of RAMP1 only results in significant 
reductions of tumour growth after 25 days [105]. This may be a consequence of using 
knockdown of RAMP1 instead of complete gene knockout. The authors also do not 
mention injection of cells with Matrigel in their methods and materials. This may 
explain why the first measurement of tumour volume takes place on Day 14. Mixing 
of cell suspensions with reconstituted basement membrane proteins such as 
Matrigel has been shown to promote the establishments of subcutaneous tumours 
in vivo  and may therefore have yielded a larger window of measurements to see the 
effect of RAMP1 depletion in more detail [208]. Nevertheless, the finding that 
complete deletion of RAMP1 using gene knockout can result in more pronounced 
reductions in tumour growth is important. The complete cessation of tumour growth 
in RAMP1 KO PC3 xenografts is compelling evidence for the implication of RAMP1 in 
the progression of aggressive prostate cancer.  
 
Although the lack of effect of Telcagepant treated mice may suggest this 
antagonist is not appropriate for use in mouse models it is also possible that the 
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RAMP1 KO effect on tumour growth is not related to CGRP. Either of these 
hypotheses could yield interesting research questions that may be further 
investigated in future and could reveal whether clinically available CGRP antagonists 
such as Telcagepant should be used as a therapeutic intervention in prostate cancer 
patients. Further investigations may also explore the role of RAMP1 in the bone 
metastatic niche. Prostate cancer metastasis occurs in bone in 80% of cases and it is 
therefore imperative that the effect of RAMP1 deletion is investigated in the bone 
microenvironment. This can be achieved in vitro using co-culture experiments but in 
vivo models are key to exploring the true value of RAMP1 in prostate cancer 
metastasis.  
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 CHAPTER 6: GENERAL DISCUSSION 
 
 This study has successfully used CRISPR/Cas9 to delete RAMP1 in a PC3 cell 
line and enabled the role of RAMP1 to be more fully elucidated in prostate cancer. 
Deletion of RAMP1 not only results in a 40% reduction in cell viability but protects 
against apoptosis induced by serum starvation. This implicates RAMP1 as an 
important regulator of prostate cancer cell survival and further in vitro testing has 
shown that it has a strong influence in processes of metastasis such as invasion, 
colony formation and adhesion. These results were reflected when using in vivo 
models of prostate tumour growth, where the deletion of RAMP1 led to the 
complete cessation of subcutaneous tumour growth. RAMP1 KO cells also showed 
reduced levels of phosphorylated proteins associated with the progression of 
prostate cancer from an androgen sensitive disease to an aggressive and metastatic 
cancer. These unprecedented findings provide compelling evidence that RAMP1 is 
not only a key player in the mechanisms behind advanced prostate cancer but also 
that it should be considered as a therapeutic target for the treatment of high risk 
prostate cancer patients.   
 
 Although PC3 cells express both components of the CGRP receptor, and 
secrete CGRP itself, evidence suggests that RAMP1 is promoting prostate cancer 
through a CGRP-independent mechanism. This study aimed to generate 
CRISPR/Cas9 knockouts for RAMPs 1-3 in the hope of identifying if the CGRP or 
adrenomedullin receptors are involved in prostate cancer progression. Despite only 
generating successful knockouts for RAMP1, this has led to novel findings that 
dispute CGRP as the relevant peptide in promoting prostate cancer through RAMP1. 
The viability of PC3 cells was found to be unaffected by CGRP peptide or CGRP 
antagonists in vitro. In addition, treatment with Telcagepant, a CGRP antagonist had 
no effect on subcutaneous tumour growth in Balb/c nude mice, despite inhibitory 
effects found on mouse cancer cell lines in vitro. This leads to the conclusion that 
RAMP1 may be trafficking other GPCRs to promote prostate cancer. RAMP1 can 
traffic other receptors to the cell surface apart from CLR, such as the calcium sensing 
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receptor and GPRC6A, both of which have been linked with prostate cancer 
progression [58, 60, 107, 236]. Future work will be required to answer this 
hypothesis but for now it can be undisputed that findings from this study warrant 
further investigations into RAMP1 and its role in prostate cancer.  
 
This study was conducted with a two-fold objective: 
 
§ To knockout RAMPs 1-3 individually in a prostate cancer cell line and measure 
the effect of this deletion on function both in vitro and in vivo 
 
§ To determine if the effect of RAMP1 deletion is due to CGRP or other RAMP-
associated peptides.  
 
The CRISPR/Cas9 technique was chosen to delete RAMPs 1-3 in a prostate cancer 
cell line and in the hope of providing insight into the role of the individual CGRP or 
AM receptors. Previous reports using gene knockout are limited to the use of 
knockout mice to investigate the individual receptor components of CGRP and AM 
receptors. Findings have shown that RAMPs can have distinct physiological and 
pathological roles. Homozygous deletion of the AM, CLR or RAMP2 in mice leads to 
lethality in utero during mid-gestation [158, 237-239]. This provides evidence that 
the CLR:RAMP2 heterodimer that forms the AM2 receptor is essential for 
development, however RAMP3 knockout mice appear to be unaffected until they 
reach old age whereupon they begin to experience weight loss [237]. RAMP1 
knockout mice have no abnormalities other than increased blood pressure but have 
normal heart rates. These mice also have elevated serum levels of CGRP, showing 
that RAMP1 is an essential component of the CGRP receptor [240]. The effect of the 
deletion of the AM1 and AM2 receptors has not been previously studied in the 
context of prostate cancer. Deletion of RAMPs 1-3 in vitro may therefore provide 
useful information on which receptor components are responsible for the effect of 
CGRP and AM in prostate cancer.  
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RAMP knockouts were generated in a PC3 cell line, this is a highly invasive 
prostate cancer cell line that represents advanced stages of the disease. By selecting 
an aggressive cell line, it can be determined whether RAMPs and their appropriate 
GPCRs play an important role in advanced prostate cancer which is currently an 
unmet clinical need. However, future investigations may include RAMP1 deletion in 
other prostate cancer cell lines, such as LNCaP as this would provide insight into the 
role of RAMP1 in an androgen dependent environment. It is important to understand 
the mechanisms involved during the transition from low risk androgen sensitive 
prostate cancer to a resistant and metastatic disease.  Previous studies have 
confirmed the expression of AM, CLR, RAMP1 and RAMP2 mRNA transcripts in PC3 
cells, although RAMP3 expression was not found [241].  While the authors did not 
find RAMP3 expression in PC3 cells, they found it to be upregulated in prostate 
carcinomas more significantly when compared with prostate hyperplasia. 
Alternative studies have found all components of the AM receptors, including 
RAMP3 to be expressed at an mRNA level in PC3 cells [85]. These results are further 
evidence of discrepancies between immortalised cell lines and primary cells and 
tissues. PC3 cells like many other cell lines are genetically different to their origin 
tissue as they have undergone a series of passages causing genotypic and phenotypic 
changes over an extended period of time. It is therefore advised that care be taken 
when using cell lines and key findings should always be confirmed in primary cells or 
in vivo if possible [242]. 
 
 In this study, protein expression was first investigated using antibodies 
targeting RAMPs 1-3 and CLR. Western blotting revealed positive results for RAMPs 
1-3 and CLR in PC3 cell protein samples, however no AM antibody could be optimised 
to determine AM protein levels. The reliability of these antibodies should be 
questioned as manufacturers of the monoclonal RAMP1 antibody (AbCam) have 
since stated that on retesting of the antibody it was found to have incorrect 
subcellular staining. They maintain that the antibody is still appropriate for western 
blotting but later analysis using RAMP1 CRISPR clones with no mRNA RAMP1 
expression showed false positive staining. Nevertheless, this study has found 
expression of AM, CLR and RAMPs 1-3 in PC3 cells at an mRNA level (see Fig 2.9). 
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This finding led to targeting the RAMPs for deletion using the CRISPR/Cas9 gene 
editing technique to effectively remove both CGRP and AM receptors in a PC3 cell 
line.  
 
The use of CRISPR/Cas9 has allowed complete gene deletion in a prostate 
cancer cell line in order to explore the potential role of the target gene in promoting 
prostate cancer progression. Previous studies using knockdown techniques in cancer 
cell lines have led to false conclusions that have since been validated using gene 
knockout and therefore the decision to use CRISPR/Cas9 avoids this risk [142]. When 
studying the role of AM in prostate cancer, previous studies have used different 
techniques including treatment with AM in prostate cancer cell lines or inducing 
overexpression of the AM gene (which is often a transient effect). Often, treatment 
with AM to cells in culture can be hampered by AM that is secreted by the cells 
naturally. An example of this is ambiguous effects seen in the proliferation of 
prostate cancer cell lines after treatment with AM, which authors have attributed to 
maximal proliferative effects already being achieved due to AM secretion [80]. 
Prostate cancer cell lines can be transiently transfected with gene overexpression 
constructs which may be useful in determining the possible role of AM but can often 
have unforeseen consequences. Increasing the expression of a gene from its native 
level within a cell can put pressure on downstream factors which then becoming 
limited. It has also been argued that overproduction of a single protein that networks 
with other proteins (as many regulatory proteins do) can lead to misfolding and 
inactive subcomplexes that alter biological activity [243].  
 
These in vitro techniques also fail to investigate the AM receptors individually 
and their role in prostate cancer. Studies blocking AM using an antibody cocktail 
show significant effects on prostate cancer cell growth in vitro and in xenograft 
tumours but it is unknown which of the AM receptors is responsible for this effect 
as CLR, RAMP2 and RAMP3 have been targeted simultaneously [85]. The same issue 
is present when linking CGRP and prostate cancer, clinical investigations show a 
correlation between serum levels in prostate cancer patients and staging but no 
studies have investigated the mechanism behind this effect [102, 244]. Although, the 
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role of RAMP1 in prostate cancer cell lines has been explored using shRNA 
knockdown in PC3 and LNCaP cells, the effects seen are minimal but significant. In 
RAMP1 knockdown cells, reductions in proliferation in vitro are only seen after 6 
days of growth and significant differences in xenograft tumour volume is also only 
present at late stages of growth [105]. It would therefore be apt to completely delete 
the RAMP1 gene in prostate cancer cells and see if these effects are seen and if they 
are more pronounced when compared with gene depletion.  
 
Gene knockout is a useful tool for determining if AM, CGRP and their 
corresponding receptor components are important for the progression of prostate 
cancer. However, gene knockouts cannot be considered a realistic view of the 
physiology of primary cells and tissues. It is important to highlight that the use of 
CRISPR/Cas9 is a research tool that allows pinpointing of relevant genes. Like all gene 
expression techniques, CRISPR/Cas9 has limitations, such as off target effects. Care 
has been taken to avoid off target effects by choosing a CRISPR/Cas9 system that is 
highly specific. Incorporating CRISPR constructs using homology directed repair 
(HDR) not only reduces off target effects but allows insertion of an expression 
cassette which then aids the validation process when confirming successful gene 
knockouts. Unfortunately, CRISPR constructs targeting RAMP2 and RAMP3 were not 
successful, nevertheless this may be an interesting find in itself. RAMP2 knockout 
mice are known to not survive mid-gestation and this is also relevant in cell culture 
[237].  RAMP2 has been found to be essential for cell barrier regulation in endothelial 
cells and also regulates permeability, suggesting it’s deletion could have 
consequences on cell structure [158]. It may be that in future, when determining the 
role of RAMP2 in prostate cancer, knockdown techniques must be used to ensure 
cell survival.  
 
Nevertheless, RAMP1 knockouts were successfully generated in a PC3 cell 
line and gene deletion was confirmed at an mRNA level using quantitative PCR (see 
Fig 3.21). Despite repeated experiments using heavily concentrated cDNA samples 
that indicated a lack of RAMP1 mRNA, western blotting still produced positive results 
for RAMP1 protein expression. Recent retesting of this antibody by the 
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manufacturers has led to a doubt in its reliability. For these reasons, this result was 
regarded as a false positive result as probing with the RAMP1 antibody also displays 
bands at correct size of 17kDa on the protein standards ladder (see Fig 3.23). In order 
to ensure a population of knockout cells, CRISPR targeted PC3 cells were sorted using 
a fluorescence marker present in the expression cassette that is incorporated into 
the gene when targeted for knockout. Cells were sorted into single cells to ensure a 
complete knockout population, as incorporation of the expression cassette may 
occur without gene knockout in a small subset of cells. These cells would be 
essentially wild type in both genotype and phenotype, leading to a “mixed” 
population and effectively a gene knockdown instead of knockout. This technique of 
isolating CRISPR cell clones has been previously used in different investigations in 
the hope identifying the role of regulatory genes in cancers including breast, colon 
and lung (in both mouse and human cell lines) [245-247].  The use of single cell clones 
has obvious limitations as this does not represent the heterogeneous population 
seen in real prostate tumours and therefore care must be taken when drawing 
conclusions from such studies. To alleviate this multiple CRISPR clones that were 
validated as successful RAMP1 knockouts were used for all functional testing in vitro 
in order to determine whether observations were a RAMP1 or “clonal” effect.  
 
Three different CRISPR clones had RAMP1 mRNA deletion when validated 
using qPCR and reduced viability when cultured for 3 days and compared with PC3 
wild type cells (see Fig 3.21 & 4.9). These clones were then selected for all functional 
testing in vitro to ensure results were not based on a single clone effect.  PC3 wild 
type cells were used as positive controls for all in vitro and in vivo experiments as no 
scrambled CRISPR construct could be provided by the manufacturer. Interestingly, 
variation was seen in viability results between other CRISPR clones (see Fig 4.9). 
These clones did not show reduced viability until towards the end of the experiments 
which is concomitant with previous studies using RAMP1 knockdown in PC3 cells 
[105]. Interestingly the clones in question also showed slightly higher expression 
levels of RAMP1 mRNA expression (<10%) after DD CT analysis and could therefore 
be heterozygous edits and considered RAMP1 knockdown cells instead of complete 
knockouts. This would explain the similarity in findings compared with Logan et al. 
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The overall finding that RAMP1 deletion results in reduced viability of PC3 cells and 
decreases their rate of growth is clinically significant. Prostate cancer enters its most 
advanced stages after becoming androgen independent. Studies have found that 
pro-proliferative factors such as aldoketoreductase (AKR1C3) influence the 
transition of prostate cancer cells to androgen independence also promote 
proliferation [248]. This therefore results in relapsing patients who have increasing 
growth of once benign tumours that have since gained androgen independence. It is 
yet unknown what mechanism RAMP1 is utilising in promoting the viability and 
proliferation of prostate cancer cells but it is irrefutably an important pathway and 
further understanding will benefit advanced prostate cancer patients. RAMP1 KO in 
alternative prostate cancer cell lines, for example androgen sensitive LNCaP may 
provide interesting and clinically relevant insight into the role of this protein in 
prostate cancer relapse and the triggering of metastasis.  
 
A crucial step in the metastasis of prostate cancer involves the ability of cells 
to leave the primary site, invade through the surrounding extracellular matrix and 
migrate to distant sites. It has been suggested that these functional processes are 
key to detecting the transition from low risk disease to advanced metastatic prostate 
cancer which significantly lowers a patients prognosis [249]. The deletion of RAMP1 
in PC3 cells did not reduce migration when tested in vitro. In fact, it was observed 
that multiple RAMP1 clones migrated faster compared with PC3 wild type controls 
(see Fig 4.12). This may represent a limitation of in vitro assays which fail to 
recapitulate the true physiological conditions that prostate cancer cells face when 
migrating across the body. There are currently no published studies testing the effect 
of RAMP1 on the migration of cancer cells specifically, however treatment of CGRP 
does seem to affect the migratory capacity of several prostate cancer cell lines [104, 
178]. This may suggest that results seen in RAMP1 KO cells are not a “CGRP effect”.  
Nevertheless, RAMP1 has been found to regulate migratory patterns of vascular 
smooth muscle cells via inhibition of the NF-kB pathway [190]. It has also been found 
to interact with tubulin, an important component of the cell cytoskeleton and 
essential for migration of prostate cancer cells [250]. In fact, tubulin has also been 
implicated in the promotion of androgen independence and it has been suggested 
 196
that targeting of the cytoskeleton itself may have value in future prostate cancer 
treatments [251, 252]. The role of RAMP1 in migration can be investigated further 
by exploring its effect on downstream signalling pathways associated with this 
process, rather than relying on simplistic in vitro assays.  
 
It is interesting that RAMP1 KO cells did show an increased invasive 
phenotype compared with PC3 wild type controls, despite the absence of a pro-
migratory effect (see Fig 4.14). It has however been suggested that these two 
mechanisms do not necessarily occur simultaneously and that migration is not 
always characterised by an epithelial-to-mesenchymal transition (EMT) of the cancer 
cells [176]. The ability of prostate cancer cells to invade the surrounding stroma does 
require EMT and this is often characterised as a switch in the expression of cadherin 
markers. In prostate cancer specifically, an increase in N-cadherin and decrease in E-
cadherin expression is not only a marker of EMT in prostate cells but also correlates 
with higher Gleason scores [253].  
 
Although there are no current findings associating RAMP1 with cadherin 
expression, others RAMPs such as RAMP3 have been found to promote a 
mesenchymal phenotype in breast cancer by regulating E-cadherin expression [254]. 
Although this is an unpublished thesis study, it is interesting that this family of 
receptor components could be influencing such specific pathways of cancer 
metastasis. Another important factor to consider is that the invasion of prostate 
cancer cells requires degradation of the surrounding extracellular matrix. This is 
achieved through the action of matrix metalloproteinases (MMPs) and serine 
proteases such as urokinase-type plasminogen activator (uPA) [255]. It has been 
shown that uPA acts on PC3 and DU145 cells and results in an invasive phenotype 
with increased proliferation [256]. It may therefore be important to investigate the 
possible role of RAMP1 in uPA and other MMPs in promoting prostate cancer 
invasion as these factors also correlate with clinical outcomes in patients [257].  
 
The adhesive properties of prostate cancer cells undergo pronounced 
changes to initiate the process of metastasis. First, cells must lose their ability to 
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adhere to each other and the surrounding stroma. This is described as cell-cell or 
cell-ECM adhesion. When a cell has metastatic potential is has been suggested that 
its interactions with the ECM changes [249]. This represents the colonisation of 
cancer cells at the distant site through adhesion to the ECM. The ability of RAMP1 
KO PC3 cells to adhere to fibronectin, an extracellular matrix protein was tested in 
vitro. It was found that these cells had a reduction in adhesion to ECM compared 
with PC3 cells (see Fig 4.18). It was also found that the ability of RAMP1 KO cells to 
form colonies in cultures was decreased in both number and size of colonies (see Fig 
4.16 & 4.17). These processes are key to the progression of advanced prostate 
cancer [195, 249]. It is therefore essential to investigate the mechanisms RAMP1 
may be regulating to influence both adhesion and colonisation in metastasis. An 
important factor in cell adhesion is focal adhesion kinase and levels of expression are 
correlated with a greater metastatic potential in different prostate cancer cell lines 
and also staging and progression of prostate adenocarcinomas [258, 259]. Although 
there is no current evidence of RAMP1 regulating FAK, or other adhesion factors, 
CGRP has been shown to enhance vascular tube formation in human umbilical vein 
endothelial cells (HUVECs) through the upregulation of FAK and VEGF receptors 
[260]. Further investigation into the role of RAMP1 is required to determine whether 
the effect of its deletion is due to a lack of CGRP effect or other receptors are 
responsible.  
 
In vitro studies are indicative of RAMP1 being an important factor in PC3 cells 
and therefore could also in the advanced aggressive stages of prostate cancer. 
However, cell lines do not efficiently represent the true pathology of the disease 
studied and it is important to always validate results found in vitro using in vivo 
models. Subcutaneous xenografts of RAMP1 KO PC3 cells resulted in a dramatic 
difference in the volume and mass of subcutaneous tumours compared with wild 
type PC3 (see Fig 5.5 & 5.6). In fact, it appeared that RAMP1 KO tumours failed to 
grow at all and many could not be located during dissection. This result could be 
expected due to the clear differences in cell viability and growth rates in vitro, 
however after histological analysis it was found that the presence of Ki67 positive 
cells was not different between RAMP1 KO and PC3 wild type tumours (see Fig 5.14). 
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This therefore suggests that alternative mechanisms are being influenced by RAMP1 
during the promotion of prostate tumour growth. CD31 staining was also found to 
be significantly higher in RAMP1 KO tumours, suggesting a higher prevalence of 
endothelial cells leading to the assumption that more blood vessels were present in 
these tumours (see Fig 5.16). However, CD31 staining was observed to be highly non-
specific in RAMP1 KO tumours due to different tissue structure compared with PC3 
wild type tumours. RAMP1 KO tumours appeared to be composed of more 
extracellular matrix and showed traces of collagen, whereas PC3 wild type tumours 
were more densely packed with tumour tissue alone (see Fig 5.15). Quantitative 
analysis was hindered by the increased background in tumours with more 
extracellular matrix and collagen fibres. Nevertheless, this finding does not provide 
evidence that the reduction in tumour growth seen in RAMP1 KO cells can be 
attributed to a lack of vascular supply.  
 
It was also found in subcutaneous xenograft experiments that treatment of 
a CGRP antagonist, Telcagepant, had no effect on tumour growth (see Fig 5.7). 
Telcagepant has been heavily reported in the field of migraine research and is a 
clinically approved compound for the treatment of migraine [228, 229, 233]. 
Therefore, if the effect seen in RAMP1 KO cells in prostate cancer is a CGRP effect, it 
could be hypothesised that the treatment of an approved CGRP antagonist such as 
Telcagepant could be beneficial to advanced prostate cancer patients. Previous 
studies have used rat or human dosing of Telcagepant and so dosing for mice was 
calculated by scaling down these doses to 5mg/kg [233]. Telcagepant has a short 
half-life of 6 hours and so mice were treated with 10mg/kg daily to counter this 
effect. Previous studies have shown that Telcagepant has a 1000-fold lower affinity 
for the CGRP receptor in rats and dogs, leading to most preclinical work being done 
in rhesus monkeys [261]. The lack of effect seen in treated mice could be a result of 
incorrect dosing or reflect the reduced potency of the antagonist in rodent species. 
Another possible explanation is that RAMP1 is acting in a CGRP-independent manner 
in prostate cancer. In vitro testing of PC3 wild type cells showed that treatment with 
CGRP has no effect on cell growth (see Fig 4.10). Experiments have shown using 
immunoassays that CGRP is secreted into the media from PC3 cells in culture (see 
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Fig 2.12). It could be argued that treatment may have no effect as the cells already 
display maximum proliferation. However, it was also found that treatment with 
Telcagepant at varying doses also had no effect to viability or cell growth (see Fig 
4.10). This evidence suggests that PC3 cells are not driven by CGRP and that RAMP1 
may be acting through alternative mechanisms. Although human PC3 cells were the 
source of subcutaneous tumours, the surrounding stroma and tumour environment 
was mouse. It was therefore important to investigate the effect of Telcagepant on a 
mouse cell line. Stimulation with CGRP results in a dose response of cAMP 
production which was measured using a LANCE TR-FRET assay (see Fig 5.4). It was 
then found that Telcagepant only had inhibitory effects at high doses of <1µM (see 
Fig 5.17). Other CGRP antagonists were tested such as MK-3207 and Olcegepant and 
these also were inhibitory at very high doses (see Fig 5.17). Treatment of mice with 
10mg/kg Telcagepant approximately equates to a daily treatment of 3mM.  
 
Although it is unknown how efficiently Telcagepant is absorbed this can still 
be considered a very high dose and therefore it could be concluded that the lack of 
effect seen in treatment groups is not due to a lack of Telcagepant efficacy but most 
likely tumour growth is not driven by CGRP. This possibility must be further 
investigated in future studies as it is important to establish the true mechanism 
pertaining to the role of RAMP1 in prostate cancer. RAMP1 is important in CGRP 
signalling as it traffics the calcitonin-like receptor (CLR) to the cell surface and 
therefore without the RAMP1:CLR complex, CGRP cannot exert any cellular 
functions. Other receptors have been found to be trafficked by RAMP1 and co-
localise on the cell surface.  
 
Results of the subcutaneous xenograft experiment show a clear role for 
RAMP1 in the growth of PC3 cells in a more physiologically relevant setting. 
However, this model is far from similar to the environment of prostate tumours in 
situ and also does not investigate the effect of RAMP1 deletion in metastasis. 
Orthotopic models represent clinical stages of prostate cancer most accurately as 
cells are faced with a native host environment [262]. However there has been a lack 
of standardisation over the number of injected tumour cells in orthotopic models 
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and are often used to study effects in localised prostate tumour environments [263]. 
Prostate cancer is a disease the is lethal after metastasis, in which over 80% of cases 
are skeletal [189]. It is therefore imperative to recapitulate this in a mouse model of 
prostate cancer. This will also reveal the role of RAMP1 in promoting metastasis of 
prostate cancer cells and their development within the bone environment. To 
understand the effect of RAMP1 deletion on bone metastasis a model of cell 
colonisation in bone using intracardiac injection of RAMP1 PC3 cells could be 
performed in the future [264]. Before injection cells can be stained with fluorescent 
lipophilic membrane dyes (e.g. DiD or Dil). After cells have travelled through 
circulation and metastasised to the bone they can be quantified using two-photon 
microscopy. When the cells divide they will not retain the dye and so only colonising 
cells will be quantified therefore showing whether the number of RAMP1 KO cells to 
successfully metastasise to bone is different from PC3 wild type cells.  
 
It is also important to measure the ability of RAMP1 KO PC3 cells to grow 
within the bone environment. It is possible that the deletion of RAMP1 may have 
downstream consequences that effect the metastatic niche and this could reveal a 
novel role for RAMP1 in the tumour microenvironment. Tagging of wild type and KO 
cells with luciferase can allow the real-time measurement of bone metastasis growth 
following intracardiac injection [216-218, 265]. Bones can then be dissected and 
analysed using microCT and histological staining to investigate the effect of RAMP1 
on the bone environment. Size and number of metastatic sites will reveal the effect 
of RAMP1 on tumour growth in the bone. This is very relevant to prostate cancer 
patients who have a significantly low prognosis after bone metastasis. Currently, 
there is a lack of agreed treatment for these advanced patients and their best hope 
is to enter a clinical trial [37]. Therefore, understanding what important factors and 
mechanisms are acting on metastatic tumours is vital for developing new 
therapeutic treatments.    
 
In an effort to develop new therapies for advanced prostate cancer patients, 
it is vital to examine the molecular mechanisms behind the transition from androgen 
dependence to independence that leads to relapsing patients with aggressive 
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metastatic disease and a poor prognosis. The effect of RAMP1 deletion was 
investigated with regards to downstream signalling pathways in PC3 cells. Using a 
magnetic bead assay targeting multiple phosphorylated proteins from different 
signalling pathways it was found that RAMP1 KO cells show reduced levels of 
phosphorylated Akt and STAT3 compared with PC3 cells (see Fig 4.20). Akt is an 
important member of the P13K cell survival pathway and is often mutated in cancer 
cells [266]. In fact, in prostate cancer it has been found to be activated by IL-6 to 
promote cell survival by inhibiting apoptosis [201, 267].  
 
Previous studies have also implicated RAMP1 in the regulation of IL-6 
expression in prostate cancer cells [105]. Interestingly, IL-6 can promote growth in 
androgen independent cell lines such as PC3 and DU145 by increasing STAT3 binding 
activity and its expression has been linked with promoting androgen independence 
in LNCaP cells [202, 268]. This association between IL-6 and STAT3 has led to 
preclinical models using inhibitors of upstream STAT3 effectors, JAK1 and JAK2. 
Overexpression of IL-6 in DU145 cells results in a seven-fold increase in lung 
metastases in nude mice, however this effect was almost completely abolished after 
daily treatments of AZD1480, a JAK1/2 inhibitor. This effect was also achieved using 
shRNA knockdown of STAT3 [269]. This has led to recent reviews questioning the 
relevance of STAT3 inhibitors in the treatment of prostate cancer [270, 271]. 
Nevertheless, limitations with drug potency in phase I clinical trials have led to 
reviewers calling for further investigation into the STAT3 molecular pathway in 
cancer. Results showing that RAMP1 may be important for STAT3 signalling are 
therefore highly clinically relevant and further investigation of RAMP1 deletion on 
IL-6 in both advanced and androgen sensitive cell lines may provide interestingly 
results.   
 
Upstream mechanisms acting with RAMP1 remain unclear, however 
evidence from this study suggests that CGRP may not be responsible for the effect 
seen in RAMP1 KO PC3 cells. It is therefore apposite to look to other RAMP1 
associated GPCRs.  The calcium sensing receptor (CaSR) should first be considered as 
a potential mechanism by which RAMP1 can promote prostate cancer. Previous 
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work in this group has found that in thyroid human carcinoma cells, RAMP1 (and 
RAMP3) are able to chaperone CaSR to the cell surface and that knockdown of 
RAMP1 using siRNA results in a 50% reduction in CaSR signalling in response to 
known CaSR-associated ligands [58].  Expression of this receptor correlates with risk 
of developing advanced prostate cancer and it has also been suggested to be 
involved in the process of bone metastasis in both breast and prostate cancer [272, 
273]. Knockdown of CaSR results in decreased proliferation in PC3 cells in both in 
vivo and in vitro [274]. It could therefore be hypothesised that the effect of RAMP1 
deletion in PC3 cells is the result of CaSR no longer being trafficked to the cell surface 
efficiently. 
 
 Unpublished work in this group has also found that RAMP1 may traffic the G 
protein-coupled receptor family C group 6 member A (GPRC6A) to the cell surface of 
thyroid human carcinoma cells [60]. Knockdown of this receptor not only effects PC3 
cell proliferation but also reduced ERK activity. These effects could then be reversed 
after treatment with GPRC6A-associated ligands (e.g. extracellular calcium, 
osteocalcin, testosterone)[59, 107]. As previously mentioned it is vital to confirm in 
vitro results with appropriate in vivo models. This was achieved by crossing GPRC6A 
-/- mice onto the transgenic adenocarcinoma of the mouse prostate (TRAMP) model. 
Traditionally, TRAMP mice displayed evidence of hyperplasia of the prostate after 30 
weeks [275]. However, GPRC6A -/- mice had reduced hyperplasia and an increased 
survival rate of 23% [107].  RAMP1 KO cells should be tested for CaSR and GPRC6A 
expression and signalling as this could provide information on signalling mechanisms 
important for advanced prostate cancer progression.  
 
To continue the investigation of RAMP1 in prostate cancer, other GPCRs must 
be considered and explored. Both the CaSR and GPRC6A have been shown to be 
highly associated with prostate cancer both in vitro and in vivo. Our group has shown 
that these receptors rely on RAMP1 for cell surface trafficking and therefore they 
may be responsible for the effect seen in RAMP1 KO PC3 cells. Future studies must 
investigate the signalling of these receptors in PC3 WT and PC3 RAMP1 KO cells to 
discriminate which (if not both) is required for promoting prostate cancer 
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progression. The crystal structure of the CaSR has enabled the development of 
potent antagonists which are clinically available and have been used clinical trials for 
diseases such as osteoporosis [276]. In cancer, CaSR compounds have been shown 
to be tumour suppressive in colorectal cancer [277].  
 
The structure of GPRC6A has not been fully described however its similarities 
with other Class C GPCRs has allowed the development of low micromolar range 
antagonists that show 9-fold selectivity for GPRC6A over other GPCRs [278]. If future 
work attributes the effect of RAMP1 deletion in prostate cancer to one of these 
receptors, it will provide further evidence for a new therapeutic treatment for men 
with aggressive prostate cancer. Studies specifically looking at the signalling of 
RAMP1 and its relevant GPCR may provide insight into mechanisms that promote 
cancer progression and it is possible that these mechanisms may be conserved 
across many solid cancers. RAMP1 has been found to regulate downstream 
pathways linked with hormone refractory prostate cancer. RAMP1 should therefore 
also be investigated in the process of androgen resistance, by testing its role in 
androgen sensitive cell lines such as LNCaP. This may provide useful insights into the 
mechanisms behind androgen resistance in prostate cancer and explain why 
relapsing patients experience this process.  
 
 Future Work 
 
Further investigations can be done to precede this PhD project, including 
further validation and characterisation of the RAMP1 KO PC3 cells and the 
continuation of testing functional effects of RAMP1 deletion both in vitro and in vivo. 
If antibodies targeting RAMP1 can be optimised in the future, this will be useful for 
determining if RAMP1 is present at the cell surface of RAMP1 KO PC3 cells. Further 
characterisation of both wild type and RAMP1 KO PC3 cells could also investigate the 
presence of CGRP, CaSR and GPRC6A at an mRNA and protein level. To determine if 
the effects of PC3 cells are regulated by the CGRP receptor, treatment with CGRP 
and its antagonists can be implemented in in vitro assays modelling prostate cancer 
cell growth and metastasis.  Alternatively, the effect of RAMP1 deletion can be 
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investigated in downstream signaling pathways associated with mechanisms such as 
invasion and adhesion. This can be achieved by looking at expression levels of 
important factors such as a5b1-integrin or focal adhesion kinases which have been 
previously implicated in many solid cancers [279, 280]. Similarly, additional 
downstream targets associated with apoptosis can also be investigated to validate 
effects seen in caspase 3/7 levels after RAMP1 deletion. These downstream 
investigations could also be expanded by using RNAseq technology to determine any 
significant differences in mRNA targets between wild type and RAMP1 KO PC3 cells.  
 
To test hypotheses that CaSR or GPRC6A may be signaling through RAMP1 in 
PC3 cells, further in vitro assays could be used. Evidence for CaSR or GPRC6A 
involvement can be gathered by stimulating both wild type and RAMP1 KO PC3 cells 
with known agonists or antagonists and measuring downstream responses. 
Cinacalcet is a known agonist of the CaSR and intracellular calcium levels can be 
measured using cell permeant, calcium indicator fluorescent dyes. Alternatively, 
CaSR antagonists have been developed and are also available such as NPS 2143. 
GPRC6A can be stimulated by multiple endogenous ligands such as testosterone, 
osteocalcin and amino acids such as L-arginine. However, these ligands are not 
selective for the GPRC6A receptor and therefore changes in levels of phosphorylated 
ERK, cAMP or intracellular calcium may not provide conclusive evidence. 
Fortunately, recent work using computational models has identified selective 
agonists for the GPRC6A receptor and these could be used in the future to provide 
further evidence on the possible involvement of this receptor [281].  
 
Further investigation using in vivo studies will also provide more information 
about the role of RAMP1 in metastatic disease. Intracardiac mouse models can be 
used in the future to determine the effect of RAMP1 deletion on PC3 growth in a 
bone environment. Testing of CGRP antagonists also found Olcegepant to be more 
potent on mouse cancer cells compared with Telcagepant, therefore subcutaneous 
xenograft studies could also be repeated with this antagonist to further test the role 
of CGRP in prostate tumour growth.  By generating RAMP1 knock outs in other 
prostate cancer cell lines, more can be learned about its role in other prostate cancer 
 205 
phenotypes. RAMP1 was found to regulate downstream pathways linked with 
hormone refractory prostate cancer. RAMP1 should therefore also be investigated 
in the process of androgen resistance, by testing its role in androgen sensitive cell 
lines such as LNCaP. This may provide useful insights into the mechanisms behind 
androgen resistance in prostate cancer and explain why relapsing patients 
experience this process. Alternatively, more aggressive cell lines such as C42B 
(derived from LNCaP osseous tumours grown in castrated mice) could also be used 
to generate RAMP1 knock outs to examine the role of RAMP1 in prostate cancer 
bone metastasis.  
 
 Conclusion  
 
Together, the results of this study have highlighted RAMP1 as an important 
player in advanced prostate cancer both in vitro and in vivo. This protein not only 
promotes cell survival in an aggressive prostate cancer cell line but is also involved 
in key processes of metastasis. RAMP1 has been found to be essential for invasion, 
adhesion and colony formation of PC3 cells and its deletion leads to the 
dysregulation of signalling pathways known to be be important in prostate cancer, 
specifically the development of androgen independent, aggressive tumours that 
lead to metastasis. RAMP1 is also vital for the growth of tumours in a prostate cancer 
in vivo model, where its deletion causes complete inhibition of tumour growth. This 
pronounced effect on an aggressive metastatic prostate cell line shows great 
promise for relapsing patients who after initial treatment transition to an 
increasingly poor prognosis and limited treatment options. This study provides 
compelling evidence that RAMP1 should be further considered for therapeutic 
targeting in advanced prostate cancer and that additional investigations may yield 
interesting information about the molecular mechanisms behind this protein target. 
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CHAPTER 7: APPENDIX 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sanger sequence for wild type PC3 targeting RAMP1 analysed using 4Peaks software 
shows 67% accurate base calling. Background noise found 1-40bp, target size = 
256bp. Screenshot of Sanger sequence for RAMP2 aligned with NCBI NM_005854.2 
RAMP2 mRNA sequence. 90% identity match was found.   
A 
B 
Figure 0.1 Sanger sequencing PC3 WT and RAMP1 
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Sanger sequence for wild type PC3 targeting RAMP3 analysed using 4Peaks software 
shows 87% accurate base calling. Background noise found 1-20bp, target size = 
227bp. Screenshot of Sanger sequence for RAMP3 aligned with NCBI NM_005856.2 
RAMP3 mRNA sequence. 98% identity match was found.  
  
A 
B 
Figure 0.2 Sanger sequencing PC3 and RAMP3 
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(A) Sanger sequence for wild type PC3 targeting CLR analysed using 4Peaks software 
shows 87% accurate base calling. Background noise found 1-40bp, target size = 
302bp. (B) Screenshot of Sanger sequence for CLR aligned with NCBI 
NM_001271751.1 CLR mRNA sequence. 99% identity match was found.  
A 
B 
Figure 0.3 Sanger sequencing PC3 and CLR 
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Sanger sequence for wild type PC3 targeting AM analysed using 4Peaks software 
shows 88% accurate base calling. Background noise found 1-40bp, target size = 
3276bp. Screenshot of Sanger sequence for AM aligned with NCBI NM_001124.2 AM 
mRNA sequence. 99% identity match was found. 
 
A 
B 
Figure 0.4 Sanger sequencing PC3 and AM 
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Sanger sequencing results of CRISPR clone “A7” matches with the EF1-alpha 
promoter from the CRISPR HDR expression cassette. This demonstrates that the HDR 
cassette has been inserted into the RAMP1 gene.  
Figure 0.5 Sanger sequencing of CRISPR clone A7 and EF1-alpha promoter region 
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BLAST alignment of RAMP1 CRISPR clone “A7” matches sequence of the EF1-alpha 
promoter in the CRISPR HDR insert. This demonstrates that the HDR cassette has 
been inserted into the RAMP1 gene. 
 
 
 
 
Figure 0.6 BLAST alignment for CRISPR clone A7 
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Sanger sequencing results of CRISPR clone “A7” match with the left homology arm 
from the CRISPR HDR construct and also the RAMP1 gene upstream from the 
homology arm. This demonstrates that the CRISPR construct has correctly targeted 
the RAMP1 gene.  
  
Figure 0.7 Sanger sequencing for CRISPR clone A7 and left homology arm 
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BLAST alignment of RAMP1 CRISPR clone “A7” matches homology arm sequence 
(highlighted yellow) designed for the CRISPR construct and also the RAMP1 gene 
upstream from the homology arm (unhighlighted). This demonstrates that the 
CRISPR construct has correctly targeted the RAMP1 gene.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 0.8 BLAST alignment of RAMP1 CRISPR clone A7 and left homology arm. 
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Sanger sequencing results of CRISPR clone “C1” match with the left homology arm 
from the CRISPR HDR construct and also the RAMP1 gene upstream from the 
homology arm. This demonstrates that the CRISPR construct has correctly targeted 
the RAMP1 gene. 
  
Figure 0.9 Sanger sequencing of CRISPR clone C1 and left homology arm. 
 216
 
Figure 0.10 BLAST alignment of CRISPR clone C1 and EF1-alpha promoter 
BLAST alignment of RAMP1 CRISPR clone “C1” matches sequence of the EF1-alpha 
promoter in the CRISPR HDR insert. This demonstrates that the HDR cassette has 
been inserted into the RAMP1 gene. 
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BLAST alignment of RAMP1 CRISPR clone “C1” matches homology arm sequence 
(highlighted yellow) designed for the CRISPR construct and also the RAMP1 gene 
upstream from the homology arm (unhighlighted). This demonstrates that the 
CRISPR construct has targeted the RAMP1 gene correctly. 
 
 
 
 
 
 
 
 
Figure 0.11 BLAST alignment of CRISPR clone C1 and left homology arm. 
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Figure 0.12 Sanger sequencing for PC3 and RAMP2 
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BLAST alignment of wild type PC3 with NCBI sequence for RAMP2 (NM_005854) 
results in a 90% sequence match.  
 
 
 
 
 
BLAST alignment of RAMP1 KO clone “A7” with wild type PC3 sanger sequences 
results in a 74% match.  
 
Figure 0.13 BLAST alignment of PC3 for RAMP2 
Figure 0.14 BLAST alignment of CRISPR clone A7 and PC3 wild type 
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Figure 0.15 Sanger sequencing for CRISPR clone A7 and RAMP2 
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BLAST search of RAMP1 KO clone “A7” sequence results in a 90% sequence match 
with NCBI RAMP2 sequence (NM_005854).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 0.16 BLAST alignment for CRISPR clone A7 and RAMP2 
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Figure 0.17 Sanger sequencing for CRISPR clone C1 and RAMP2 
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Figure 0.18 BLAST alignment of CRISPR clone C1 and PC3 wild type 
BLAST alignment of RAMP1 KO clone “C1” and wild type PC3 Sanger sequences result 
in an 82% match.  
 
 
 
 
 
 
 
 
Figure 0.19 BLAST alignment of CRISPR clone C1 and RAMP2 
BLAST search of RAMP1 KO clone “C1” results in a 90% match with NCBI RAMP2 
sequence (NM_005854). 
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Figure 0.20 Sanger sequencing for CRISPR clone D5 and RAMP2 
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Figure 0.21 BLAST alignment of CRISPR clone D5 and PC3 wild type 
BLAST alignment of RAMP1 KO clone “D5” and wild type PC3 sequences results in a 
74% match.  
 
 
 
 
 
Figure 0.22 BLAST alignment of CRISPR clone D5 and RAMP2 
BLAST search of RAMP1 KO clone “D5” sequence results in a 99% match with NCBI 
RAMP2 sequence (NM_005854).  
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Table 0.1 List of manufacturers and reagents 
Reagent Company, Product No. 
Cell Culture 
RPMI 1640, GlutaMAX Thermo Fisher, 61870 
Fetal Bovine Serum Sigma-Aldrich, F7524 
Penicillin-Streptomycin (P/S) Thermo Fisher, 15140 
Dulbecco’s Phosphate-Buffered Saline (PBS) Thermo Fisher, 14040 
TrypLE Express Enzyme Thermo Fisher, 12605 
Trypan Blue Solution, 0.4% Thermo Fisher, 15250 
Polymerase Chain Reaction (Endpoint and Quantitative) 
Reliaprep Cell Miniprep System Promega, TM370 
High-Capacity RNA-to-cDNA™ Kit Thermo Fisher, 4387406 
GoTaq® G2 Flexi DNA Polymerase Promega, M7801 
5X GoTaq G2 Green Buffer  Thermo Fisher, AM9780 
MgCl2  Promega, M7481 
dNTP mix  Promega U1511 
PCR Primer Oligonucleotides  Eurofins 
microLYSIS-Plus Microzone 
Phusion High-Fidelity DNA Polymerase Thermo Scientific, F530S 
Gel Electrophoresis 
Agarose Fisher Scientific, BP1356 
Tris Acetate EDTA (TAE) National Diagnostics, EC861 
Ethidium Bromide Sigma Aldrich, E1385 
FullRanger 100bp DNA Ladder GeneFlow, L3-0014 
Western Blot 
Tergitol (NP40) Sigma-Aldrich, NP40S 
Sodium Chloride Fisher Scientific, S/3120/63 
Tris Base Fisher Scientific, BP152-1 
Halt™ Protease and Phosphatase Inhibitor 
Cocktail (100x) Thermo Fisher, 78440 
DC Protein Assay Kit II Bio-Rad, 5000002 
4x Laemmli Buffer Bio-Rad, 1610747 
Dithiothreitol (DTT) Fisher Scientific, R0861 
 10x Tris/Glycine/SDS (TGS) Bio-Rad, 1610772 
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Precision Plus Protein WesternC Standards Bio-Rad, 16103796 
4-20% Mini-PROTEAN® Precast Protein Gels Bio-Rad, 4561094 
Trans-Blot® Turbo™ Mini PVDF Transfer Packs Bio-Rad, 1704156 
SuperSignal™ West Dura Extended Duration 
Substrate Thermo Fisher, 34075 
ELISA 
Human CGRP fluorescent enzyme immunoassay 
(EIA) 
Phoenix 
Pharmaceuticals, FEK-
015-02 
cAMP Assay 
LANCE cAMP 384 Kit PerkinElmer, AD0264 
384-well Optiplates PerkinElmer, 6007299 
Hank’s Buffered Saline Solution (HBSS) Thermo Scientific, 24020 
Hank’s Buffered Saline Solution (no Ca2+, no 
Mg2+) 
Thermo Scientific, 
14170 
Stabilizer, 7.5% (DTPA-purified BSA) PerkinElmer, CR84 
3-isobutyl-1-methylxanthine Sigma-Aldrich, I5879 
HEPES Fisher Scientific, BP310-1 
Forskolin Sigma-Aldrich, F3917 
Human adrenomedullin Anaspec, AS-60447 
Human calcitonin gene-related peptide Sigma-Aldrich, SCP0060 
Rat amylin Bachem, H-9475 
Telcagepant MedChem Express, HY-32709 
MK3207 MedChem Express, HY-10302 
Olcegepant MedChem Express, HY-10095A 
CRISPR Transfections 
RS-1  TOCRIS Bioscience, 5810 
Scr7 Pyrazine TOCRIS Bioscience, 53410 
OptiMEM Reduced Serum Media Gibco, 31985062 
Lipofectamine 3000 Thermo Scientific, L3000001 
RAMP1 HDR + Cas9 Plasmids 
Santa Cruz 
Biotechnology, sc-
424560 
RAMP2 HDR + Cas9 Plasmids 
Santa Cruz 
Biotechnology, sc-
424864 
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RAMP3 HDR + Cas9 Plasmids 
Santa Cruz 
Biotechnology, sc-
425003 
Control CRISPR/Cas9 Plasmid Santa Cruz, sc-418922 
Viability Assay 
RealTime-Glo™ MT Cell Viability Assay Promega, G9712 
Corning™ Costar™ 96-Well White Clear-Bottom 
Plates Corning, 3610 
Apoptosis Assays 
Caspase-Glo™ 3/7 Apoptosis Assay Promega, G8093 
Migration/Invasion/Adhesion/CFU 
Mitomycin C Sigma, M4287 
Toluidine Blue Sigma, T3260 
Sodium Tetraborate Sigma, 221732 
BD BiocoatÔ MatrigelÔ Transwell Chambers Corning, 354481   
Crystal Violet Sigma, 61135 
Calcein AM Thermo Scientific, C1430 
Fibronectin-coated 96 well plates Corning, 354409 
Multiplex Bead Assay 
MILLIPLEX Map Multi-Pathway Magnetic Bead 9-
plex – Cell Signalling Multiplex Assay Kit  Merck, 48-680MAG 
Protease Inhibitor Cocktail Set III Merck, 539134 
Ultrafree-MC VV Centrifugal Filter Merck, UFC30VV25 
Subcutaneous In Vivo Study 
Telcagepant MedChem Express, HY-32709 
Kolliphor® HS 15 Sigma-Aldrich, 42966 
Kollisolv® PEG E 400 Sigma-Aldrich, 06855 
PBS Thermo Fisher, 10010 
Dimethyl Sulfoxide (DMSO) Sigma-Aldrich, D8418 
Corning® Matrigel® Basement Matrix Corning, 354234 
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Immunohistochemistry 
Rat anti-mouse CD31 mAb (Clone SZ31) Dianova, DIA-310 
Rabbit anti-human Ki67 pAb Abcam, ab15580 
VECTASTAIN® ABC-HRP Kit (Peroxidase, Rat IgG) Vector Laboratories, PK-4004 
VECTASTAIN® ABC-HRP Kit (Peroxidase, Rabbit IgG) Vector Laboratories, PK-4001 
ImmPACT DAB EqV Peroxidase (HRP) Substrate Vector Laboratories, SK-4103 
100x Citrate Buffer pH 6.0 Abcam, ab93678 
Tris Base Fisher Scientific, BP337-500 
Sodium chloride  Fisher Scientific, 5/3120/63 
PBS Tablets Thermo Fisher, BR0014G 
Tween-20 Fisher Scientific, BP337-500 
UltraPure EDTA Thermo Fisher, 15575020 
30% Hydrogen Peroxide Solution Sigma-Aldrich, 31642 
ImmEdge Hydrophobic Barrier PAP Pen Vector Laboratories, H-4000 
DPX Mountant Sigma-Aldrich, 06522 
Gill’s Haemotoxylin Merck, 105174 
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